<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="review-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Vaccines (Basel)</journal-id><journal-id journal-id-type="iso-abbrev">Vaccines (Basel)</journal-id><journal-id journal-id-type="pmc-domain-id">2764</journal-id><journal-id journal-id-type="pmc-domain">vaccines</journal-id><journal-id journal-id-type="publisher-id">vaccines</journal-id><journal-title-group><journal-title>Vaccines</journal-title></journal-title-group><issn pub-type="epub">2076-393X</issn><publisher><publisher-name>Multidisciplinary Digital Publishing Institute  (MDPI)</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC11436118</article-id><article-id pub-id-type="pmcid-ver">PMC11436118.1</article-id><article-id pub-id-type="pmcaid">11436118</article-id><article-id pub-id-type="pmcaiid">11436118</article-id><article-id pub-id-type="pmid">39340101</article-id><article-id pub-id-type="doi">10.3390/vaccines12091071</article-id><article-id pub-id-type="publisher-id">vaccines-12-01071</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Virulence and Immune Evasion Strategies of FMDV: Implications for Vaccine Design</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-8663-3786</contrib-id><name name-style="western"><surname>Medina</surname><given-names initials="GN">Gisselle N.</given-names></name><xref rid="af1-vaccines-12-01071" ref-type="aff">1</xref><xref rid="af2-vaccines-12-01071" ref-type="aff">2</xref><xref rid="c1-vaccines-12-01071" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Diaz San Segundo</surname><given-names initials="F">Fayna</given-names></name><xref rid="af3-vaccines-12-01071" ref-type="aff">3</xref><xref rid="c1-vaccines-12-01071" ref-type="corresp">*</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name name-style="western"><surname>De la Torre</surname><given-names initials="J">Juan</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-vaccines-12-01071"><label>1</label>National Bio and Agro-Defense Facility (NBAF), ARS, USDA, Manhattan, KS 66502, USA</aff><aff id="af2-vaccines-12-01071"><label>2</label>Plum Island Animal Disease Center (PIADC), ARS, USDA, Orient Point, NY 11957, USA</aff><aff id="af3-vaccines-12-01071"><label>3</label>National Institute of Health, NIAID, DMID, OBRRTR, Bethesda, MD 20892, USA</aff><author-notes><corresp id="c1-vaccines-12-01071"><label>*</label>Correspondence: <email>gisselle.medina@usda.gov</email> (G.N.M.); <email>fayna.diazsansegundo@nih.gov</email> (F.D.S.S.)</corresp></author-notes><pub-date pub-type="epub"><day>19</day><month>9</month><year>2024</year></pub-date><pub-date pub-type="collection"><month>9</month><year>2024</year></pub-date><volume>12</volume><issue>9</issue><issue-id pub-id-type="pmc-issue-id">471656</issue-id><elocation-id>1071</elocation-id><history><date date-type="received"><day>20</day><month>8</month><year>2024</year></date><date date-type="rev-recd"><day>02</day><month>9</month><year>2024</year></date><date date-type="accepted"><day>10</day><month>9</month><year>2024</year></date></history><pub-history><event event-type="pmc-release"><date><day>19</day><month>09</month><year>2024</year></date></event><event event-type="pmc-live"><date><day>28</day><month>09</month><year>2024</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-09-29 15:25:18.037"><day>29</day><month>09</month><year>2024</year></date></event></pub-history><permissions><copyright-statement>&#169; 2024 by the authors.</copyright-statement><copyright-year>2024</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="vaccines-12-01071.pdf"/><abstract><p>Foot-and-mouth disease (FMD) is globally recognized as a highly economically devastating and prioritized viral disease affecting livestock. Vaccination remains a crucial preventive measure against FMD. The improvement of current vaccine platforms could help control outbreaks, leading to the potential eradication of the disease. In this review, we describe the variances in virulence and immune responses among FMD-susceptible host species, specifically bovines and pigs, highlighting the details of host&#8211;pathogen interactions and their impact on the severity of the disease. This knowledge serves as an important foundation for translating our insights into the rational design of vaccines and countermeasure strategies, including the use of interferon as a biotherapeutic agent. Ultimately, in this review, we aim to bridge the gap between our understanding of FMDV biology and the practical approaches to control and potentially eradicate FMD. </p></abstract><kwd-group><kwd>foot-and-mouth disease</kwd><kwd>vaccines</kwd><kwd>livestock diseases</kwd></kwd-group><funding-group><award-group><funding-source>USDA ARS-CRIS</funding-source><award-id>401-3022-505-064-00D</award-id></award-group><funding-statement>This work was funded by USDA ARS-CRIS Project 401-3022-505-064-00D.</funding-statement></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-license-ref</meta-name><meta-value>CC BY</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="sec1-vaccines-12-01071"><title>1. Introduction</title><p>Foot-and-mouth disease (FMD), one of the most economically devastating diseases in the livestock industry worldwide, is caused by FMD virus (FMDV), a highly contagious, positive-sense, single-stranded RNA virus. FMDV belongs to the <italic toggle="yes">Aphthovirus</italic> genus of the <italic toggle="yes">Picornaviridae</italic> family. The FMDV viral genome is approximately 8500 nucleotides (nt) long and is organized in a single open reading frame (ORF) flanked by highly structured 5&#8242; and 3&#8242; non-coding regions (NCRs) (<xref rid="vaccines-12-01071-f001" ref-type="fig">Figure 1</xref>). After infecting a cell, FMDV is rapidly translated into a single polyprotein, which is then processed into mature viral proteins. These proteins are essential for viral replication and enable the virus to spread quickly throughout the cell. The virus exhibits high antigenic variability, with six serotypes currently in circulation (A, O, Asia1, SAT1, SAT2, and SAT3), one &#8220;extinct&#8221; serotype C [<xref rid="B1-vaccines-12-01071" ref-type="bibr">1</xref>], and multiple circulating subtypes [<xref rid="B2-vaccines-12-01071" ref-type="bibr">2</xref>]. While clinical symptoms are similar among subtypes, cross-immunity and cross-protection are limited, potentially contributing to recurrent outbreaks in endemic regions. Interestingly, studies such as that by Grant et al. have provided insights into overcoming the challenges of cross-protection. Their research demonstrated that implementing a sequential vaccination approach with various FMDV serotypes can stimulate the production of antibodies that exhibit cross-reactivity with serotypes not directly encountered before the challenge [<xref rid="B3-vaccines-12-01071" ref-type="bibr">3</xref>]. Vaccination remains a crucial preventive and responsive measure against FMD. The improvement of current vaccine platforms could help control outbreaks in endemic areas and contribute to the potential eradication of FMD, reducing the economic burden on farmers and enhancing livestock productivity. However, it is crucial to highlight that FMDV maintains a natural reservoir in the wild, specifically in the African buffalo, thereby increasing the likelihood of transmission events between wildlife and cattle. To effectively address this issue, it is imperative to implement additional mitigation strategies, such as regulating movement, enhancing sanitary measures, and administering vaccines.</p><p>FMDV exhibits remarkable replication efficiency in susceptible hosts (i.e., swine and cattle), and exposure to the virus leads to nearly 100% morbidity. Complete disease manifestation occurs within 2&#8211;5 days after infection, resulting in fever, vesicular lesions, and ulcers in various areas, such as the mouth, tongue, nostrils, muzzle, feet, and teats [<xref rid="B4-vaccines-12-01071" ref-type="bibr">4</xref>]. FMDV can be transmitted through respiratory, oral, or percutaneous routes [<xref rid="B5-vaccines-12-01071" ref-type="bibr">5</xref>], which contributes to its virulence, as it can influence the number of infected animals, the ease of spread between hosts, and the efficiency of viral replication in the target tissues of the infected host [<xref rid="B6-vaccines-12-01071" ref-type="bibr">6</xref>]. This swift dynamic of infection depends on several factors, including but not limited to the presence of the cellular receptor, the intrinsic viral replication capacity, and the effectiveness of specific viral proteins to counteract the host immune response.</p><p>FMD viral virulence, as with other viruses, can be defined as &#8220;the ability to cause disease in an infected host&#8221; [<xref rid="B7-vaccines-12-01071" ref-type="bibr">7</xref>]. Considering the error-prone nature of viral RNA-dependent RNA polymerases, various genetically related FMDV variants (quasispecies) can emerge, each with different degrees of virulence [<xref rid="B8-vaccines-12-01071" ref-type="bibr">8</xref>]. This genomic variability can influence FMDV virulence across factors, such as the viral serotype/strain, host species, tissues, viral load, route of exposure, and the ability to evade the host&#8217;s immune system. Understanding these factors is critical for the development of vaccines to control FMD. In this review, we focus on the molecular features encoded in the FMDV genome and its evolutionary pathway for improving immune evasion strategies with the aim of enhancing the design and development of vaccines (<xref rid="vaccines-12-01071-t001" ref-type="table">Table 1</xref>).</p></sec><sec id="sec2-vaccines-12-01071"><title>2. Virulence Factors of FMDV and Their Roles in Immune Evasion</title><p>FMDV has evolved a cost-effective genome size strategy, referred to as &#8220;genomic economy&#8221; [<xref rid="B61-vaccines-12-01071" ref-type="bibr">61</xref>], allowing almost every region of its genome to fulfill specific functions within the virus life cycle. Various functions, including host cell entry, replication, and the blocking of host cell immune responses, are efficiently encoded in the compact genomic space contained within the icosahedron structure of FMDV. Recent in vitro studies have shown the diverse roles of FMDV non-coding regions (NCR), non-structural proteins (NSP), and structural proteins (SPs) in blocking immune responses at multiple levels [<xref rid="B62-vaccines-12-01071" ref-type="bibr">62</xref>,<xref rid="B63-vaccines-12-01071" ref-type="bibr">63</xref>]. This section analyzes the studies on viral determinants that shape the virulence of FMDV, highlighting how these research efforts have played a role in enhancing the development of more effective countermeasures against FMD. Refer to <xref rid="vaccines-12-01071-f001" ref-type="fig">Figure 1</xref> for a visual representation of the various regions of the FMDV genome discussed throughout this section.</p><sec id="sec2dot1-vaccines-12-01071"><title>2.1. Non-Coding Regions (NCRs)</title><p>The NCRs of FMDV including the 5&#8242; terminal S (short) fragment, the internal ribosome entry site (IRES), and the 3&#8242; NCR, house secondary RNA structures crucial for viral replication and translation. Various studies have highlighted that these non-coding segments can trigger an antiviral response when introduced independently into FMDV-susceptible cells and in an FMD mouse model [<xref rid="B64-vaccines-12-01071" ref-type="bibr">64</xref>]. This suggests that FMDV must employ additional mechanisms to evade the activation of antiviral responses during infection to ensure successful viral replication.</p><p>The initial RNA structure of the 5&#8242; NCR is the S fragment, which encompasses approximately 350 nt, and adopts a stem&#8211;loop conformation. Investigations aimed at unraveling the 5&#8242; NCR S fragment immunomodulatory functions have involved the introduction of deletions within the S fragment in the A24 cruzeiro (A24<sub>Cru</sub>) infectious clone. These manipulations yielded viable viruses displaying attenuating characteristics in vitro. Interestingly, a direct correlation was observed between the degree of the S fragment deletion in mutant viruses and their capacity to stimulate increased levels of IFN-&#946; mRNA and various ISG mRNA levels within infected cells [<xref rid="B57-vaccines-12-01071" ref-type="bibr">57</xref>]. Importantly, the inoculation of mice with FMDV S fragment-deleted mutants confirmed in vivo attenuation but still allowed the production of antibody responses that effectively protected the animals when challenged with the wild-type (WT) virus. Most recently, deletions within the S fragment combined with an amino acid insertion in Lpro were detected in a naturally arising viral strain, which led to a shift in viral tropism [<xref rid="B65-vaccines-12-01071" ref-type="bibr">65</xref>]. Specifically, this virus only induced disease in pigs and not in cattle. These studies underscore both the plasticity of the S fragment in driving virus evolution that changes FMDV virulence and the potential for manipulating this region to create attenuated FMDV strains.</p><p>Downstream of the S fragment is the polycytidine (polyC) tract, recognized as a &#8220;viral security&#8221; RNA element, which spans between 150 and 250 nt in length, with greater variability in lab and vaccine strains (reviewed in [<xref rid="B66-vaccines-12-01071" ref-type="bibr">66</xref>]). Initial investigations into the potential virulence-related functions of these segments were carried out in vitro, focusing on evaluating the importance of the polyC tract length [<xref rid="B21-vaccines-12-01071" ref-type="bibr">21</xref>,<xref rid="B67-vaccines-12-01071" ref-type="bibr">67</xref>,<xref rid="B68-vaccines-12-01071" ref-type="bibr">68</xref>]. In these investigations, it was observed that deletions or truncations of the polyC segment did not have a detectable impact on virus viability [<xref rid="B21-vaccines-12-01071" ref-type="bibr">21</xref>]; however, increasing or decreasing this fragment significantly reduced its virulence in mice and/or cattle [<xref rid="B67-vaccines-12-01071" ref-type="bibr">67</xref>]. Although in vitro studies have cast doubt on the presence of a direct correlation between the length of the polyC tract and FMDV virulence, in vivo studies have suggested that increases in the polyC tract of FMDV are associated with persistent infection in the nasopharyngeal mucosa in cattle [<xref rid="B69-vaccines-12-01071" ref-type="bibr">69</xref>]. However, further studies confirming whether a long polyC tract offers an advantage for persistent FMDV remain to be evaluated.</p><p>The pseudoknots (PKs) of FMDV, integral to the 5&#8217; NCR, typically occur in two to four tandem arrays, depending on the virus strain. Recent research has linked these PKs to the regulation of virus virulence; for instance, viruses with deletions in the PK region have shown an attenuated phenotype in bovine cells, but not in porcine cells, indicating a potential role for PKs in modulating viral host specificity [<xref rid="B70-vaccines-12-01071" ref-type="bibr">70</xref>]. Furthermore, viruses devoid of all PKs can still drive viral replication, although the production of infectious virions is compromised [<xref rid="B71-vaccines-12-01071" ref-type="bibr">71</xref>], suggesting a potential role of PKs in viral assembly due to the presence of a predicted packaging signal in this region [<xref rid="B72-vaccines-12-01071" ref-type="bibr">72</xref>]. These findings further highlight the multifaceted functions of FMDV pseudoknots in both replication and virion assembly.</p><p>The study of FMDV IRES virulence-related roles has proven challenging in in vivo contexts. However, through reverse genetics studies, the replacement of a single nucleotide (cytosine 351) within the FMDV IRES of serotypes A, Asia1, and O led to the creation of an attenuated virus that displayed immunoprotective features when assessed in mice, pigs, and cattle [<xref rid="B73-vaccines-12-01071" ref-type="bibr">73</xref>]. It is probable that alterations within specific IRES domains could impact the translation of the FMDV genome, driving the attenuation profiles of FMDV IRES mutants. This influence could compromise essential RNA&#8211;RNA interactions, as described by the interplay between FMDV IRES and 3&#8242; UTR [<xref rid="B74-vaccines-12-01071" ref-type="bibr">74</xref>,<xref rid="B75-vaccines-12-01071" ref-type="bibr">75</xref>,<xref rid="B76-vaccines-12-01071" ref-type="bibr">76</xref>]. Moreover, these modifications could disrupt the interactions between FMDV IRES and cellular proteins [<xref rid="B77-vaccines-12-01071" ref-type="bibr">77</xref>,<xref rid="B78-vaccines-12-01071" ref-type="bibr">78</xref>,<xref rid="B79-vaccines-12-01071" ref-type="bibr">79</xref>].</p></sec><sec id="sec2dot2-vaccines-12-01071"><title>2.2. Non-Structural Proteins (NSPs)</title><sec id="sec2dot2dot1-vaccines-12-01071"><title>2.2.1. Lpro</title><p>One of the most significant virulence factors identified in the FMDV genome is the leader (Lpro) coding region, which has been extensively studied through investigations involving deletions in this region in the context of the infectious clone [<xref rid="B80-vaccines-12-01071" ref-type="bibr">80</xref>]. FMDV Lpro is a papain-like protease (PLP) that effectively inhibits the cellular innate immune response, acting at both the transcriptional and translational levels. Through diverse mechanisms, Lpro effectively blocks the IFN response by targeting different cellular proteins (i.e., eIF4G, NF-kB, TBK, MDA5, ISG15, G3BP1/2, etc.) which have been described in detail elsewhere (reviewed in [<xref rid="B81-vaccines-12-01071" ref-type="bibr">81</xref>]). Thereby, modifications in the Lpro region, including full and partial deletions and/or amino acid substitutions, have proven to be a successful approach for creating attenuated strains with the potential to become effective modified live-attenuated (MLA) vaccines. For instance, the introduction of two specific amino acid mutations (I55A and L58A) in the SAP domain of Lpro in the A12 infectious clone (pRMC35) rendered a virus incapable of degrading NF-&#954;B, leading to increased expression of various cytokines when tested in vitro [<xref rid="B82-vaccines-12-01071" ref-type="bibr">82</xref>]. Most interestingly, the in vivo assessment of this mutant virus yielded a remarkable outcome: pigs inoculated with the mutant virus remained completely healthy, without any sign of illness, viremia, or virus shedding, even when exposed to doses 100 times higher than those required to induce disease with wild-type (WT) virus [<xref rid="B51-vaccines-12-01071" ref-type="bibr">51</xref>]. Other mutations in Lpro (i.e., W105A and H138L) have resulted in somewhat similar attenuating profiles, mainly when evaluated in vitro, in FMD mouse models, and/or in swine [<xref rid="B52-vaccines-12-01071" ref-type="bibr">52</xref>,<xref rid="B53-vaccines-12-01071" ref-type="bibr">53</xref>]. However, a shared concern with all these mutants is the risk of reverting to a virulent state due to the few changes made in their genomes.</p><p>Attenuated FMDV leaderless strains in the A12 and A24<sub>cru</sub> infectious clones have been studied for their virulence and evaluated in vaccine efficacy studies in pigs and cows [<xref rid="B83-vaccines-12-01071" ref-type="bibr">83</xref>,<xref rid="B84-vaccines-12-01071" ref-type="bibr">84</xref>]. These studies have shown promising results as potential vaccination platforms. Despite the reduced pathogenicity of the leaderless virus in swine and cattle [<xref rid="B85-vaccines-12-01071" ref-type="bibr">85</xref>], the modified virus was so attenuated that vaccinated animals were not completely protected against homologous wild-type (WT) virus challenge. However, the use of leaderless strains with other modifications, including the addition of restriction sites for capsid swapping and the incorporation of known DIVA (differentiating infected animals from vaccinated animals)-compatible antigen markers [<xref rid="B23-vaccines-12-01071" ref-type="bibr">23</xref>], is currently being developed as inactivated vaccine seeds to be formulated with adjuvants [<xref rid="B24-vaccines-12-01071" ref-type="bibr">24</xref>]. Together, these findings highlight the importance of Lpro to rationally design FMD vaccines.</p></sec><sec id="sec2dot2dot2-vaccines-12-01071"><title>2.2.2. 2B</title><p>The coding sequence for the 2B protein of FMDV is highly conserved across strains [<xref rid="B86-vaccines-12-01071" ref-type="bibr">86</xref>], and recent studies have characterized 2B as a viroporin, meaning it can insert into cellular membranes and oligomerize to form an ion-conducting pore [<xref rid="B87-vaccines-12-01071" ref-type="bibr">87</xref>,<xref rid="B88-vaccines-12-01071" ref-type="bibr">88</xref>]. Recent studies have suggested that 2B can function in suppressing immune responses.</p><p>Weerawardhana et al. [<xref rid="B89-vaccines-12-01071" ref-type="bibr">89</xref>] demonstrated that FMDV 2B targets type I interferon (IFN) responses by degrading important cytosolic sensors, such as RIG-I and MDA5. These sensors are vital for detecting viral RNA and initiating subsequent immune responses. Furthermore, FMDV 2B has been shown to impact other host proteins, like NLRP3, NOD2, and LGP2 [<xref rid="B90-vaccines-12-01071" ref-type="bibr">90</xref>,<xref rid="B91-vaccines-12-01071" ref-type="bibr">91</xref>,<xref rid="B92-vaccines-12-01071" ref-type="bibr">92</xref>], thus contributing to different ways to modulate the cellular immune response during viral replication.</p><p>Limited evidence exists regarding the potential impact of alterations in the 2B region on FMDV virulence or infectivity during natural infection. However, a study conducted by Nishi et al. in 2019 [<xref rid="B93-vaccines-12-01071" ref-type="bibr">93</xref>] showed that on two isolated strains of FMDV (O/JPN/2000 and O/JPN/2010), which were associated with outbreaks of varying disease severity in cattle, three non-synonymous mutations specifically located in the 2B region were identified. Whether these mutations affect FMDV 2B&#8217;s ability to block the host&#8217;s innate immune response remains to be determined.</p><p>In the context of vaccine development via genetic engineering, the use of FMDV 2B has shown promise in optimizing vaccine design when administered via the Adenovirus type 5 platform. The incorporation of FMDV 2B was found to improve efficacy [<xref rid="B31-vaccines-12-01071" ref-type="bibr">31</xref>]. Furthermore, FMDV 2B of serotype O has been linked to the induction of protective CD4+ and CD8+ T cell responses [<xref rid="B94-vaccines-12-01071" ref-type="bibr">94</xref>].</p></sec><sec id="sec2dot2dot3-vaccines-12-01071"><title>2.2.3. 2C</title><p>FMDV 2C, along with 2B, plays a crucial role in rearranging cell membranes during virus replication [<xref rid="B95-vaccines-12-01071" ref-type="bibr">95</xref>]. These rearrangements, also known as vesicularization, are essential for the formation of viral replication complexes during infection. FMDV 2C has been found to interact with distinct proteins, including vimentin and Beclin1, which are associated with cytoskeletal dynamics and autophagy processes, respectively [<xref rid="B96-vaccines-12-01071" ref-type="bibr">96</xref>,<xref rid="B97-vaccines-12-01071" ref-type="bibr">97</xref>]. Recently, in vitro experiments have shown that FMDV 2C can bind to a specific class of pattern recognition receptors (PRRs)&#8212;NOD2 [<xref rid="B91-vaccines-12-01071" ref-type="bibr">91</xref>]. The overexpression of FMDV 2C led to a significant decrease in NOD2 protein expression, highlighting its role in counteracting immune responses and its potential for immune evasion.</p><p>The virulence of FMDV may also be influenced by alterations in the coding sequence of the 2C protein. Importantly, certain substitutions in 2C, referred to as joker mutations, have been linked to enhanced viral fitness in diverse environments, including those influenced by antivirals like ribavirin and guanidinium chloride [<xref rid="B98-vaccines-12-01071" ref-type="bibr">98</xref>,<xref rid="B99-vaccines-12-01071" ref-type="bibr">99</xref>]. Supporting these observations, Yuan et al. [<xref rid="B100-vaccines-12-01071" ref-type="bibr">100</xref>] reported a unique substitution in 2C (T135I) that increased FMDV replication by stimulating viral RNA synthesis.</p></sec><sec id="sec2dot2dot4-vaccines-12-01071"><title>2.2.4. 3A</title><p>The FMDV 3A protein plays a crucial role in determining host tropism [<xref rid="B101-vaccines-12-01071" ref-type="bibr">101</xref>,<xref rid="B102-vaccines-12-01071" ref-type="bibr">102</xref>], with its interactions with vimentin influencing membrane association [<xref rid="B103-vaccines-12-01071" ref-type="bibr">103</xref>] and its modulation of ER interactions regulating host protein secretion [<xref rid="B104-vaccines-12-01071" ref-type="bibr">104</xref>]. Interestingly, strains with specific codon deletions in the 3A coding region showed reduced virulence in cattle, while maintaining a virulent phenotype in pigs [<xref rid="B102-vaccines-12-01071" ref-type="bibr">102</xref>,<xref rid="B105-vaccines-12-01071" ref-type="bibr">105</xref>]. These deletions did not block the virus from initiating the infection of the nasopharyngeal mucosa, much like virulent FMDV strains [<xref rid="B106-vaccines-12-01071" ref-type="bibr">106</xref>]. Alterations in the 3A protein can confer new adaptive phenotypes to FMDV, offering the potential for enhancing vaccine safety during production. Recent studies have shed light on the role of FMDV 3A in immune responses, revealing interactions with DDX56 [<xref rid="B107-vaccines-12-01071" ref-type="bibr">107</xref>], as well as its impact on antiviral pathways triggered by IFN-&#946; [<xref rid="B108-vaccines-12-01071" ref-type="bibr">108</xref>], RIG-I, and G3BP1 [<xref rid="B109-vaccines-12-01071" ref-type="bibr">109</xref>].</p></sec><sec id="sec2dot2dot5-vaccines-12-01071"><title>2.2.5. 3B</title><p>FMDV 3B (also referred to as VPg) is critical for viral replication. Unlike other picornaviruses, the FMDV genome encodes three analogous copies&#8212;3B1, 3B2, and 3B3 [<xref rid="B110-vaccines-12-01071" ref-type="bibr">110</xref>]&#8212;that are conserved in almost all FMDV isolates [<xref rid="B86-vaccines-12-01071" ref-type="bibr">86</xref>]. Additionally, the 3B protein plays a crucial role in viral pathogenesis by suppressing the host immune response. This is achieved by the interaction and inhibition of host antiviral proteins such as RIG-I, resulting in the suppression of IFN-&#946; and ISG expression [<xref rid="B111-vaccines-12-01071" ref-type="bibr">111</xref>].</p><p>Despite the observed conservation of all three 3Bs, genetic engineering has allowed the derivation of FMDV variants lacking one or featuring two non-functional 3B copies [<xref rid="B112-vaccines-12-01071" ref-type="bibr">112</xref>]. Interestingly, viruses lacking the first two 3B copies have exhibited a compromised ability to replicate in cell cultures and caused milder disease in pigs, suggesting that 3B may play a role in shaping the virus pathogenicity and host range [<xref rid="B113-vaccines-12-01071" ref-type="bibr">113</xref>]. Furthermore, mutations in FMDV 3B and 3D served as valuable negative antigenic markers in the development of a DIVA marker. This marker proved invaluable as a companion test for animals vaccinated with either an FMDV live attenuated vaccine candidate or inactivated vaccine lacking Lpro in the A24<sub>cru</sub> backbone [<xref rid="B23-vaccines-12-01071" ref-type="bibr">23</xref>,<xref rid="B24-vaccines-12-01071" ref-type="bibr">24</xref>].</p></sec><sec id="sec2dot2dot6-vaccines-12-01071"><title>2.2.6. 3C</title><p>FMDV 3C is a chymotrypsin-like cysteine protease required for the cleavage of the FMDV polyprotein into mature proteins. Additionally, it can cleave translation factors, specifically eIF4G and eIF4A [<xref rid="B114-vaccines-12-01071" ref-type="bibr">114</xref>], at later time points of infection, which can also contribute to the overall cellular shut-off of translation. Recently, the 3C protein has been demonstrated to impair the host&#8217;s innate immune responses during infection (reviewed in [<xref rid="B63-vaccines-12-01071" ref-type="bibr">63</xref>]). Most notably, 3C disrupts the JAK-STAT signaling pathway by preventing the STAT1/STAT2 nuclear translocation [<xref rid="B115-vaccines-12-01071" ref-type="bibr">115</xref>]; it can also induce the cleavage or degradation of NF-&#954;B essential modulator (NEMO) [<xref rid="B116-vaccines-12-01071" ref-type="bibr">116</xref>] and cytosolic RNA sensors like MDA-5 and RIG-I [<xref rid="B117-vaccines-12-01071" ref-type="bibr">117</xref>] and modulate the phosphorylation of key signaling molecules in NF-&#954;B signaling pathways and stress granule formation [<xref rid="B118-vaccines-12-01071" ref-type="bibr">118</xref>]. These functions were found to be dependent on the optimal protease activity of FMDV 3C, and any disruptions in 3C enzymatic activity, like substitutions in cysteine (i.e., C127T), can result in in vivo attenuation [<xref rid="B117-vaccines-12-01071" ref-type="bibr">117</xref>].</p></sec><sec id="sec2dot2dot7-vaccines-12-01071"><title>2.2.7. 3D</title><p>FMDV 3D serves as the RNA-dependent RNA polymerase (RdRNA pol) and orchestrates the synthesis of a complementary RNA strand using the viral RNA as a template [<xref rid="B62-vaccines-12-01071" ref-type="bibr">62</xref>]. Given its central role in viral replication, FMDV 3D has emerged as a key target for antiviral drug development.</p><p>Since FMDV 3D polymerase lacks a proofreading function, high mutation rates in its viral genome are expected. Indeed, this contributes to the rapid evolution of the virus, enabling it to overcome bottlenecks during intra-host transmission and adapt to fluctuating environments [<xref rid="B119-vaccines-12-01071" ref-type="bibr">119</xref>]. Therefore, modulation of 3D polymerase&#8217;s fidelity can be employed as a strategy to attenuate FMDV replication. Several studies have indeed demonstrated that both natural variations and targeted modifications of specific amino acids within the 3D protein can influence FMDV pathogenicity [<xref rid="B55-vaccines-12-01071" ref-type="bibr">55</xref>,<xref rid="B93-vaccines-12-01071" ref-type="bibr">93</xref>,<xref rid="B120-vaccines-12-01071" ref-type="bibr">120</xref>,<xref rid="B121-vaccines-12-01071" ref-type="bibr">121</xref>]. Notably, changes in 3D that result in altered RdRpol fidelity have been shown to attenuate viral replication in FMDV animal models [<xref rid="B55-vaccines-12-01071" ref-type="bibr">55</xref>]. This attenuation is a sought-after characteristic for the generation of safer and genetically stable vaccine strains. However, the following question arises: can we solely rely on the use of 3D fidelity variants for the development of FMDV vaccine candidates? While high-fidelity variants may hold promise due to their potential to minimize mutation rates [<xref rid="B122-vaccines-12-01071" ref-type="bibr">122</xref>], thereby reducing the likelihood of virulence, it may be prudent to integrate these with additional, established attenuating mutations to synergistically diminish the risk of reverting to a virulent FMDV.</p></sec></sec><sec id="sec2dot3-vaccines-12-01071"><title>2.3. Structural Proteins (SPs)</title><p>The structural proteins of FMDV play a critical role in its life cycle, including genome packaging, the assembly of viral particles, and entry into host cells to initiate infection. The P1 precursor protein is composed of all the necessary sequences for viral capsid formation. These capsids display a marked vulnerability to acidic conditions and elevated temperatures, which can cause them to disassemble [<xref rid="B17-vaccines-12-01071" ref-type="bibr">17</xref>,<xref rid="B123-vaccines-12-01071" ref-type="bibr">123</xref>]. Importantly, the degree of stability can vary among serotypes, with FMDV O, and SAT being the most unstable [<xref rid="B124-vaccines-12-01071" ref-type="bibr">124</xref>,<xref rid="B125-vaccines-12-01071" ref-type="bibr">125</xref>]. This is a consideration that is essential for the production of stable virus-like particles when developing them as a vaccine platform.</p><p>The most notable characteristic of the FMDV viral capsid is the G-H loop, located in residues 140&#8211;160 of the VP1, which contains a highly conserved arginine-glycine-aspartate (RGD) motif [<xref rid="B126-vaccines-12-01071" ref-type="bibr">126</xref>]. The VP1 G-H loop is a highly antigenic determinant of the virus, with synthetic peptides mimicking this sequence known to induce protective neutralizing antibody responses [<xref rid="B127-vaccines-12-01071" ref-type="bibr">127</xref>,<xref rid="B128-vaccines-12-01071" ref-type="bibr">128</xref>]. Additionally, the VP1 G-H loop is critical for the attachment to integrin receptors on host cells, which are essential for FMDV entry [<xref rid="B129-vaccines-12-01071" ref-type="bibr">129</xref>]. The dual function of this loop facilitates the evolution of the FMDV antigenicity and its specificity for host cells, a feature that significantly contributes to its ability to adapt to diverse selective pressures.</p><p>In addition to providing the basis for antigenic variation to escape antibody neutralization, FMDV structural proteins have also been implicated in the suppression of immune responses, at least in vitro. In a study by Zhang et al. [<xref rid="B130-vaccines-12-01071" ref-type="bibr">130</xref>], it was discovered that the structural protein VP1 interacts with the cellular kinase TLP2, prompting the ubiquitination and subsequent degradation of TLP2, which leads to the diminished expression of antiviral cytokines. Similarly, research by Li et al. (2016) demonstrated that VP3 interacts with the cellular adaptor protein VISA, blocking the IFN-&#946; signaling pathway [<xref rid="B131-vaccines-12-01071" ref-type="bibr">131</xref>]. These recent findings highlight the multifaceted role of FMDV structural proteins, which not only confer potent antigenicity and facilitate the evasion of antibody neutralization but also play a crucial role in modulating immune responses, particularly those driven by the innate immune system.</p></sec></sec><sec id="sec3-vaccines-12-01071"><title>3. Host Pathogenesis and Immune Response to Understand FMDV in In Vivo Immune Evasion Strategies</title><p>FMDV has a wide host range, with each animal species exhibiting slightly different variations in disease pathogenesis. Understanding the pathogenesis from the point of initial infection to the triggered local and systemic immune responses&#8212;both innate and adaptive&#8212;is key to grasping how the virus impacts various tissues. A deeper understanding of how FMDV evades immune defenses in economically relevant species, such as cattle and swine, is crucial. This knowledge is essential for the rational development of vaccine and control strategies, which are necessary for managing outbreaks and reducing the burden in endemic regions.</p></sec><sec id="sec4-vaccines-12-01071"><title>4. Pathogenesis</title><p>Although the gold standard for a successful FMD vaccine would be to use a universal vaccine effective across all species, marked differences in the pathogenesis among cattle and swine may require tailored vaccines. In cattle, the initial FMDV infection targets the lymphoid-associated epithelium of the nasopharyngeal mucosa [<xref rid="B6-vaccines-12-01071" ref-type="bibr">6</xref>,<xref rid="B132-vaccines-12-01071" ref-type="bibr">132</xref>], followed by a clinical phase in which the virus spreads systemically and multiplies in vesicular lesions at peripheral sites, including the oral mucosa and coronary bands of the feet [<xref rid="B132-vaccines-12-01071" ref-type="bibr">132</xref>]. By contrast, primary FMDV infection in pigs originates in the epithelial crypts of the oropharyngeal tonsils [<xref rid="B133-vaccines-12-01071" ref-type="bibr">133</xref>]. Although the initial site of infection differs anatomically between cattle and pigs, the micro-anatomic and phenotypic characteristics of the infected lymphoid-associated epithelium are strikingly similar in both host species; therefore, a vaccine that effectively induces robust mucosal immunity could provide early protection universally. A significant difference between cattle and swine is the carrier state&#8212;approximately 50% of cattle may harbor a prolonged subclinical persistent phase of infection, a phenomenon not observed in pigs [<xref rid="B134-vaccines-12-01071" ref-type="bibr">134</xref>,<xref rid="B135-vaccines-12-01071" ref-type="bibr">135</xref>]. During this carrier state, infectious FMDV remains confined to distinct regions of the lymphoid-associated epithelium of the nasopharyngeal mucosa, similar to the primary infection sites [<xref rid="B134-vaccines-12-01071" ref-type="bibr">134</xref>,<xref rid="B136-vaccines-12-01071" ref-type="bibr">136</xref>,<xref rid="B137-vaccines-12-01071" ref-type="bibr">137</xref>]. Targeting these mucosal sites could not only reduce transmission but also prevent long-term persistence in cattle. This approach mirrors strategies against other respiratory viruses like SARS-CoV2, in which vaccine formulations are being developed to stimulate local mucosal immunity, particularly in the nasopharyngeal tract, to limit viral replication and transmission [<xref rid="B138-vaccines-12-01071" ref-type="bibr">138</xref>].</p></sec><sec id="sec5-vaccines-12-01071"><title>5. Innate Immune Responses In Vivo</title><sec id="sec5dot1-vaccines-12-01071"><title>5.1. Cytokine Immune Response</title><p>Viral infections trigger the innate immune system, serving as the first line of defense, which involves various cytokines, including the production of interferons (IFNs). At the onset of FMDV infection in cattle, studies have shown mixed results regarding the local antiviral responses in the nasopharyngeal mucosa; some have indicated minimal changes in IFN expression [<xref rid="B6-vaccines-12-01071" ref-type="bibr">6</xref>,<xref rid="B106-vaccines-12-01071" ref-type="bibr">106</xref>,<xref rid="B132-vaccines-12-01071" ref-type="bibr">132</xref>,<xref rid="B139-vaccines-12-01071" ref-type="bibr">139</xref>,<xref rid="B140-vaccines-12-01071" ref-type="bibr">140</xref>]. Systemically, cattle exhibit a robust activation of type I and III IFNs during the clinical phase of FMD [<xref rid="B139-vaccines-12-01071" ref-type="bibr">139</xref>,<xref rid="B140-vaccines-12-01071" ref-type="bibr">140</xref>,<xref rid="B141-vaccines-12-01071" ref-type="bibr">141</xref>,<xref rid="B142-vaccines-12-01071" ref-type="bibr">142</xref>,<xref rid="B143-vaccines-12-01071" ref-type="bibr">143</xref>], along with increased expression of several immune-related genes (i.e., Mx-1, OAS-1, CXCL10, ISG15, OAS1, and RIG-I) in PBMCs [<xref rid="B144-vaccines-12-01071" ref-type="bibr">144</xref>]. By contrast, the systemic IFN response in swine varies with the FMDV serotype [<xref rid="B145-vaccines-12-01071" ref-type="bibr">145</xref>,<xref rid="B146-vaccines-12-01071" ref-type="bibr">146</xref>,<xref rid="B147-vaccines-12-01071" ref-type="bibr">147</xref>] and, in general, remains less understood. Moreover, FMDV infection influences other cytokines in both swine and cattle. The early phases of infection show a systemic decrease in pro-inflammatory cytokines (IL-1&#946;, IL-6, and TNF&#945;), accompanied by an increase in the anti-inflammatory cytokine IL-10 [<xref rid="B51-vaccines-12-01071" ref-type="bibr">51</xref>,<xref rid="B148-vaccines-12-01071" ref-type="bibr">148</xref>,<xref rid="B149-vaccines-12-01071" ref-type="bibr">149</xref>]. This shift most likely impacts the cellular immune response. Given that FMDV can block the IFN signaling pathway to replicate effectively, the prophylactic use of IFNs or other cytokines constitutes a possible route to rapidly block the virus after infection, and IFNs could also be formulated with FMD vaccines as adjuvants (reviewed in [<xref rid="B150-vaccines-12-01071" ref-type="bibr">150</xref>]).</p></sec><sec id="sec5dot2-vaccines-12-01071"><title>5.2. Cellular Immune Response</title><p>Following the initial FMDV infection, the virus encounters different cells of the innate immune system, including NK cells and antigen-presenting cells (APCs). This interaction occurs through the phagocytosis of infected epithelial cells [<xref rid="B151-vaccines-12-01071" ref-type="bibr">151</xref>] and/or direct contact with damaged infected tissue [<xref rid="B152-vaccines-12-01071" ref-type="bibr">152</xref>]. Additionally, macrophages (M&#966;) [<xref rid="B153-vaccines-12-01071" ref-type="bibr">153</xref>] and dendritic cells (DCs) can internalize FMDV via antibody complexes [<xref rid="B154-vaccines-12-01071" ref-type="bibr">154</xref>]. Understanding how FMDV affects these innate immune cells is critical for enhancing vaccine designs by improving early immune responses, innate to adaptive immunological transitions, antigen presentation, and cytokine environment.</p><p>Natural killer (NK) cells: In swine, NK cells decline after infection, possibly due to reduced cytokine levels (IL-2, IL-15, and IL-1 [<xref rid="B155-vaccines-12-01071" ref-type="bibr">155</xref>]). Conversely, bovine NK cells show enhanced cytotoxic activity against bovine epithelial cells in vitro [<xref rid="B156-vaccines-12-01071" ref-type="bibr">156</xref>]. Recent studies have highlighted the importance of NK cells in orchestrating a diverse immune response and facilitating B-cell interactions for pathogen-specific immunity [<xref rid="B157-vaccines-12-01071" ref-type="bibr">157</xref>]. Although early therapeutic targeting of NK cells has shown promise in viral infections like vaccinia viral infection [<xref rid="B158-vaccines-12-01071" ref-type="bibr">158</xref>], its application in vaccine strategies for FMDV and other livestock viruses remains unexplored.</p><p>Dendritic cells (DCs): DCs are critical in initiating primary immune responses, acting as a bridge between innate and adaptive immunity. These cells can be broadly classified into two main types: plasmacytoid DCs (pDCs), which specialize in the production of cytokines, most importantly type I and III IFNs, and conventional DCs (cDCs), known for being potent APCs [<xref rid="B159-vaccines-12-01071" ref-type="bibr">159</xref>]. In the clinical phase of FMDV infection, both cattle and swine cDCs are stimulated by the virus to produce IL-10, skewing the immune response towards a humoral rather than a T-cell mediated adaptive response [<xref rid="B160-vaccines-12-01071" ref-type="bibr">160</xref>,<xref rid="B161-vaccines-12-01071" ref-type="bibr">161</xref>], even when the FMDV infection of these cells is mostly abortive [<xref rid="B154-vaccines-12-01071" ref-type="bibr">154</xref>,<xref rid="B160-vaccines-12-01071" ref-type="bibr">160</xref>]. Furthermore, FMDV blocks the maturation of porcine DCs into cDCs [<xref rid="B160-vaccines-12-01071" ref-type="bibr">160</xref>], reducing their response to TLR ligands [<xref rid="B162-vaccines-12-01071" ref-type="bibr">162</xref>], and in the case of cattle, FMDV infection downregulates MHC-II expression and impairs exogenous antigen processing in all bovine cDC populations [<xref rid="B149-vaccines-12-01071" ref-type="bibr">149</xref>]. The impact of FMDV on pDCs varies between cattle and swine. In cattle, there was an increase in mature CD4+ MHC-II+ pDCs during FMDV infection, while immature CD4+ MHC-II- pDCs levels declined [<xref rid="B149-vaccines-12-01071" ref-type="bibr">149</xref>]. Conversely, swine experienced a depletion in pDCs in the peripheral blood, with the remaining cells producing less IFN&#945; upon ex vivo stimulation [<xref rid="B146-vaccines-12-01071" ref-type="bibr">146</xref>]. Tissue-resident Langerhans cells (LCs), a distinct subset of DCs located in the epidermis, are also affected by FMDV infection. Although FMDV infection of LCs is abortive [<xref rid="B163-vaccines-12-01071" ref-type="bibr">163</xref>], it still impairs their ability to produce IFN&#945; after ex vivo stimulation in infected swine [<xref rid="B162-vaccines-12-01071" ref-type="bibr">162</xref>]. In order to enhance the efficacy of vaccines, strategies that expedite the activation of DCs, especially resident DCs in mucosal tissues can be considered. Incorporating adjuvants that target the activation pathways of DCs&#8212;mainly through the induction/expression of cytokines and chemokines that regulate DC trafficking, such as MIP-3&#945; [<xref rid="B164-vaccines-12-01071" ref-type="bibr">164</xref>] and Flt3L [<xref rid="B165-vaccines-12-01071" ref-type="bibr">165</xref>]&#8212;could significantly improve vaccine performance.</p><p>Follicular DCs (FDCs), which reside in the lymphoid follicles of nearly all secondary lymphoid organs, are specialized in capturing and preserving antigens with their dendritic extensions [<xref rid="B166-vaccines-12-01071" ref-type="bibr">166</xref>]. Research involving cattle has indicated that FMDV can remain bound to FDCs within the lymphoid tissues even after the acute phase of infection has subsided [<xref rid="B167-vaccines-12-01071" ref-type="bibr">167</xref>]. Recent studies [<xref rid="B168-vaccines-12-01071" ref-type="bibr">168</xref>] have revealed that the proteins CR2 and CR1 play a role in this binding process, potentially influencing the retention of FMDV antigens on FDCs and the production of high-avidity and neutralizing antibodies. Further understanding of these interactions could lead to a more targeted approach in vaccine design.</p><p>Monocytes/M&#966;: these cells are essential for the rapid clearance of viruses at infection sites. In the case of FMDV, monocytes/M&#966; are susceptible to infection via antibody-dependent internalization. Although M&#966; FMDV infection is abortive, the virus remains infectious within these cells for up to 24 h, suggesting that M&#966; may act as disseminators of viable virions to distant sites of the body [<xref rid="B151-vaccines-12-01071" ref-type="bibr">151</xref>]. Studies on mouse models of FMDV [<xref rid="B169-vaccines-12-01071" ref-type="bibr">169</xref>] in which FMDV undergoes similar non-progressive replications in peritoneal M&#966;, as in swine [<xref rid="B170-vaccines-12-01071" ref-type="bibr">170</xref>], have shown that depleting M&#966; in vivo after vaccination drastically diminishes protection against FMDV challenges [<xref rid="B171-vaccines-12-01071" ref-type="bibr">171</xref>]. This underscores the importance of the M&#966; population in early protective immune responses to FMDV.</p><p>Overall, the evidence indicates that FMDV significantly influences different aspects of the innate immune response, displaying unique patterns across different natural host species, which helps make the virus a successful pathogen. Although further research is warranted, potential strategies are being considered and could be developed to counteract the virus effect and induce a better response of the innate immune system.</p></sec></sec><sec id="sec6-vaccines-12-01071"><title>6. Adaptive Immune Responses In Vivo</title><sec id="sec6dot1-vaccines-12-01071"><title>6.1. Humoral Immune Response</title><p>The humoral immune response plays a critical role in overcoming FMDV infection, with systemic neutralizing antibodies serving as key mediators for clearing the virus [<xref rid="B172-vaccines-12-01071" ref-type="bibr">172</xref>]. The rapid activation of B cells leads to early antibody response, as evidenced by detectable serum IgM within 3&#8211;4 days after infection in cattle, followed by peaks of IgA and then IgG within the following 1&#8211;2 weeks [<xref rid="B173-vaccines-12-01071" ref-type="bibr">173</xref>,<xref rid="B174-vaccines-12-01071" ref-type="bibr">174</xref>,<xref rid="B175-vaccines-12-01071" ref-type="bibr">175</xref>]. This response is not only systemic but also local, with antibodies detected in the oronasal and esophageal&#8211;pharyngeal regions as early as 4 days after aerosol exposure [<xref rid="B176-vaccines-12-01071" ref-type="bibr">176</xref>]. On the other hand, the local mucosal humoral immunity in swine is not as well characterized.</p><p>Increasing B-c-ell maturation and survival, along with promoting rapid isotype switching, could enhance vaccine efficacy and prevent carrier states in animals. Molecules such as B-cell-activating factor (BAFF) and a proliferation-inducing ligand (APRIL) are known to promote long-term B cell survival and maintain IgA and IgG responses [<xref rid="B177-vaccines-12-01071" ref-type="bibr">177</xref>,<xref rid="B178-vaccines-12-01071" ref-type="bibr">178</xref>]. Additionally, CD40 ligation enhances the expression of receptors that bind BAFF and APRIL [<xref rid="B179-vaccines-12-01071" ref-type="bibr">179</xref>], contributing to B-cell survival and function. These factors have shown promise as mucosal adjuvants against several infectious diseases. For instance, influenza and HIV vaccines incorporating some of these molecules in their design have elicited higher antibody titers and broader protection [<xref rid="B180-vaccines-12-01071" ref-type="bibr">180</xref>,<xref rid="B181-vaccines-12-01071" ref-type="bibr">181</xref>]. In livestock, Ad5 vectors expressing CD40L in combination with Porcine Reproductive and Respiratory Syndrome virus (PRRSV) antigens significantly reduce viremia in pigs [<xref rid="B182-vaccines-12-01071" ref-type="bibr">182</xref>]. Therefore, the coadministration of these molecules with existing FMD vaccines could amplify the humoral response, particularly at mucosal sites, potentially overcoming the challenge of the carrier status among cattle and other ruminants.</p></sec><sec id="sec6dot2-vaccines-12-01071"><title>6.2. Cellular Immune Response</title><p>FMDV infection can also impact T-cell dynamics, affecting both alpha-beta (&#945;&#946;) and gamma-delta (&#947;&#948;) T-cell lineages. Early during FMDV infection, there is a transient lymphopenia in both cattle and swine, with an impairment in &#945;&#946; T cell function, persisting beyond the initial lymphopenia phase [<xref rid="B160-vaccines-12-01071" ref-type="bibr">160</xref>,<xref rid="B183-vaccines-12-01071" ref-type="bibr">183</xref>]. Contrary to earlier beliefs, apoptosis is not the cause of this lymphopenia [<xref rid="B183-vaccines-12-01071" ref-type="bibr">183</xref>,<xref rid="B184-vaccines-12-01071" ref-type="bibr">184</xref>]; instead, elevated IL-10 levels during infection may be implicated [<xref rid="B149-vaccines-12-01071" ref-type="bibr">149</xref>,<xref rid="B160-vaccines-12-01071" ref-type="bibr">160</xref>]. Recent studies using IL-10 knockout mice have shown that blocking the IL-10 signaling pathway can prevent lymphopenia by reducing apoptosis and altering lymphocyte trafficking and co-inhibitory expression, thereby enhancing survival in FMDV-infected mice [<xref rid="B185-vaccines-12-01071" ref-type="bibr">185</xref>]. On the other hand, the response of &#947;&#948; T cells during FMDV infection is slightly different. In cattle, WC1<sup>+</sup> &#947;&#948; T cells exhibit an activated phenotype, with changes in surface markers and increased IFN&#947; expression after FMDV infection [<xref rid="B155-vaccines-12-01071" ref-type="bibr">155</xref>], potentially acting as APCs [<xref rid="B186-vaccines-12-01071" ref-type="bibr">186</xref>]. However, more studies are needed to determine whether the changes observed in this cell population are the result of direct virus&#8211;cell interactions or a bystander consequence.</p><p>Despite species-specific responses to FMDV, the virus generally induces an immunosuppressive environment favoring a Th2 cell/cytokine-like environment that induces a strong neutralizing antibody response. Enhancing a T-cell response through vaccination strategies could thus improve protection. Importantly, highly interspecies MHC-restricted Th lymphocyte epitopes have been identified within the FMDV genome, such as the VP4 structural protein segment [<xref rid="B187-vaccines-12-01071" ref-type="bibr">187</xref>], 3D, and 3A [<xref rid="B187-vaccines-12-01071" ref-type="bibr">187</xref>,<xref rid="B188-vaccines-12-01071" ref-type="bibr">188</xref>]. Vaccine research is actively exploring platforms that incorporate these epitopes or employ adjuvants to enhance T-cell-mediated immune responses. Some of these will be discussed in depth in <xref rid="sec4-vaccines-12-01071" ref-type="sec">Section 4</xref>.</p></sec></sec><sec id="sec7-vaccines-12-01071"><title>7. Vaccine Design Strategies against FMDV</title><p>While some parts of the world are free from FMD, FMDV remains endemic throughout much of Africa and Southern Asia, where six of the seven identified serotypes persistently circulate [<xref rid="B189-vaccines-12-01071" ref-type="bibr">189</xref>]. In these areas, the primary control measure against the disease is the use of approved vaccines based on chemically inactivated FMDV strains. Meanwhile, South American regions have witnessed significant advancements in controlling FMD through diligent vaccination efforts [<xref rid="B190-vaccines-12-01071" ref-type="bibr">190</xref>].</p><p>Globally, about 3 billion doses of FMD vaccines are used annually, mainly in China and South America [<xref rid="B191-vaccines-12-01071" ref-type="bibr">191</xref>]. These vaccines, primarily composed of binary ethyleneimine (BEI)-inactivated purified antigens depleted from viral NS proteins and combined with adjuvants, are available either as monovalent or multivalent formulations [<xref rid="B192-vaccines-12-01071" ref-type="bibr">192</xref>]. Despite their effectiveness in eradicating FMD in numerous regions and managing its spread in others, current vaccines are far from perfect. For instance, vaccine production requires expensive high-containment facilities due to the risk of viral escape, and the vaccine&#8217;s heat sensitivity demands a maintained cold chain to ensure viability from manufacture to administration [<xref rid="B192-vaccines-12-01071" ref-type="bibr">192</xref>,<xref rid="B193-vaccines-12-01071" ref-type="bibr">193</xref>]. Since there is little cross-protection between serotypes, matching between field and vaccine strains is critical for effective FMD control programs, and in some cases, new strain-specific vaccines must be developed by adapting field viruses to grow in cell culture [<xref rid="B10-vaccines-12-01071" ref-type="bibr">10</xref>]. While these vaccines are designed to prevent clinical disease, they do not completely inhibit viral replication in the nasopharynx, potentially leading to carrier animals that harbor the virus long-term [<xref rid="B136-vaccines-12-01071" ref-type="bibr">136</xref>,<xref rid="B194-vaccines-12-01071" ref-type="bibr">194</xref>]. Additionally, the DIVA characteristics of current vaccines rely on antigen purification strategies to minimize NS viral proteins [<xref rid="B195-vaccines-12-01071" ref-type="bibr">195</xref>]. Most importantly, a significant drawback is the seven-day period required for the vaccine to confer protective immunity [<xref rid="B11-vaccines-12-01071" ref-type="bibr">11</xref>,<xref rid="B196-vaccines-12-01071" ref-type="bibr">196</xref>,<xref rid="B197-vaccines-12-01071" ref-type="bibr">197</xref>], creating a vulnerability window in which rapid viral spread is possible, especially in FMD-free countries in which animals are fully susceptible to the virus.</p><p>Given these challenges, several groups throughout the world are dedicated to improving current vaccines and developing new platforms to address these gaps. In this section, we explore these innovative platforms, highlighting their benefits and constraints in the context of vaccine development (<xref rid="vaccines-12-01071-f002" ref-type="fig">Figure 2</xref>).</p><sec id="sec7dot1-vaccines-12-01071"><title>7.1. Inactivated Vaccine Platform</title><p>The inactivated vaccine for FMD is a crucial and effective platform in mitigating the disease. However, efforts are ongoing to enhance the current inactivated vaccine platform. Some of these efforts focus on developing more permissive cell lines to increase the production yields of vaccine strains, thereby reducing the need for the serotype-specific adaptation of FMDV vaccine seedstocks. This has been shown in recent reports by LaRocco et al. [<xref rid="B9-vaccines-12-01071" ref-type="bibr">9</xref>,<xref rid="B198-vaccines-12-01071" ref-type="bibr">198</xref>] and Harvey et al. [<xref rid="B10-vaccines-12-01071" ref-type="bibr">10</xref>], which have demonstrated that the overexpression of &#945;v&#946;6 integrin&#8212;a natural receptor for FMDV [<xref rid="B129-vaccines-12-01071" ref-type="bibr">129</xref>]&#8212;in cell lines can increase susceptibility to all FMDV serotypes. In parallel, there is a strong effort to improve capsid stability, which is critical for the effectiveness of vaccines since the strength of the immune response is proportional to the number of intact 146S particles in the vaccine [<xref rid="B199-vaccines-12-01071" ref-type="bibr">199</xref>]. One possibility is to introduce mutations in the capsid-coding region to produce virus particles that are more resistant to temperature fluctuations and changes in pH levels, with promising results recently reported [<xref rid="B15-vaccines-12-01071" ref-type="bibr">15</xref>,<xref rid="B16-vaccines-12-01071" ref-type="bibr">16</xref>,<xref rid="B17-vaccines-12-01071" ref-type="bibr">17</xref>,<xref rid="B18-vaccines-12-01071" ref-type="bibr">18</xref>,<xref rid="B200-vaccines-12-01071" ref-type="bibr">200</xref>]. Complementing these genetic strategies, advancements in vaccine formulation are also being evaluated. The use of stabilizers, such as trehalose, NaCl, and CuSO<sub>4</sub>&#903;5H<sub>2</sub>O, has shown promise in prolonging vaccine shelf-life [<xref rid="B201-vaccines-12-01071" ref-type="bibr">201</xref>,<xref rid="B202-vaccines-12-01071" ref-type="bibr">202</xref>].</p><p>Predicting the correct vaccine matching has always been an important topic [<xref rid="B203-vaccines-12-01071" ref-type="bibr">203</xref>,<xref rid="B204-vaccines-12-01071" ref-type="bibr">204</xref>], but it can cause significant delays in outbreak response. To mitigate this, a high-potency vaccine with a homologous potency of 6 PD50 (50% protective dose) is recommended during outbreaks (Brehm KE et al., 2008 [<xref rid="B11-vaccines-12-01071" ref-type="bibr">11</xref>]). Recent studies have explored protection offered by higher-potency FMD commercial vaccines and their ability to prevent disease spread (Dekker et al., 2020 [<xref rid="B12-vaccines-12-01071" ref-type="bibr">12</xref>]; Galdo Novo et al Vaccine, 2018 [<xref rid="B13-vaccines-12-01071" ref-type="bibr">13</xref>]; Fishbourne et al., 2017 [<xref rid="B14-vaccines-12-01071" ref-type="bibr">14</xref>]). Understanding cross-protection mechanisms is crucial for evaluating the performance of FMD vaccination in the field [<xref rid="B205-vaccines-12-01071" ref-type="bibr">205</xref>]. Research by Li et al. [<xref rid="B22-vaccines-12-01071" ref-type="bibr">22</xref>] demonstrated that a genetically modified FMDV vaccine, developed using full-length cDNA clones and incorporating amino acid changes in the most antigenic site of the virus, exhibited enhanced efficacy against the various FMDV O topotypes prevalent in China. This was observed when the vaccine was evaluated in pigs after the vaccine was inactivated and formulated with oil. This finding underscores the vaccine&#8217;s potential for broad cross-protection.</p><p>Furthermore, research is increasingly focusing on cross-protection in both mono- and multivalent vaccine formulations, with a particular interest in not only intra-serotypic variations [<xref rid="B12-vaccines-12-01071" ref-type="bibr">12</xref>,<xref rid="B206-vaccines-12-01071" ref-type="bibr">206</xref>,<xref rid="B207-vaccines-12-01071" ref-type="bibr">207</xref>,<xref rid="B208-vaccines-12-01071" ref-type="bibr">208</xref>] but also the development of evaluation methods that aim to highlight the qualitative measures of vaccine protection, particularly looking at the strength and specificity of vaccine-induced antibodies [<xref rid="B209-vaccines-12-01071" ref-type="bibr">209</xref>,<xref rid="B210-vaccines-12-01071" ref-type="bibr">210</xref>,<xref rid="B211-vaccines-12-01071" ref-type="bibr">211</xref>]. The generation of chimeric FMDVs with antigenic properties that can be engineered to display epitopes from diverse FMDV variants represents a possible path toward enhancing cross-protection, as demonstrated with viruses circulating in South Africa and China [<xref rid="B19-vaccines-12-01071" ref-type="bibr">19</xref>,<xref rid="B20-vaccines-12-01071" ref-type="bibr">20</xref>,<xref rid="B212-vaccines-12-01071" ref-type="bibr">212</xref>]. A step further in this concept is the creation of polyvalent vaccine antigens composed of mosaic proteins. These proteins are assembled from fragments of multiple natural sequences using a computational optimization method to maximize the representation of potential epitopes across various viral populations. This strategy, which was originally applied to influenza vaccines [<xref rid="B213-vaccines-12-01071" ref-type="bibr">213</xref>], is now being explored for the prevalent FMDV serotypes A, O, and Asia1, potentially leading to a more robust and comprehensive protective response against FMDV (personal communication). Notably, delivering vaccination strategies to endemic regions like Africa remains a challenge, with inactivated vaccines falling short of reaching optimal levels to control the disease [<xref rid="B214-vaccines-12-01071" ref-type="bibr">214</xref>]. The efficacy of an inactivated vaccine is significantly enhanced by the use of safe and effective adjuvants. Traditionally, the FMD vaccine has been combined with mineral oil adjuvants like Montanide<sup>&#174;</sup> ISA 201 or 206 (Seppic Inc., Castres, France), prepared as water-in-oil-in-water emulsions or aluminum-based (alum/saponin) adjuvants [<xref rid="B215-vaccines-12-01071" ref-type="bibr">215</xref>]. However, new investigations in this field are reporting important advancements, such as the development of Montanide ESSAI IMS D 12802 VG PR, which has demonstrated the capacity to shorten the time required to establish protection [<xref rid="B216-vaccines-12-01071" ref-type="bibr">216</xref>]. Other explored adjuvants, including CAvant <sup>&#174;</sup> SOE (CA V AC, Daejeon, Korea) [<xref rid="B217-vaccines-12-01071" ref-type="bibr">217</xref>], non-coding RNA [<xref rid="B218-vaccines-12-01071" ref-type="bibr">218</xref>], and a variety of natural Chinese medicine-based formulations [<xref rid="B219-vaccines-12-01071" ref-type="bibr">219</xref>,<xref rid="B220-vaccines-12-01071" ref-type="bibr">220</xref>], have recently been reported. For a more comprehensive overview of these developments, refer to reference [<xref rid="B221-vaccines-12-01071" ref-type="bibr">221</xref>].</p><p>Safety is paramount in the production of inactivated vaccines to prevent the escape of virulent strains from manufacturing facilities. This risk has led many countries to rely on imported vaccines rather than produce them domestically. Innovations in vaccine strain development&#8212;creating strains that are attenuated in animals yet viable in cell culture&#8212;may pave the way for safer, next-generation FMD-inactivated vaccines. Notably, a leaderless FMDV strain (see <xref rid="sec2-vaccines-12-01071" ref-type="sec">Section 2</xref> above) was removed from the United States Select Agent Program regulations in April 2018 (Centers for Disease Control Prevention, 2023, January, Attenuated Strains of USDA-only Select Agents Excluded, Section 121.3. <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.selectagents.gov/sat/exclusions/index.htm">https://www.selectagents.gov/sat/exclusions/index.htm</uri>, accessed on 20 August 2024); this represents a major step forward because it reduces the requirements for policies and procedures designed to maintain security. These strains are currently under development in the United States, aiming to produce high-potency vaccines that are fully DIVA-compatible. This progress holds the promise of enhancing biosecurity and self-reliance in the FMD vaccine supply.</p></sec><sec id="sec7dot2-vaccines-12-01071"><title>7.2. Virus-like Particle Vaccine Platform</title><p>Virus-like particles (VLPs) consist of viral structural proteins that self-assemble (empty capsids) within cells, resembling the live virus in appearance but lacking the capacity for replication. The VLP vaccine platform offers a clear advantage over the current vaccine by eliminating the need to grow infectious virus, thus reducing biosafety risks. VLPs, which preserve the virus structural immunogenicity needed to induce protective humoral immunity, are readily recognized by the immune system and can stimulate dendritic cells in the same way as inactivated FMDV [<xref rid="B222-vaccines-12-01071" ref-type="bibr">222</xref>]. There are generally two design approaches for VLP vaccines. Empty capsids can be produced within the vaccinated host from capsid genes carried by a viral vector (also called subunit vaccines) or in various culture systems, including bacteria, yeast, mammalian cells, insect cells, or plants, before being administered as a vaccine.</p><p>Efforts to develop subunit vaccines for FMDV have utilized a spectrum of viral vectors, including vaccinia virus [<xref rid="B25-vaccines-12-01071" ref-type="bibr">25</xref>], fowlpox virus [<xref rid="B26-vaccines-12-01071" ref-type="bibr">26</xref>], attenuated pseudorabies virus (PRV) [<xref rid="B27-vaccines-12-01071" ref-type="bibr">27</xref>] (219) or the single-cycle Semliki Forest virus (SFV) [<xref rid="B28-vaccines-12-01071" ref-type="bibr">28</xref>], and adenovirus (Ad5) [<xref rid="B29-vaccines-12-01071" ref-type="bibr">29</xref>], to induce protection against FMDV. The Ad5-FMD vaccine in particular is a licensed emergency-use vaccine in the US for FMD type A [<xref rid="B32-vaccines-12-01071" ref-type="bibr">32</xref>], and it has shown promise as an alternative to inactivated virus vaccines for worldwide use. This platform has demonstrated early protection in swine and cattle against different FMDV serotypes [<xref rid="B30-vaccines-12-01071" ref-type="bibr">30</xref>,<xref rid="B223-vaccines-12-01071" ref-type="bibr">223</xref>], with protection lasting for up to 42 days after vaccination [<xref rid="B224-vaccines-12-01071" ref-type="bibr">224</xref>]. The Ad5-FMD vaccine is distinguished by its safety profile, DIVA capabilities, and stability as well as the ability to eliminate the need for adapting field strains for vaccine production. However, the requirement for high doses to achieve protective responses makes production costly. Enhancements like adding the full-length 2B coding region to increase the synthesis of FMDV capsid proteins [<xref rid="B31-vaccines-12-01071" ref-type="bibr">31</xref>,<xref rid="B94-vaccines-12-01071" ref-type="bibr">94</xref>], inserting an extra RGD motif to the Ad5 fiber coding protein sequence for dendritic cell targeting [<xref rid="B225-vaccines-12-01071" ref-type="bibr">225</xref>], and formulating the vaccine with a synthetic double-stranded RNA stabilized with poly-L-lysine and carboxymethyl cellulose (polyICLC) [<xref rid="B226-vaccines-12-01071" ref-type="bibr">226</xref>] have proven to be successful strategies to enhance the potency of Ad5-FMD vaccines.</p><p>The most common bacteria expression system for the generation of FMDV VLPs is <italic toggle="yes">Escherichia coli</italic> [<xref rid="B39-vaccines-12-01071" ref-type="bibr">39</xref>,<xref rid="B227-vaccines-12-01071" ref-type="bibr">227</xref>], with other systems such as <italic toggle="yes">Salmonella typhimurium</italic> [<xref rid="B34-vaccines-12-01071" ref-type="bibr">34</xref>] and <italic toggle="yes">Lactococcus lactis</italic> [<xref rid="B35-vaccines-12-01071" ref-type="bibr">35</xref>] also reported. To enhance the immunogenicity and yield of these VLPs in swine, strategies such as amino acid substitutions have been employed to strengthen hydrophobic interactions within the capsid [<xref rid="B221-vaccines-12-01071" ref-type="bibr">221</xref>]. Additionally, yeasts, particularly <italic toggle="yes">Hansenula polymorpha</italic> [<xref rid="B228-vaccines-12-01071" ref-type="bibr">228</xref>] and <italic toggle="yes">Saccharomyces cerevisiae</italic> [<xref rid="B229-vaccines-12-01071" ref-type="bibr">229</xref>], have been utilized as an expression platform, with studies showing that FMDV VLPs produced in this yeast, when formulated with aluminum and CpG as adjuvants, are immunogenic [<xref rid="B228-vaccines-12-01071" ref-type="bibr">228</xref>]. Most recently, Song et al., 2024 [<xref rid="B40-vaccines-12-01071" ref-type="bibr">40</xref>] developed a VLP-based combined vaccine strategy targeting FMDV serotypes A and O as well as Seneca virus (SVA)&#8212;another picornavirus that affects livestock animals. These vaccines have shown the ability to induce strong neutralizing antibody responses in pigs, highlighting their broad-spectrum capabilities and cost-effective features.</p><p>Over the years, significant efforts have been made to produce VLPs in insect cells using the baculovirus expression system. Techniques to stabilize capsids and modify expression in this system have been refined, achieving protective responses in cattle [<xref rid="B19-vaccines-12-01071" ref-type="bibr">19</xref>,<xref rid="B37-vaccines-12-01071" ref-type="bibr">37</xref>,<xref rid="B38-vaccines-12-01071" ref-type="bibr">38</xref>]. Plant-based VLP expression is another innovative approach, as animals could be immunized by feeding them crops like alfalfa, tomato, or tobacco expressing the empty capsids. However, the effectiveness of this approach in the natural host remains to be demonstrated [<xref rid="B41-vaccines-12-01071" ref-type="bibr">41</xref>,<xref rid="B42-vaccines-12-01071" ref-type="bibr">42</xref>].</p><p>The expression of VLPs in mammalian cells has also become popular [<xref rid="B230-vaccines-12-01071" ref-type="bibr">230</xref>] for various reasons, including the ability to introduce accurate post-translational modifications, which are crucial for the structural integrity and function of proteins [<xref rid="B231-vaccines-12-01071" ref-type="bibr">231</xref>]. The ability to clone sequences from various FMDV serotypes into expression plasmids allows for rapid adaptation to newly emerging viral strains. This technology has been successfully applied to produce VLPs that confer protection in cattle and swine under experimental conditions [<xref rid="B43-vaccines-12-01071" ref-type="bibr">43</xref>], and the selection of the right adjuvant can have a great impact on the immunogenicity of the VLPs [<xref rid="B232-vaccines-12-01071" ref-type="bibr">232</xref>].</p></sec><sec id="sec7dot3-vaccines-12-01071"><title>7.3. Synthetic Peptide and DNA Vaccine Platforms</title><p>The rationale behind peptide-based vaccines is based on the accurate prediction of T-cell and B-cell epitopes that are known to elicit specific and protective immunity. This approach enables the engineering and refinement of epitope structures&#8212;mainly derived from immunodominant sequences&#8212;to increase their potential for inducing robust immune responses [<xref rid="B233-vaccines-12-01071" ref-type="bibr">233</xref>]. Furthermore, synthetic peptides offer a non-infectious alternative to conventional vaccines, with high stability and purity levels that can exceed 95%, providing a significant advantage over traditional inactivated vaccines. Multi-epitope-based vaccines have achieved success in pigs in China [<xref rid="B234-vaccines-12-01071" ref-type="bibr">234</xref>]; however, they have not been used in ruminants due to the limited efficacy observed in these species [<xref rid="B44-vaccines-12-01071" ref-type="bibr">44</xref>,<xref rid="B235-vaccines-12-01071" ref-type="bibr">235</xref>]. While the synthetic FMD peptide vaccine is extensively utilized in swine agriculture throughout China, there is a need to revise the peptide formulation to confer protection against emergent viral lineages. Notably, peptides typically have low immunogenicity, presenting a challenge for development. Innovative strategies to address these challenges, such as the use of multiple antigenic peptides (MAPs) or dendrimers (complex branched macromolecules with a peptide core attached to multiple epitopes), have shown promise. These structures, particularly when combined with a water-in-oil single-emulsion adjuvant, have successfully conferred protection in swine [<xref rid="B46-vaccines-12-01071" ref-type="bibr">46</xref>] and, to a lesser extent, in cattle [<xref rid="B47-vaccines-12-01071" ref-type="bibr">47</xref>], establishing them as potential candidates for a subunit DIVA vaccine against FMDV. Enhancing protection in cattle could be possible with the use of an adjuvant containing nanoliposomes, as described by Heshmati et al. [<xref rid="B236-vaccines-12-01071" ref-type="bibr">236</xref>] in small animal models. Other approaches to improve the effectiveness of this vaccine platform include the combinatorial use of adjuvants, such as the one provided by polyinosinic and polycytidylic acid (poly (I:C)) [<xref rid="B234-vaccines-12-01071" ref-type="bibr">234</xref>]. Most recently, the use of recombinant T4 phage nanoparticles displaying FMDV epitopes has shown potential as a cost-effective and highly immunogenic vaccine without the need for external adjuvants, offering a promising alternative [<xref rid="B237-vaccines-12-01071" ref-type="bibr">237</xref>].</p><p>Likewise, the DNA vaccine platform offers a safer alternative to inactivated vaccines, with DIVA properties and the flexibility for the rapid incorporation of sequences from emerging field strains, potentially expressing multiple antigenic sites from different serotypes. Additionally, DNA vaccines can be produced at a lower manufacturing cost and allow for adaptable design and construction. However, challenges remain regarding DNA stability and the level of antigen expression; large amounts of DNA and multiple inoculations are needed to induce a relatively low FMDV-specific neutralizing antibody response with variable protection levels [<xref rid="B49-vaccines-12-01071" ref-type="bibr">49</xref>,<xref rid="B238-vaccines-12-01071" ref-type="bibr">238</xref>,<xref rid="B239-vaccines-12-01071" ref-type="bibr">239</xref>]. Recent improvements include the co-expression of FMDV B and T-cell epitopes with an antiapoptotic protein (i.e., Bcl-xL), which improved the T-cell response in a mouse model for FMD [<xref rid="B50-vaccines-12-01071" ref-type="bibr">50</xref>]. Additionally, a DNA vaccine based on mannosylated chitosan nanoparticles (which are known to enhance intracellular transport) or a self-replicating gene vaccine was evaluated in guinea pigs, demonstrating substantial improvement in all the immunological parameters with enhanced protection [<xref rid="B240-vaccines-12-01071" ref-type="bibr">240</xref>,<xref rid="B241-vaccines-12-01071" ref-type="bibr">241</xref>]. Altogether, the applicability of these approaches will remain limited until studies with the natural host are performed.</p></sec><sec id="sec7dot4-vaccines-12-01071"><title>7.4. Modified Live-Attenuated Vaccine Platform</title><p>Modified live-attenuated vaccines (MLAVs) have played an important role in the eradication or near-eradication of various diseases in humans and animals [<xref rid="B242-vaccines-12-01071" ref-type="bibr">242</xref>,<xref rid="B243-vaccines-12-01071" ref-type="bibr">243</xref>]. These vaccines effectively mimic the natural immune response to viral infection, leading to rapid and long-lasting protection. Genetic engineering has enhanced our ability to generate attenuated strains by either deleting important regions of the viral genome or introducing mutations into known virulence genes. As previously noted (see the virulence factors section), various attenuated FMDV strains carrying deletions or modifications in Lpro have shown success as potential vaccine candidates.</p><p>Other efforts have involved the substitution of FMDV Lpro with that from another <italic toggle="yes">Aphtovirus</italic>, such as bovine rhinitis B virus (BRBV). This substitution resulted in the generation of a chimeric FMDV that showed an attenuated phenotype in cattle and induced protective immunity against challenge with wild-type homologous FMDV [<xref rid="B23-vaccines-12-01071" ref-type="bibr">23</xref>,<xref rid="B244-vaccines-12-01071" ref-type="bibr">244</xref>]. However, like the case of the FMDV SAP mutant (see virulence factor section), the possibility of reversion by recombination with circulating wild-type FMDV makes it a non-ideal candidate.</p><p>To enhance the safety profile of FMDV live-attenuated vaccine candidates and minimize the risk of reversion, codon deoptimization technology has been utilized to design attenuated strains. The recoding of the viral genome through codon deoptimization has been shown to increase CpG and UpA frequencies, which can enhance the engagement of innate immune responses and attenuate viral infections [<xref rid="B245-vaccines-12-01071" ref-type="bibr">245</xref>,<xref rid="B246-vaccines-12-01071" ref-type="bibr">246</xref>,<xref rid="B247-vaccines-12-01071" ref-type="bibr">247</xref>]. Initial research showed that the deoptimization of the P1 coding region resulted in severe attenuation in vitro and in vivo, with the induction of high titers of neutralizing antibodies in swine [<xref rid="B58-vaccines-12-01071" ref-type="bibr">58</xref>]. Although this approach led to a marked attenuation across various FMDV serotypes, it did not consistently induce a sufficiently robust adaptive immune response to confer protection [<xref rid="B60-vaccines-12-01071" ref-type="bibr">60</xref>]. A deeper understanding of the molecular determinants of attenuation when recoding the FMDV genome will aid in calibrating the optimal degree of attenuation. On the other hand, targeting more conserved regions of the FMDV genome for deoptimization could allow for the creation of a stable viral backbone. Such a backbone could be universally applied to generate chimeras with the P1 structural regions of different serotypes. Recent work by Diaz-San Segundo et al. [<xref rid="B59-vaccines-12-01071" ref-type="bibr">59</xref>] showed that the deoptimization of the non-structural P2/P3 regions is well-tolerated and triggers an adaptive immune response in both mice and swine. Interestingly, this approach, which includes DIVA markers, yielded a highly attenuated virus in cattle that also induced a strong protective immune response (manuscript in preparation), presenting an attractive platform for vaccine development. Nevertheless, additional research is required to evaluate the longevity of the immune response and to examine other safety parameters, such as the risk of recombination, before this strategy can be advanced as a commercial vaccine candidate.</p></sec><sec id="sec7dot5-vaccines-12-01071"><title>7.5. Potential Use of Novel Technologies</title><p>One of the most novel vaccine platforms recently developed is based on the use of messenger RNA (mRNA), which is quickly becoming a highly effective technology for producing vaccines and biomedical therapeutics for emerging infectious diseases. This is largely due to its short manufacturing lead time and economic scale-up production [<xref rid="B248-vaccines-12-01071" ref-type="bibr">248</xref>]. Unlike traditional vaccines, mRNA-based vaccines do not require an infectious virus or cell culture, overcoming several limitations [<xref rid="B249-vaccines-12-01071" ref-type="bibr">249</xref>]. To date, all mRNA vaccines against animal pathogens have been explored for the prevention of zoonoses, like rabies [<xref rid="B250-vaccines-12-01071" ref-type="bibr">250</xref>], tick-borne encephalitis [<xref rid="B251-vaccines-12-01071" ref-type="bibr">251</xref>], and Zika [<xref rid="B252-vaccines-12-01071" ref-type="bibr">252</xref>]. In the case of FMDV, early research showed that immunization with the full-length, genetically engineered FMDV mRNA could induce strong immune responses to FMDV in a mouse model, suggesting the potential for FMDV in natural hosts [<xref rid="B253-vaccines-12-01071" ref-type="bibr">253</xref>]. However, using the full-length viral genome presents the risk of infectivity in natural hosts. Since there is evidence that the empty capsid vaccine can be generated by the co-expression of the FMDV P1-2A capsid precursor plus the 3Cpro via baculovirus expression systems to effectively protect animals against FMDV [<xref rid="B254-vaccines-12-01071" ref-type="bibr">254</xref>], it is possible to speculate that a synthetic, thermostable modified RNA vaccine encoding the FMDV P1-2A and 3Cpro genes could be engineered to protect livestock from emerging FMD strains.</p><p>A promising technology based on the use of plasmid DNA-based FMDV minigenome was recently described [<xref rid="B255-vaccines-12-01071" ref-type="bibr">255</xref>]. When these plasmids are transfected into cells, they efficiently produce uncapped mRNAs in the cytoplasm, which then initiate the synthesis of viral genomic RNA-like molecules, leading to the creation of infectious FMDV. By applying a strategy similar to that used for mRNA vaccines, these minigenomes, which express only the FMDV P1-2A and 3Cpro genes, could be utilized to generate immunogenic FMDV VLPs tailored to distinct serotypes. However, further studies are needed to validate this approach.</p></sec></sec><sec sec-type="conclusions" id="sec8-vaccines-12-01071"><title>8. Conclusions and Future Directions</title><p>The search for effective FMDV vaccines is significantly challenged by the virus serotype diversity, including six circulating serotypes and numerous subtypes, each demanding tailored vaccines for each variant, as cross-protection is limited. This complexity is worsened by the virus&#8217;s broad host range and high mutation rates, which lead to the continuous generation of new variants that may resist the immunity provided by existing vaccines. Moreover, traditional vaccination protocols require frequent booster doses to sustain immunity, adding to the logistical and economic burdens. An additional concern is the potential for vaccinated cattle to become carriers, perpetuating virus transmission. The requirement of a cold chain to preserve most FMDV vaccines introduces further complications in terms of transport and storage, particularly in regions where FMD is endemic. Furthermore, existing vaccines do not align with DIVA capabilities, creating a significant problem for epidemiological surveillance and control efforts. To address these issues, efforts are underway to develop novel vaccine platforms, many of which show promising results in controlling FMDV. Beyond vaccination, effective disease control also requires robust surveillance programs, comprehensive economic analyses from governments, and the overcoming of educational and cultural barriers to enhance FMD management on a global scale. While these aspects are beyond the scope of this review, they are important to acknowledge</p><p>As we look to the future, it is imperative to develop next-generation FMDV vaccines that can overcome these hurdles. In the realm of vaccine innovation, LAVs have emerged as a promising approach, as they have historically paved the way for the successful control and eradication of various viruses, including yellow fever, Rinderpest, and several human respiratory viruses, such as measles and rubella [<xref rid="B242-vaccines-12-01071" ref-type="bibr">242</xref>,<xref rid="B243-vaccines-12-01071" ref-type="bibr">243</xref>,<xref rid="B256-vaccines-12-01071" ref-type="bibr">256</xref>,<xref rid="B257-vaccines-12-01071" ref-type="bibr">257</xref>]. These vaccines are known to elicit broader and long-lasting protective humoral and cell-mediated immunity due to their ability to replicate, which can engage the host mucosal along with systemic immune defenses. However, using this strategy for FMDV entails complexities surrounding safety and the inherent genetic stability of the virus, which must be addressed to ensure viability. Notably, in recent years, LAV candidates for FMDV with DIVA capabilities have been developed using codon deoptimization strategies, offering promising outcomes in experimental studies [<xref rid="B58-vaccines-12-01071" ref-type="bibr">58</xref>,<xref rid="B59-vaccines-12-01071" ref-type="bibr">59</xref>,<xref rid="B60-vaccines-12-01071" ref-type="bibr">60</xref>]. Ongoing studies are critical to evaluate the safety profile in multiple animal species and the broader applicability across multiple FMDV-susceptible species, refine strategies to achieve cross-protection against diverse serotypes, and evaluate the vaccine capacity to stimulate mucosal immunity. Before considering a particular LAV candidate, it is also essential to conduct studies on transmission from animals inoculated with LAV candidates to naive in-contact animals of the same species including wildlife species and under different experimental conditions reflecting livestock production environments. Additionally, the potential issue of recombination events between attenuated FMDV strains and wild-type strains must be addressed through in vivo studies. Government perspectives on implementing such a strategy may be cautious unless comprehensive safety studies are carried out.</p><p>A clear approach to overcoming safety concerns with vaccines is the use of subunits or VLPs, which have demonstrated encouraging outcomes. Advancements in the understanding of FMDV biology have enabled the identification of amino acids within the virus&#8217;s structural proteins that can be manipulated to increase thermostability, which can solve problems of storage and transport in countries where the disease is endemic. However, the use of these subunit- or VLP-based platforms often requires higher doses and multiple boost immunizations or supplementation with adjuvants to achieve the desired level of immunogenicity. Similarly, multi-epitope vaccines offer a dual advantage of safety and the potential to open the door toward the world of a &#8220;universal&#8221; vaccine. These vaccines can be tailored to provide protection against a wide range of serotypes and subtypes in a single dose. The concerted efforts of numerous research groups are dedicated to enhancing and refining this innovative platform [<xref rid="B258-vaccines-12-01071" ref-type="bibr">258</xref>,<xref rid="B259-vaccines-12-01071" ref-type="bibr">259</xref>].</p><p>Enhancing our understanding of the diverse immune compartments and the various immune cells that interact with FMDV or are stimulated by it during infections in swine and cattle, beginning at mucosal surfaces and subsequently spreading systemically, is essential for the informed development of vaccines or adjuvants. To this end, employing multi-omic strategies, such as transcriptomic and proteomic analyses, can deepen our insight into virus&#8211;host interactions. These approaches should provide valuable information about the changes in gene expression and protein profiles experienced by immune cells during infection or in response to vaccination.</p></sec></body><back><ack><title>Acknowledgments</title><p>We thank Teresa de los Santos for her meticulous review and invaluable feedback on this manuscript.</p></ack><fn-group><fn><p><bold>Disclaimer/Publisher&#8217;s Note:</bold> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p></fn></fn-group><notes><title>Author Contributions</title><p>Conceptualization, G.N.M. and F.D.S.S.; investigation, G.N.M. and F.D.S.S.; writing-original draft preparation, G.N.M. and F.D.S.S.; visualization, G.N.M. and F.D.S.S.; supervision, G.N.M.; project administration, G.N.M.; funding acquisition, G.N.M. All authors have read and agreed to the published version of the manuscript.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declared no conflicts of interest.</p></notes><ref-list><title>References</title><ref id="B1-vaccines-12-01071"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Paton</surname><given-names>D.J.</given-names></name><name name-style="western"><surname>Di Nardo</surname><given-names>A.</given-names></name><name name-style="western"><surname>Knowles</surname><given-names>N.J.</given-names></name><name name-style="western"><surname>Wadsworth</surname><given-names>J.</given-names></name><name name-style="western"><surname>Pituco</surname><given-names>E.M.</given-names></name><name name-style="western"><surname>Cosivi</surname><given-names>O.</given-names></name><name name-style="western"><surname>Rivera</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Kassimi</surname><given-names>L.B.</given-names></name><name name-style="western"><surname>Brocchi</surname><given-names>E.</given-names></name><name name-style="western"><surname>de Clercq</surname><given-names>K.</given-names></name><etal/></person-group><article-title>The history of foot-and-mouth disease virus serotype C: The first known extinct serotype?</article-title><source>Virus Evol.</source><year>2021</year><volume>7</volume><fpage>veab009</fpage><pub-id pub-id-type="doi">10.1093/ve/veab009</pub-id><pub-id pub-id-type="pmid">35186323</pub-id><pub-id pub-id-type="pmcid">PMC8102019</pub-id></element-citation></ref><ref id="B2-vaccines-12-01071"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yoon</surname><given-names>S.H.</given-names></name><name name-style="western"><surname>Park</surname><given-names>W.</given-names></name><name name-style="western"><surname>King</surname><given-names>D.P.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>H.</given-names></name></person-group><article-title>Phylogenomics and molecular evolution of foot-and-mouth disease virus</article-title><source>Mol. Cells</source><year>2011</year><volume>31</volume><fpage>413</fpage><lpage>421</lpage><pub-id pub-id-type="doi">10.1007/s10059-011-0249-6</pub-id><pub-id pub-id-type="pmid">21448588</pub-id><pub-id pub-id-type="pmcid">PMC3887601</pub-id></element-citation></ref><ref id="B3-vaccines-12-01071"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Grant</surname><given-names>C.F.J.</given-names></name><name name-style="western"><surname>Carr</surname><given-names>B.V.</given-names></name><name name-style="western"><surname>Kotecha</surname><given-names>A.</given-names></name><name name-style="western"><surname>van den Born</surname><given-names>E.</given-names></name><name name-style="western"><surname>Stuart</surname><given-names>D.I.</given-names></name><name name-style="western"><surname>Hammond</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Charleston</surname><given-names>B.</given-names></name></person-group><article-title>The B Cell Response to Foot-and-Mouth Disease Virus in Cattle following Sequential Vaccination with Multiple Serotypes</article-title><source>J. Virol.</source><year>2017</year><volume>91</volume><fpage>10</fpage><lpage>1128</lpage><pub-id pub-id-type="doi">10.1128/JVI.02157-16</pub-id><pub-id pub-id-type="pmid">28228594</pub-id><pub-id pub-id-type="pmcid">PMC5391442</pub-id></element-citation></ref><ref id="B4-vaccines-12-01071"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alexandersen</surname><given-names>S.</given-names></name><name name-style="western"><surname>Mowat</surname><given-names>N.</given-names></name></person-group><article-title>Foot-and-mouth disease: Host range and pathogenesis</article-title><source>Curr. Top. Microbiol. Immunol.</source><year>2005</year><volume>288</volume><fpage>9</fpage><lpage>42</lpage><pub-id pub-id-type="pmid">15648173</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/3-540-27109-0_2</pub-id></element-citation></ref><ref id="B5-vaccines-12-01071"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Paton</surname><given-names>D.J.</given-names></name><name name-style="western"><surname>Gubbins</surname><given-names>S.</given-names></name><name name-style="western"><surname>King</surname><given-names>D.P.</given-names></name></person-group><article-title>Understanding the transmission of foot-and-mouth disease virus at different scales</article-title><source>Curr. Opin. Virol.</source><year>2018</year><volume>28</volume><fpage>85</fpage><lpage>91</lpage><pub-id pub-id-type="doi">10.1016/j.coviro.2017.11.013</pub-id><pub-id pub-id-type="pmid">29245054</pub-id></element-citation></ref><ref id="B6-vaccines-12-01071"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Arzt</surname><given-names>J.</given-names></name><name name-style="western"><surname>Pacheco</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Rodriguez</surname><given-names>L.L.</given-names></name></person-group><article-title>The early pathogenesis of foot-and-mouth disease in cattle after aerosol inoculation. Identification of the nasopharynx as the primary site of infection</article-title><source>Vet. Pathol.</source><year>2010</year><volume>47</volume><fpage>1048</fpage><lpage>1063</lpage><pub-id pub-id-type="doi">10.1177/0300985810372509</pub-id><pub-id pub-id-type="pmid">20587691</pub-id></element-citation></ref><ref id="B7-vaccines-12-01071"><label>7.</label><element-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Nathanson</surname><given-names>N.</given-names></name><name name-style="western"><surname>Gonz&#225;lez-Scarano</surname><given-names>F.</given-names></name></person-group><article-title>Patterns of Infection: Unwanted Guests&#8212;Quick Visits and Extended Stays</article-title><source>Viral Pathogenesis</source><person-group person-group-type="editor"><name name-style="western"><surname>Katze</surname><given-names>M.G.</given-names></name><name name-style="western"><surname>Korth</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Law</surname><given-names>G.L.</given-names></name><name name-style="western"><surname>Nathanson</surname><given-names>N.</given-names></name></person-group><publisher-name>Academic Press</publisher-name><publisher-loc>New York, NY, USA</publisher-loc><year>2016</year><fpage>81</fpage><lpage>94</lpage></element-citation></ref><ref id="B8-vaccines-12-01071"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Domingo</surname><given-names>E.</given-names></name><name name-style="western"><surname>Garcia-Crespo</surname><given-names>C.</given-names></name><name name-style="western"><surname>Perales</surname><given-names>C.</given-names></name></person-group><article-title>Historical Perspective on the Discovery of the Quasispecies Concept</article-title><source>Annu. Rev. Virol.</source><year>2021</year><volume>8</volume><fpage>51</fpage><lpage>72</lpage><pub-id pub-id-type="doi">10.1146/annurev-virology-091919-105900</pub-id><pub-id pub-id-type="pmid">34586874</pub-id></element-citation></ref><ref id="B9-vaccines-12-01071"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>LaRocco</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ahmed</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Rodriguez-Calzada</surname><given-names>M.</given-names></name><name name-style="western"><surname>Azzinaro</surname><given-names>P.A.</given-names></name><name name-style="western"><surname>Barrette</surname><given-names>R.</given-names></name><name name-style="western"><surname>Krug</surname><given-names>P.</given-names></name><name name-style="western"><surname>Rodriguez</surname><given-names>L.L.</given-names></name><name name-style="western"><surname>de Los Santos</surname><given-names>T.</given-names></name><name name-style="western"><surname>Medina</surname><given-names>G.N.</given-names></name></person-group><article-title>An adventitious agent-free clonal cell line that is highly susceptible to foot -and-mouth disease virus</article-title><source>Biologicals</source><year>2021</year><volume>72</volume><fpage>33</fpage><lpage>41</lpage><pub-id pub-id-type="doi">10.1016/j.biologicals.2021.05.003</pub-id><pub-id pub-id-type="pmid">34092457</pub-id></element-citation></ref><ref id="B10-vaccines-12-01071"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Harvey</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Jackson</surname><given-names>B.</given-names></name><name name-style="western"><surname>Carr</surname><given-names>B.V.</given-names></name><name name-style="western"><surname>Childs</surname><given-names>K.</given-names></name><name name-style="western"><surname>Moffat</surname><given-names>K.</given-names></name><name name-style="western"><surname>Freimanis</surname><given-names>G.</given-names></name><name name-style="western"><surname>Tennakoon</surname><given-names>C.</given-names></name><name name-style="western"><surname>Juleff</surname><given-names>N.</given-names></name><name name-style="western"><surname>Seago</surname><given-names>J.</given-names></name></person-group><article-title>An Improved alphavbeta6-Receptor-Expressing Suspension Cell Line for Foot-and-Mouth Disease Vaccine Production</article-title><source>Viruses</source><year>2022</year><volume>14</volume><elocation-id>621</elocation-id><pub-id pub-id-type="doi">10.3390/v14030621</pub-id><pub-id pub-id-type="pmid">35337028</pub-id><pub-id pub-id-type="pmcid">PMC8951101</pub-id></element-citation></ref><ref id="B11-vaccines-12-01071"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brehm</surname><given-names>K.E.</given-names></name><name name-style="western"><surname>Kumar</surname><given-names>N.</given-names></name><name name-style="western"><surname>Thulke</surname><given-names>H.H.</given-names></name><name name-style="western"><surname>Haas</surname><given-names>B.</given-names></name></person-group><article-title>High potency vaccines induce protection against heterologous challenge with foot-and-mouth disease virus</article-title><source>Vaccine</source><year>2008</year><volume>26</volume><fpage>1681</fpage><lpage>1687</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2008.01.038</pub-id><pub-id pub-id-type="pmid">18313814</pub-id></element-citation></ref><ref id="B12-vaccines-12-01071"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dekker</surname><given-names>A.</given-names></name><name name-style="western"><surname>Sanz-Bernardo</surname><given-names>B.</given-names></name><name name-style="western"><surname>Singanallur</surname><given-names>N.B.</given-names></name><name name-style="western"><surname>Ludi</surname><given-names>A.B.</given-names></name><name name-style="western"><surname>Horsington</surname><given-names>J.</given-names></name><name name-style="western"><surname>Eble</surname><given-names>P.L.</given-names></name><name name-style="western"><surname>King</surname><given-names>D.P.</given-names></name><name name-style="western"><surname>Vosloo</surname><given-names>W.</given-names></name></person-group><article-title>Cross-Protection Induced by a A/MAY/97 Emergency Vaccine Against Intra-Serotype Heterologous Challenge with a Foot-and-Mouth Disease Virus from the A/ASIA/G-VII Lineage</article-title><source>Vaccines</source><year>2020</year><volume>8</volume><elocation-id>24</elocation-id><pub-id pub-id-type="doi">10.3390/vaccines8010024</pub-id><pub-id pub-id-type="pmid">31947514</pub-id><pub-id pub-id-type="pmcid">PMC7157754</pub-id></element-citation></ref><ref id="B13-vaccines-12-01071"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Galdo Novo</surname><given-names>S.</given-names></name><name name-style="western"><surname>Malirat</surname><given-names>V.</given-names></name><name name-style="western"><surname>Maradei</surname><given-names>E.D.</given-names></name><name name-style="western"><surname>Pedemonte</surname><given-names>A.R.</given-names></name><name name-style="western"><surname>Espinoza</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Smitsaart</surname><given-names>E.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>K.N.</given-names></name><name name-style="western"><surname>Park</surname><given-names>J.H.</given-names></name><name name-style="western"><surname>Bergmann</surname><given-names>I.E.</given-names></name></person-group><article-title>Efficacy of a high quality O1/Campos foot-and-mouth disease vaccine upon challenge with a heterologous Korean O Mya98 lineage virus in pigs</article-title><source>Vaccine</source><year>2018</year><volume>36</volume><fpage>1570</fpage><lpage>1576</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2018.02.015</pub-id><pub-id pub-id-type="pmid">29472132</pub-id></element-citation></ref><ref id="B14-vaccines-12-01071"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fishbourne</surname><given-names>E.</given-names></name><name name-style="western"><surname>Ludi</surname><given-names>A.B.</given-names></name><name name-style="western"><surname>Wilsden</surname><given-names>G.</given-names></name><name name-style="western"><surname>Hamblin</surname><given-names>P.</given-names></name><name name-style="western"><surname>Statham</surname><given-names>B.</given-names></name><name name-style="western"><surname>Bin-Tarif</surname><given-names>A.</given-names></name><name name-style="western"><surname>Brocchi</surname><given-names>E.</given-names></name><name name-style="western"><surname>Grazioli</surname><given-names>S.</given-names></name><name name-style="western"><surname>Dekker</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ebl&#233;</surname><given-names>P.</given-names></name><etal/></person-group><article-title>Efficacy of a high potency O<sub>1</sub> Manisa foot-and-mouth disease vaccine in cattle against heterologous challenge with a field virus from the O/ME-SA/Ind-2001 lineage collected in North Africa</article-title><source>Vaccine</source><year>2017</year><volume>35</volume><fpage>2761</fpage><lpage>2765</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2017.02.047</pub-id><pub-id pub-id-type="pmid">28396208</pub-id></element-citation></ref><ref id="B15-vaccines-12-01071"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Scott</surname><given-names>K.A.</given-names></name><name name-style="western"><surname>Kotecha</surname><given-names>A.</given-names></name><name name-style="western"><surname>Seago</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ren</surname><given-names>J.</given-names></name><name name-style="western"><surname>Fry</surname><given-names>E.E.</given-names></name><name name-style="western"><surname>Stuart</surname><given-names>D.I.</given-names></name><name name-style="western"><surname>Charleston</surname><given-names>B.</given-names></name><name name-style="western"><surname>Maree</surname><given-names>F.F.</given-names></name></person-group><article-title>SAT2 Foot-and-Mouth Disease Virus Structurally Modified for Increased Thermostability</article-title><source>J. Virol.</source><year>2017</year><volume>91</volume><fpage>10</fpage><lpage>1128</lpage><pub-id pub-id-type="doi">10.1128/JVI.02312-16</pub-id><pub-id pub-id-type="pmid">28298597</pub-id><pub-id pub-id-type="pmcid">PMC5411616</pub-id></element-citation></ref><ref id="B16-vaccines-12-01071"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dong</surname><given-names>H.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Mu</surname><given-names>S.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>N.</given-names></name><name name-style="western"><surname>Du</surname><given-names>P.</given-names></name><name name-style="western"><surname>Zhi</surname><given-names>X.</given-names></name><name name-style="western"><surname>Wen</surname><given-names>X.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>S.</given-names></name><etal/></person-group><article-title>A Heat-Induced Mutation on VP1 of Foot-and-Mouth Disease Virus Serotype O Enhanced Capsid Stability and Immunogenicity</article-title><source>J. Virol.</source><year>2021</year><volume>95</volume><fpage>e0017721</fpage><pub-id pub-id-type="doi">10.1128/JVI.00177-21</pub-id><pub-id pub-id-type="pmid">34011545</pub-id><pub-id pub-id-type="pmcid">PMC8312871</pub-id></element-citation></ref><ref id="B17-vaccines-12-01071"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lopez-Arguello</surname><given-names>S.</given-names></name><name name-style="western"><surname>Rincon</surname><given-names>V.</given-names></name><name name-style="western"><surname>Rodriguez-Huete</surname><given-names>A.</given-names></name><name name-style="western"><surname>Martinez-Salas</surname><given-names>E.</given-names></name><name name-style="western"><surname>Belsham</surname><given-names>G.J.</given-names></name><name name-style="western"><surname>Valbuena</surname><given-names>A.</given-names></name><name name-style="western"><surname>Mateu</surname><given-names>M.G.</given-names></name></person-group><article-title>Thermostability of the Foot-and-Mouth Disease Virus Capsid Is Modulated by Lethal and Viability-Restoring Compensatory Amino Acid Substitutions</article-title><source>J. Virol.</source><year>2019</year><volume>93</volume><fpage>10</fpage><lpage>1128</lpage><pub-id pub-id-type="doi">10.1128/JVI.02293-18</pub-id><pub-id pub-id-type="pmcid">PMC6498042</pub-id><pub-id pub-id-type="pmid">30867300</pub-id></element-citation></ref><ref id="B18-vaccines-12-01071"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yuan</surname><given-names>H.</given-names></name><name name-style="western"><surname>Li</surname><given-names>P.</given-names></name><name name-style="western"><surname>Bao</surname><given-names>H.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>P.</given-names></name><name name-style="western"><surname>Bai</surname><given-names>X.</given-names></name><name name-style="western"><surname>Bai</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Li</surname><given-names>N.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>X.</given-names></name><name name-style="western"><surname>Cao</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Fu</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>Engineering viable foot-and-mouth disease viruses with increased acid stability facilitate the development of improved vaccines</article-title><source>Appl. Microbiol. Biotechnol.</source><year>2020</year><volume>104</volume><fpage>1683</fpage><lpage>1694</lpage><pub-id pub-id-type="doi">10.1007/s00253-019-10280-9</pub-id><pub-id pub-id-type="pmid">31900553</pub-id><pub-id pub-id-type="pmcid">PMC6985056</pub-id></element-citation></ref><ref id="B19-vaccines-12-01071"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kotecha</surname><given-names>A.</given-names></name><name name-style="western"><surname>Perez-Martin</surname><given-names>E.</given-names></name><name name-style="western"><surname>Harvey</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>F.</given-names></name><name name-style="western"><surname>Ilca</surname><given-names>S.L.</given-names></name><name name-style="western"><surname>Fry</surname><given-names>E.E.</given-names></name><name name-style="western"><surname>Jackson</surname><given-names>B.</given-names></name><name name-style="western"><surname>Maree</surname><given-names>F.</given-names></name><name name-style="western"><surname>Scott</surname><given-names>K.</given-names></name><name name-style="western"><surname>Hecksel</surname><given-names>C.W.</given-names></name><etal/></person-group><article-title>Chimeric O1K foot-and-mouth disease virus with SAT2 outer capsid as an FMD vaccine candidate</article-title><source>Sci. Rep.</source><year>2018</year><volume>8</volume><elocation-id>13654</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-018-31856-x</pub-id><pub-id pub-id-type="pmid">30209254</pub-id><pub-id pub-id-type="pmcid">PMC6135822</pub-id></element-citation></ref><ref id="B20-vaccines-12-01071"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>P.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>S.</given-names></name><name name-style="western"><surname>Zha</surname><given-names>J.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>P.</given-names></name><name name-style="western"><surname>Li</surname><given-names>D.</given-names></name><name name-style="western"><surname>Bao</surname><given-names>H.</given-names></name><name name-style="western"><surname>Cao</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Bai</surname><given-names>X.</given-names></name><name name-style="western"><surname>Fu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>X.</given-names></name><etal/></person-group><article-title>Evaluation of immunogenicity and cross-reactive responses of vaccines prepared from two chimeric serotype O foot-and-mouth disease viruses in pigs and cattle</article-title><source>Vet. Res.</source><year>2022</year><volume>53</volume><fpage>56</fpage><pub-id pub-id-type="doi">10.1186/s13567-022-01072-7</pub-id><pub-id pub-id-type="pmid">35804412</pub-id><pub-id pub-id-type="pmcid">PMC9270804</pub-id></element-citation></ref><ref id="B21-vaccines-12-01071"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rieder</surname><given-names>E.</given-names></name><name name-style="western"><surname>Bunch</surname><given-names>T.</given-names></name><name name-style="western"><surname>Brown</surname><given-names>F.</given-names></name><name name-style="western"><surname>Mason</surname><given-names>P.W.</given-names></name></person-group><article-title>Genetically engineered foot-and-mouth disease viruses with poly(C) tracts of two nucleotides are virulent in mice</article-title><source>J. Virol.</source><year>1993</year><volume>67</volume><fpage>5139</fpage><lpage>5145</lpage><pub-id pub-id-type="doi">10.1128/jvi.67.9.5139-5145.1993</pub-id><pub-id pub-id-type="pmid">8394441</pub-id><pub-id pub-id-type="pmcid">PMC237911</pub-id></element-citation></ref><ref id="B22-vaccines-12-01071"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>P.</given-names></name><name name-style="western"><surname>Bai</surname><given-names>X.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>P.</given-names></name><name name-style="western"><surname>Li</surname><given-names>D.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Cao</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Fu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Bao</surname><given-names>H.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Xie</surname><given-names>B.</given-names></name><etal/></person-group><article-title>Evaluation of a genetically modified foot-and-mouth disease virus vaccine candidate generated by reverse genetics</article-title><source>BMC Vet. Res.</source><year>2012</year><volume>8</volume><elocation-id>57</elocation-id><pub-id pub-id-type="doi">10.1186/1746-6148-8-57</pub-id><pub-id pub-id-type="pmid">22591597</pub-id><pub-id pub-id-type="pmcid">PMC3488552</pub-id></element-citation></ref><ref id="B23-vaccines-12-01071"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Uddowla</surname><given-names>S.</given-names></name><name name-style="western"><surname>Hollister</surname><given-names>J.</given-names></name><name name-style="western"><surname>Pacheco</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Rodriguez</surname><given-names>L.L.</given-names></name><name name-style="western"><surname>Rieder</surname><given-names>E.</given-names></name></person-group><article-title>A safe foot-and-mouth disease vaccine platform with two negative markers for differentiating infected from vaccinated animals</article-title><source>J. Virol.</source><year>2012</year><volume>86</volume><fpage>11675</fpage><lpage>11685</lpage><pub-id pub-id-type="doi">10.1128/JVI.01254-12</pub-id><pub-id pub-id-type="pmid">22915802</pub-id><pub-id pub-id-type="pmcid">PMC3486329</pub-id></element-citation></ref><ref id="B24-vaccines-12-01071"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hardham</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Krug</surname><given-names>P.</given-names></name><name name-style="western"><surname>Pacheco</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Thompson</surname><given-names>J.</given-names></name><name name-style="western"><surname>Dominowski</surname><given-names>P.</given-names></name><name name-style="western"><surname>Moulin</surname><given-names>V.</given-names></name><name name-style="western"><surname>Gay</surname><given-names>C.G.</given-names></name><name name-style="western"><surname>Rodriguez</surname><given-names>L.L.</given-names></name><name name-style="western"><surname>Rieder</surname><given-names>E.</given-names></name></person-group><article-title>Novel Foot-and-Mouth Disease Vaccine Platform: Formulations for Safe and DIVA-Compatible FMD Vaccines With Improved Potency</article-title><source>Front. Vet. Sci.</source><year>2020</year><volume>7</volume><elocation-id>554305</elocation-id><pub-id pub-id-type="doi">10.3389/fvets.2020.554305</pub-id><pub-id pub-id-type="pmid">33088833</pub-id><pub-id pub-id-type="pmcid">PMC7544895</pub-id></element-citation></ref><ref id="B25-vaccines-12-01071"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Steigerwald</surname><given-names>R.</given-names></name><name name-style="western"><surname>Brake</surname><given-names>D.A.</given-names></name><name name-style="western"><surname>Barrera</surname><given-names>J.</given-names></name><name name-style="western"><surname>Schutta</surname><given-names>C.J.</given-names></name><name name-style="western"><surname>Kalla</surname><given-names>M.</given-names></name><name name-style="western"><surname>Wennier</surname><given-names>S.T.</given-names></name><name name-style="western"><surname>Volkmann</surname><given-names>A.</given-names></name><name name-style="western"><surname>Hurtle</surname><given-names>W.</given-names></name><name name-style="western"><surname>Clark</surname><given-names>B.A.</given-names></name><name name-style="western"><surname>Zurita</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Evaluation of modified Vaccinia Ankara-based vaccines against foot-and-mouth disease serotype A24 in cattle</article-title><source>Vaccine</source><year>2020</year><volume>38</volume><fpage>769</fpage><lpage>778</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2019.10.103</pub-id><pub-id pub-id-type="pmid">31718901</pub-id></element-citation></ref><ref id="B26-vaccines-12-01071"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ma</surname><given-names>M.</given-names></name><name name-style="western"><surname>Jin</surname><given-names>N.</given-names></name><name name-style="western"><surname>Shen</surname><given-names>G.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>G.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>H.J.</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>M.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Huo</surname><given-names>X.</given-names></name><name name-style="western"><surname>Jin</surname><given-names>M.</given-names></name><name name-style="western"><surname>Yin</surname><given-names>G.</given-names></name><etal/></person-group><article-title>Immune responses of swine inoculated with a recombinant fowlpox virus co-expressing P12A and 3C of FMDV and swine IL-18</article-title><source>Vet. Immunol. Immunopathol.</source><year>2008</year><volume>121</volume><fpage>1</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1016/j.vetimm.2007.06.029</pub-id><pub-id pub-id-type="pmid">17706296</pub-id></element-citation></ref><ref id="B27-vaccines-12-01071"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hong</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Qian</surname><given-names>P.</given-names></name><name name-style="western"><surname>Li</surname><given-names>X.M.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>X.L.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>H.C.</given-names></name></person-group><article-title>A recombinant pseudorabies virus co-expressing capsid proteins precursor P1-2A of FMDV and VP2 protein of porcine parvovirus: A trivalent vaccine candidate</article-title><source>Biotechnol. Lett.</source><year>2007</year><volume>29</volume><fpage>1677</fpage><lpage>1683</lpage><pub-id pub-id-type="doi">10.1007/s10529-007-9459-6</pub-id><pub-id pub-id-type="pmid">17628752</pub-id></element-citation></ref><ref id="B28-vaccines-12-01071"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gullberg</surname><given-names>M.</given-names></name><name name-style="western"><surname>Lohse</surname><given-names>L.</given-names></name><name name-style="western"><surname>Botner</surname><given-names>A.</given-names></name><name name-style="western"><surname>McInerney</surname><given-names>G.M.</given-names></name><name name-style="western"><surname>Burman</surname><given-names>A.</given-names></name><name name-style="western"><surname>Jackson</surname><given-names>T.</given-names></name><name name-style="western"><surname>Polacek</surname><given-names>C.</given-names></name><name name-style="western"><surname>Belsham</surname><given-names>G.J.</given-names></name></person-group><article-title>A Prime-Boost Vaccination Strategy in Cattle to Prevent Foot-and-Mouth Disease Using a &#8220;Single-Cycle&#8221; Alphavirus Vector and Empty Capsid Particles</article-title><source>PLoS ONE</source><year>2016</year><volume>11</volume><elocation-id>e0157435</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0157435</pub-id><pub-id pub-id-type="pmid">27294397</pub-id><pub-id pub-id-type="pmcid">PMC4905628</pub-id></element-citation></ref><ref id="B29-vaccines-12-01071"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mayr</surname><given-names>G.A.</given-names></name><name name-style="western"><surname>Chinsangaram</surname><given-names>J.</given-names></name><name name-style="western"><surname>Grubman</surname><given-names>M.J.</given-names></name></person-group><article-title>Development of replication-defective adenovirus serotype 5 containing the capsid and 3C protease coding regions of foot-and-mouth disease virus as a vaccine candidate</article-title><source>Virology</source><year>1999</year><volume>263</volume><fpage>496</fpage><lpage>506</lpage><pub-id pub-id-type="doi">10.1006/viro.1999.9940</pub-id><pub-id pub-id-type="pmid">10544121</pub-id></element-citation></ref><ref id="B30-vaccines-12-01071"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Moraes</surname><given-names>M.P.</given-names></name><name name-style="western"><surname>Mayr</surname><given-names>G.A.</given-names></name><name name-style="western"><surname>Mason</surname><given-names>P.W.</given-names></name><name name-style="western"><surname>Grubman</surname><given-names>M.J.</given-names></name></person-group><article-title>Early protection against homologous challenge after a single dose of replication-defective human adenovirus type 5 expressing capsid proteins of foot-and-mouth disease virus (FMDV) strain A24</article-title><source>Vaccine</source><year>2002</year><volume>20</volume><fpage>1631</fpage><lpage>1639</lpage><pub-id pub-id-type="doi">10.1016/S0264-410X(01)00483-2</pub-id><pub-id pub-id-type="pmid">11858872</pub-id></element-citation></ref><ref id="B31-vaccines-12-01071"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pena</surname><given-names>L.</given-names></name><name name-style="western"><surname>Moraes</surname><given-names>M.P.</given-names></name><name name-style="western"><surname>Koster</surname><given-names>M.</given-names></name><name name-style="western"><surname>Burrage</surname><given-names>T.</given-names></name><name name-style="western"><surname>Pacheco</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Segundo</surname><given-names>F.D.</given-names></name><name name-style="western"><surname>Grubman</surname><given-names>M.J.</given-names></name></person-group><article-title>Delivery of a foot-and-mouth disease virus empty capsid subunit antigen with nonstructural protein 2B improves protection of swine</article-title><source>Vaccine</source><year>2008</year><volume>26</volume><fpage>5689</fpage><lpage>5699</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2008.08.022</pub-id><pub-id pub-id-type="pmid">18762225</pub-id></element-citation></ref><ref id="B32-vaccines-12-01071"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Grubman</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Diaz-San Segundo</surname><given-names>F.</given-names></name><name name-style="western"><surname>Dias</surname><given-names>C.C.</given-names></name><name name-style="western"><surname>Moraes</surname><given-names>M.</given-names></name><name name-style="western"><surname>Perez-Martin</surname><given-names>E.</given-names></name><name name-style="western"><surname>de Los Santos</surname><given-names>T.</given-names></name></person-group><article-title>Use of replication-defective adenoviruses to develop vaccines and biotherapeutics against foot-and-mouth disease</article-title><source>Future Virol.</source><year>2012</year><volume>7</volume><fpage>12</fpage><pub-id pub-id-type="doi">10.2217/fvl.12.65</pub-id></element-citation></ref><ref id="B33-vaccines-12-01071"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schutta</surname><given-names>C.</given-names></name><name name-style="western"><surname>Barrera</surname><given-names>J.</given-names></name><name name-style="western"><surname>Pisano</surname><given-names>M.</given-names></name><name name-style="western"><surname>Zsak</surname><given-names>L.</given-names></name><name name-style="western"><surname>Grubman</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Mayr</surname><given-names>G.A.</given-names></name><name name-style="western"><surname>Moraes</surname><given-names>M.P.</given-names></name><name name-style="western"><surname>Kamicker</surname><given-names>B.J.</given-names></name><name name-style="western"><surname>Brake</surname><given-names>D.A.</given-names></name><name name-style="western"><surname>Ettyreddy</surname><given-names>D.</given-names></name><etal/></person-group><article-title>Multiple efficacy studies of an adenovirus-vectored foot-and-mouth disease virus serotype A24 subunit vaccine in cattle using homologous challenge</article-title><source>Vaccine</source><year>2016</year><volume>34</volume><fpage>3214</fpage><lpage>3220</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2015.12.018</pub-id><pub-id pub-id-type="pmid">26707216</pub-id></element-citation></ref><ref id="B34-vaccines-12-01071"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhi</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Ji</surname><given-names>H.J.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>H.</given-names></name><name name-style="western"><surname>Lim</surname><given-names>J.H.</given-names></name><name name-style="western"><surname>Byun</surname><given-names>E.B.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>W.S.</given-names></name><name name-style="western"><surname>Seo</surname><given-names>H.S.</given-names></name></person-group><article-title>Salmonella Vaccine Vector System for Foot-and-Mouth Disease Virus and Evaluation of Its Efficacy with Virus-Like Particles</article-title><source>Vaccines</source><year>2021</year><volume>9</volume><elocation-id>22</elocation-id><pub-id pub-id-type="doi">10.3390/vaccines9010022</pub-id><pub-id pub-id-type="pmid">33466461</pub-id><pub-id pub-id-type="pmcid">PMC7824887</pub-id></element-citation></ref><ref id="B35-vaccines-12-01071"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Qi</surname><given-names>L.</given-names></name><name name-style="western"><surname>Lv</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>P.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Pan</surname><given-names>L.</given-names></name></person-group><article-title>The immune response to a recombinant Lactococcus lactis oral vaccine against foot-and-mouth disease virus in mice</article-title><source>Biotechnol. Lett.</source><year>2020</year><volume>42</volume><fpage>1907</fpage><lpage>1917</lpage><pub-id pub-id-type="doi">10.1007/s10529-020-02900-6</pub-id><pub-id pub-id-type="pmid">32385744</pub-id><pub-id pub-id-type="pmcid">PMC7210100</pub-id></element-citation></ref><ref id="B36-vaccines-12-01071"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kotecha</surname><given-names>A.</given-names></name><name name-style="western"><surname>Seago</surname><given-names>J.</given-names></name><name name-style="western"><surname>Scott</surname><given-names>K.</given-names></name><name name-style="western"><surname>Burman</surname><given-names>A.</given-names></name><name name-style="western"><surname>Loureiro</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ren</surname><given-names>J.</given-names></name><name name-style="western"><surname>Porta</surname><given-names>C.</given-names></name><name name-style="western"><surname>Ginn</surname><given-names>H.M.</given-names></name><name name-style="western"><surname>Jackson</surname><given-names>T.</given-names></name><name name-style="western"><surname>Perez-Martin</surname><given-names>E.</given-names></name><etal/></person-group><article-title>Structure-based energetics of protein interfaces guides foot-and-mouth disease virus vaccine design</article-title><source>Nat. Struct. Mol. Biol.</source><year>2015</year><volume>22</volume><fpage>788</fpage><lpage>794</lpage><pub-id pub-id-type="doi">10.1038/nsmb.3096</pub-id><pub-id pub-id-type="pmid">26389739</pub-id><pub-id pub-id-type="pmcid">PMC5985953</pub-id></element-citation></ref><ref id="B37-vaccines-12-01071"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Porta</surname><given-names>C.</given-names></name><name name-style="western"><surname>Kotecha</surname><given-names>A.</given-names></name><name name-style="western"><surname>Burman</surname><given-names>A.</given-names></name><name name-style="western"><surname>Jackson</surname><given-names>T.</given-names></name><name name-style="western"><surname>Ren</surname><given-names>J.</given-names></name><name name-style="western"><surname>Loureiro</surname><given-names>S.</given-names></name><name name-style="western"><surname>Jones</surname><given-names>I.M.</given-names></name><name name-style="western"><surname>Fry</surname><given-names>E.E.</given-names></name><name name-style="western"><surname>Stuart</surname><given-names>D.I.</given-names></name><name name-style="western"><surname>Charleston</surname><given-names>B.</given-names></name></person-group><article-title>Rational engineering of recombinant picornavirus capsids to produce safe, protective vaccine antigen</article-title><source>PLoS Pathog.</source><year>2013</year><volume>9</volume><elocation-id>e1003255</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1003255</pub-id><pub-id pub-id-type="pmid">23544011</pub-id><pub-id pub-id-type="pmcid">PMC3609824</pub-id></element-citation></ref><ref id="B38-vaccines-12-01071"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ganji</surname><given-names>V.K.</given-names></name><name name-style="western"><surname>Biswal</surname><given-names>J.K.</given-names></name><name name-style="western"><surname>Lalzampuia</surname><given-names>H.</given-names></name><name name-style="western"><surname>Basagoudanavar</surname><given-names>S.H.</given-names></name><name name-style="western"><surname>Saravanan</surname><given-names>P.</given-names></name><name name-style="western"><surname>Tamil Selvan</surname><given-names>R.P.</given-names></name><name name-style="western"><surname>Umapathi</surname><given-names>V.</given-names></name><name name-style="western"><surname>Reddy</surname><given-names>G.R.</given-names></name><name name-style="western"><surname>Sanyal</surname><given-names>A.</given-names></name><name name-style="western"><surname>Dechamma</surname><given-names>H.J.</given-names></name></person-group><article-title>Mutation in the VP2 gene of P1-2A capsid protein increases the thermostability of virus-like particles of foot-and-mouth disease virus serotype O</article-title><source>Appl. Microbiol. Biotechnol.</source><year>2018</year><volume>102</volume><fpage>8883</fpage><lpage>8893</lpage><pub-id pub-id-type="doi">10.1007/s00253-018-9278-9</pub-id><pub-id pub-id-type="pmid">30136205</pub-id></element-citation></ref><ref id="B39-vaccines-12-01071"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xiao</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>H.Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Yin</surname><given-names>B.</given-names></name><name name-style="western"><surname>Lv</surname><given-names>C.</given-names></name><name name-style="western"><surname>Mo</surname><given-names>X.</given-names></name><name name-style="western"><surname>Yan</surname><given-names>H.</given-names></name><name name-style="western"><surname>Xuan</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Pang</surname><given-names>W.</given-names></name><etal/></person-group><article-title>Large-scale production of foot-and-mouth disease virus (serotype Asia1) VLP vaccine in <italic toggle="yes">Escherichia coli</italic> and protection potency evaluation in cattle</article-title><source>BMC Biotechnol.</source><year>2016</year><volume>16</volume><elocation-id>56</elocation-id><pub-id pub-id-type="doi">10.1186/s12896-016-0285-6</pub-id><pub-id pub-id-type="pmid">27371162</pub-id><pub-id pub-id-type="pmcid">PMC4930597</pub-id></element-citation></ref><ref id="B40-vaccines-12-01071"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Song</surname><given-names>H.</given-names></name><name name-style="western"><surname>Waheed Abdullah</surname><given-names>S.</given-names></name><name name-style="western"><surname>Yin</surname><given-names>S.</given-names></name><name name-style="western"><surname>Dong</surname><given-names>H.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Tan</surname><given-names>S.</given-names></name><name name-style="western"><surname>Bai</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ding</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Teng</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Virus-like particle-based multipathogen vaccine of FMD and SVA elicits balanced and broad protective efficacy in mice and pigs</article-title><source>Vaccine</source><year>2024</year><volume>42</volume><fpage>3789</fpage><lpage>3801</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2024.04.092</pub-id><pub-id pub-id-type="pmid">38714448</pub-id></element-citation></ref><ref id="B41-vaccines-12-01071"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dus Santos</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Carrillo</surname><given-names>C.</given-names></name><name name-style="western"><surname>Ardila</surname><given-names>F.</given-names></name><name name-style="western"><surname>Rios</surname><given-names>R.D.</given-names></name><name name-style="western"><surname>Franzone</surname><given-names>P.</given-names></name><name name-style="western"><surname>Piccone</surname><given-names>M.E.</given-names></name><name name-style="western"><surname>Wigdorovitz</surname><given-names>A.</given-names></name><name name-style="western"><surname>Borca</surname><given-names>M.V.</given-names></name></person-group><article-title>Development of transgenic alfalfa plants containing the foot and mouth disease virus structural polyprotein gene P1 and its utilization as an experimental immunogen</article-title><source>Vaccine</source><year>2005</year><volume>23</volume><fpage>1838</fpage><lpage>1843</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2004.11.014</pub-id><pub-id pub-id-type="pmid">15734052</pub-id></element-citation></ref><ref id="B42-vaccines-12-01071"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Veerapen</surname><given-names>V.P.</given-names></name><name name-style="western"><surname>van Zyl</surname><given-names>A.R.</given-names></name><name name-style="western"><surname>Wigdorovitz</surname><given-names>A.</given-names></name><name name-style="western"><surname>Rybicki</surname><given-names>E.P.</given-names></name><name name-style="western"><surname>Meyers</surname><given-names>A.E.</given-names></name></person-group><article-title>Novel expression of immunogenic foot-and-mouth disease virus-like particles in Nicotiana benthamiana</article-title><source>Virus Res.</source><year>2017</year><volume>244</volume><fpage>213</fpage><lpage>217</lpage><pub-id pub-id-type="doi">10.1016/j.virusres.2017.11.027</pub-id><pub-id pub-id-type="pmid">29196195</pub-id></element-citation></ref><ref id="B43-vaccines-12-01071"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Puckette</surname><given-names>M.</given-names></name><name name-style="western"><surname>Primavera</surname><given-names>V.</given-names></name><name name-style="western"><surname>Martel</surname><given-names>E.</given-names></name><name name-style="western"><surname>Barrera</surname><given-names>J.</given-names></name><name name-style="western"><surname>Hurtle</surname><given-names>W.</given-names></name><name name-style="western"><surname>Clark</surname><given-names>B.</given-names></name><name name-style="western"><surname>Kamicker</surname><given-names>B.</given-names></name><name name-style="western"><surname>Zurita</surname><given-names>M.</given-names></name><name name-style="western"><surname>Brake</surname><given-names>D.</given-names></name><name name-style="western"><surname>Neilan</surname><given-names>J.</given-names></name></person-group><article-title>Transiently Transfected Mammalian Cell Cultures: An Adaptable and Effective Platform for Virus-like Particle-Based Vaccines against Foot-and-Mouth Disease Virus</article-title><source>Viruses</source><year>2022</year><volume>14</volume><elocation-id>989</elocation-id><pub-id pub-id-type="doi">10.3390/v14050989</pub-id><pub-id pub-id-type="pmid">35632734</pub-id><pub-id pub-id-type="pmcid">PMC9147724</pub-id></element-citation></ref><ref id="B44-vaccines-12-01071"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>C.Y.</given-names></name><name name-style="western"><surname>Chang</surname><given-names>T.Y.</given-names></name><name name-style="western"><surname>Walfield</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Ye</surname><given-names>J.</given-names></name><name name-style="western"><surname>Shen</surname><given-names>M.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>S.P.</given-names></name><name name-style="western"><surname>Li</surname><given-names>M.C.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>Y.L.</given-names></name><name name-style="western"><surname>Jong</surname><given-names>M.H.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>P.C.</given-names></name><etal/></person-group><article-title>Effective synthetic peptide vaccine for foot-and-mouth disease in swine</article-title><source>Vaccine</source><year>2002</year><volume>20</volume><fpage>2603</fpage><lpage>2610</lpage><pub-id pub-id-type="doi">10.1016/S0264-410X(02)00148-2</pub-id><pub-id pub-id-type="pmid">12057619</pub-id></element-citation></ref><ref id="B45-vaccines-12-01071"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rodriguez</surname><given-names>L.L.</given-names></name><name name-style="western"><surname>Barrera</surname><given-names>J.</given-names></name><name name-style="western"><surname>Kramer</surname><given-names>E.</given-names></name><name name-style="western"><surname>Lubroth</surname><given-names>J.</given-names></name><name name-style="western"><surname>Brown</surname><given-names>F.</given-names></name><name name-style="western"><surname>Golde</surname><given-names>W.T.</given-names></name></person-group><article-title>A synthetic peptide containing the consensus sequence of the G-H loop region of foot-and-mouth disease virus type-O VP1 and a promiscuous T-helper epitope induces peptide-specific antibodies but fails to protect cattle against viral challenge</article-title><source>Vaccine</source><year>2003</year><volume>21</volume><fpage>3751</fpage><lpage>3756</lpage><pub-id pub-id-type="doi">10.1016/S0264-410X(03)00364-5</pub-id><pub-id pub-id-type="pmid">12922108</pub-id></element-citation></ref><ref id="B46-vaccines-12-01071"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Blanco</surname><given-names>E.</given-names></name><name name-style="western"><surname>Guerra</surname><given-names>B.</given-names></name><name name-style="western"><surname>de la Torre</surname><given-names>B.G.</given-names></name><name name-style="western"><surname>Defaus</surname><given-names>S.</given-names></name><name name-style="western"><surname>Dekker</surname><given-names>A.</given-names></name><name name-style="western"><surname>Andreu</surname><given-names>D.</given-names></name><name name-style="western"><surname>Sobrino</surname><given-names>F.</given-names></name></person-group><article-title>Full protection of swine against foot-and-mouth disease by a bivalent B-cell epitope dendrimer peptide</article-title><source>Antivir. Res.</source><year>2016</year><volume>129</volume><fpage>74</fpage><lpage>80</lpage><pub-id pub-id-type="doi">10.1016/j.antiviral.2016.03.005</pub-id><pub-id pub-id-type="pmid">26956030</pub-id></element-citation></ref><ref id="B47-vaccines-12-01071"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Soria</surname><given-names>I.</given-names></name><name name-style="western"><surname>Quattrocchi</surname><given-names>V.</given-names></name><name name-style="western"><surname>Langellotti</surname><given-names>C.</given-names></name><name name-style="western"><surname>Gammella</surname><given-names>M.</given-names></name><name name-style="western"><surname>Digiacomo</surname><given-names>S.</given-names></name><name name-style="western"><surname>Garcia de la Torre</surname><given-names>B.</given-names></name><name name-style="western"><surname>Andreu</surname><given-names>D.</given-names></name><name name-style="western"><surname>Montoya</surname><given-names>M.</given-names></name><name name-style="western"><surname>Sobrino</surname><given-names>F.</given-names></name><name name-style="western"><surname>Blanco</surname><given-names>E.</given-names></name><etal/></person-group><article-title>Dendrimeric peptides can confer protection against foot-and-mouth disease virus in cattle</article-title><source>PLoS ONE</source><year>2017</year><volume>12</volume><elocation-id>e0185184</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0185184</pub-id><pub-id pub-id-type="pmid">28949998</pub-id><pub-id pub-id-type="pmcid">PMC5614567</pub-id></element-citation></ref><ref id="B48-vaccines-12-01071"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fowler</surname><given-names>V.</given-names></name><name name-style="western"><surname>Robinson</surname><given-names>L.</given-names></name><name name-style="western"><surname>Bankowski</surname><given-names>B.</given-names></name><name name-style="western"><surname>Cox</surname><given-names>S.</given-names></name><name name-style="western"><surname>Parida</surname><given-names>S.</given-names></name><name name-style="western"><surname>Lawlor</surname><given-names>C.</given-names></name><name name-style="western"><surname>Gibson</surname><given-names>D.</given-names></name><name name-style="western"><surname>O&#8217;Brien</surname><given-names>F.</given-names></name><name name-style="western"><surname>Ellefsen</surname><given-names>B.</given-names></name><name name-style="western"><surname>Hannaman</surname><given-names>D.</given-names></name><etal/></person-group><article-title>A DNA vaccination regime including protein boost and electroporation protects cattle against foot-and-mouth disease</article-title><source>Antivir. Res.</source><year>2012</year><volume>94</volume><fpage>25</fpage><lpage>34</lpage><pub-id pub-id-type="doi">10.1016/j.antiviral.2012.02.002</pub-id><pub-id pub-id-type="pmid">22330893</pub-id></element-citation></ref><ref id="B49-vaccines-12-01071"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Borrego</surname><given-names>B.</given-names></name><name name-style="western"><surname>Argilaguet</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Perez-Martin</surname><given-names>E.</given-names></name><name name-style="western"><surname>Dominguez</surname><given-names>J.</given-names></name><name name-style="western"><surname>Perez-Filgueira</surname><given-names>M.</given-names></name><name name-style="western"><surname>Escribano</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Sobrino</surname><given-names>F.</given-names></name><name name-style="western"><surname>Rodriguez</surname><given-names>F.</given-names></name></person-group><article-title>A DNA vaccine encoding foot-and-mouth disease virus B and T-cell epitopes targeted to class II swine leukocyte antigens protects pigs against viral challenge</article-title><source>Antivir. Res.</source><year>2011</year><volume>92</volume><fpage>359</fpage><lpage>363</lpage><pub-id pub-id-type="doi">10.1016/j.antiviral.2011.07.017</pub-id><pub-id pub-id-type="pmid">21820470</pub-id></element-citation></ref><ref id="B50-vaccines-12-01071"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gulce Iz</surname><given-names>S.</given-names></name><name name-style="western"><surname>Doskaya</surname><given-names>M.</given-names></name><name name-style="western"><surname>Borrego</surname><given-names>B.</given-names></name><name name-style="western"><surname>Rodriguez</surname><given-names>F.</given-names></name><name name-style="western"><surname>Guruz</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Gurhan</surname><given-names>I.D.</given-names></name></person-group><article-title>Co-expression of the Bcl-xL antiapoptotic protein enhances the induction of Th1-like immune responses in mice immunized with DNA vaccines encoding FMDV B and T cell epitopes</article-title><source>Vet. Res. Commun.</source><year>2013</year><volume>37</volume><fpage>187</fpage><lpage>196</lpage><pub-id pub-id-type="doi">10.1007/s11259-013-9560-3</pub-id><pub-id pub-id-type="pmid">23483312</pub-id></element-citation></ref><ref id="B51-vaccines-12-01071"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Diaz-San Segundo</surname><given-names>F.</given-names></name><name name-style="western"><surname>Weiss</surname><given-names>M.</given-names></name><name name-style="western"><surname>Perez-Martin</surname><given-names>E.</given-names></name><name name-style="western"><surname>Dias</surname><given-names>C.C.</given-names></name><name name-style="western"><surname>Grubman</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Santos Tde</surname><given-names>L.</given-names></name></person-group><article-title>Inoculation of swine with foot-and-mouth disease SAP-mutant virus induces early protection against disease</article-title><source>J. Virol.</source><year>2012</year><volume>86</volume><fpage>1316</fpage><lpage>1327</lpage><pub-id pub-id-type="doi">10.1128/JVI.05941-11</pub-id><pub-id pub-id-type="pmid">22114339</pub-id><pub-id pub-id-type="pmcid">PMC3264347</pub-id></element-citation></ref><ref id="B52-vaccines-12-01071"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Medina</surname><given-names>G.N.</given-names></name><name name-style="western"><surname>Azzinaro</surname><given-names>P.</given-names></name><name name-style="western"><surname>Ramirez-Medina</surname><given-names>E.</given-names></name><name name-style="western"><surname>Gutkoska</surname><given-names>J.</given-names></name><name name-style="western"><surname>Fang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Diaz-San Segundo</surname><given-names>F.</given-names></name><name name-style="western"><surname>de Los Santos</surname><given-names>T.</given-names></name></person-group><article-title>Impairment of the DeISGylation Activity of Foot-and-Mouth Disease Virus Lpro Causes Attenuation In Vitro and In Vivo</article-title><source>J. Virol.</source><year>2020</year><volume>94</volume><fpage>10</fpage><lpage>1128</lpage><pub-id pub-id-type="doi">10.1128/JVI.00341-20</pub-id><pub-id pub-id-type="pmid">32295921</pub-id><pub-id pub-id-type="pmcid">PMC7307143</pub-id></element-citation></ref><ref id="B53-vaccines-12-01071"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Azzinaro</surname><given-names>P.A.</given-names></name><name name-style="western"><surname>Medina</surname><given-names>G.N.</given-names></name><name name-style="western"><surname>Rai</surname><given-names>D.</given-names></name><name name-style="western"><surname>Ramirez-Medina</surname><given-names>E.</given-names></name><name name-style="western"><surname>Spinard</surname><given-names>E.</given-names></name><name name-style="western"><surname>Rodriguez-Calzada</surname><given-names>M.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Rieder</surname><given-names>E.</given-names></name><name name-style="western"><surname>de Los Santos</surname><given-names>T.</given-names></name><name name-style="western"><surname>Diaz-San Segundo</surname><given-names>F.</given-names></name></person-group><article-title>Mutation of FMDV L(pro) H138 residue drives viral attenuation in cell culture and in vivo in swine</article-title><source>Front. Vet. Sci.</source><year>2022</year><volume>9</volume><elocation-id>1028077</elocation-id><pub-id pub-id-type="doi">10.3389/fvets.2022.1028077</pub-id><pub-id pub-id-type="pmid">36387381</pub-id><pub-id pub-id-type="pmcid">PMC9661595</pub-id></element-citation></ref><ref id="B54-vaccines-12-01071"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Uddowla</surname><given-names>S.</given-names></name><name name-style="western"><surname>Pacheco</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Larson</surname><given-names>C.</given-names></name><name name-style="western"><surname>Bishop</surname><given-names>E.</given-names></name><name name-style="western"><surname>Rodriguez</surname><given-names>L.L.</given-names></name><name name-style="western"><surname>Rai</surname><given-names>D.K.</given-names></name><name name-style="western"><surname>Arzt</surname><given-names>J.</given-names></name><name name-style="western"><surname>Rieder</surname><given-names>E.</given-names></name></person-group><article-title>Characterization of a chimeric foot-and-mouth disease virus bearing a bovine rhinitis B virus leader proteinase</article-title><source>Virology</source><year>2013</year><volume>447</volume><fpage>172</fpage><lpage>180</lpage><pub-id pub-id-type="doi">10.1016/j.virol.2013.08.035</pub-id><pub-id pub-id-type="pmid">24210112</pub-id></element-citation></ref><ref id="B55-vaccines-12-01071"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rai</surname><given-names>D.K.</given-names></name><name name-style="western"><surname>Diaz-San Segundo</surname><given-names>F.</given-names></name><name name-style="western"><surname>Campagnola</surname><given-names>G.</given-names></name><name name-style="western"><surname>Keith</surname><given-names>A.</given-names></name><name name-style="western"><surname>Schafer</surname><given-names>E.A.</given-names></name><name name-style="western"><surname>Kloc</surname><given-names>A.</given-names></name><name name-style="western"><surname>de Los Santos</surname><given-names>T.</given-names></name><name name-style="western"><surname>Peersen</surname><given-names>O.</given-names></name><name name-style="western"><surname>Rieder</surname><given-names>E.</given-names></name></person-group><article-title>Attenuation of Foot-and-Mouth Disease Virus by Engineered Viral Polymerase Fidelity</article-title><source>J. Virol.</source><year>2017</year><volume>91</volume><fpage>10</fpage><lpage>1128</lpage><pub-id pub-id-type="doi">10.1128/JVI.00081-17</pub-id><pub-id pub-id-type="pmcid">PMC5651715</pub-id><pub-id pub-id-type="pmid">28515297</pub-id></element-citation></ref><ref id="B56-vaccines-12-01071"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rodr&#237;guez Pulido</surname><given-names>M.</given-names></name><name name-style="western"><surname>Sobrino</surname><given-names>F.</given-names></name><name name-style="western"><surname>Borrego</surname><given-names>B.</given-names></name><name name-style="western"><surname>S&#225;iz</surname><given-names>M.</given-names></name></person-group><article-title>Attenuated foot-and-mouth disease virus RNA carrying a deletion in the 3&#8242; noncoding region can elicit immunity in swine</article-title><source>J. Virol.</source><year>2009</year><volume>83</volume><fpage>3475</fpage><lpage>3485</lpage><pub-id pub-id-type="doi">10.1128/JVI.01836-08</pub-id><pub-id pub-id-type="pmid">19211755</pub-id><pub-id pub-id-type="pmcid">PMC2663259</pub-id></element-citation></ref><ref id="B57-vaccines-12-01071"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kloc</surname><given-names>A.</given-names></name><name name-style="western"><surname>Diaz-San Segundo</surname><given-names>F.</given-names></name><name name-style="western"><surname>Schafer</surname><given-names>E.A.</given-names></name><name name-style="western"><surname>Rai</surname><given-names>D.K.</given-names></name><name name-style="western"><surname>Kenney</surname><given-names>M.</given-names></name><name name-style="western"><surname>de Los Santos</surname><given-names>T.</given-names></name><name name-style="western"><surname>Rieder</surname><given-names>E.</given-names></name></person-group><article-title>Foot-and-mouth disease virus 5&#8242;-terminal S fragment is required for replication and modulation of the innate immune response in host cells</article-title><source>Virology</source><year>2017</year><volume>512</volume><fpage>132</fpage><lpage>143</lpage><pub-id pub-id-type="doi">10.1016/j.virol.2017.08.036</pub-id><pub-id pub-id-type="pmid">28961454</pub-id></element-citation></ref><ref id="B58-vaccines-12-01071"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Diaz-San Segundo</surname><given-names>F.</given-names></name><name name-style="western"><surname>Medina</surname><given-names>G.N.</given-names></name><name name-style="western"><surname>Ramirez-Medina</surname><given-names>E.</given-names></name><name name-style="western"><surname>Velazquez-Salinas</surname><given-names>L.</given-names></name><name name-style="western"><surname>Koster</surname><given-names>M.</given-names></name><name name-style="western"><surname>Grubman</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>de los Santos</surname><given-names>T.</given-names></name></person-group><article-title>Synonymous Deoptimization of Foot-and-Mouth Disease Virus Causes Attenuation In Vivo while Inducing a Strong Neutralizing Antibody Response</article-title><source>J. Virol.</source><year>2015</year><volume>90</volume><fpage>1298</fpage><lpage>1310</lpage><pub-id pub-id-type="doi">10.1128/JVI.02167-15</pub-id><pub-id pub-id-type="pmid">26581977</pub-id><pub-id pub-id-type="pmcid">PMC4719607</pub-id></element-citation></ref><ref id="B59-vaccines-12-01071"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Diaz-San Segundo</surname><given-names>F.</given-names></name><name name-style="western"><surname>Medina</surname><given-names>G.N.</given-names></name><name name-style="western"><surname>Spinard</surname><given-names>E.</given-names></name><name name-style="western"><surname>Kloc</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ramirez-Medina</surname><given-names>E.</given-names></name><name name-style="western"><surname>Azzinaro</surname><given-names>P.</given-names></name><name name-style="western"><surname>Mueller</surname><given-names>S.</given-names></name><name name-style="western"><surname>Rieder</surname><given-names>E.</given-names></name><name name-style="western"><surname>de Los Santos</surname><given-names>T.</given-names></name></person-group><article-title>Use of Synonymous Deoptimization to Derive Modified Live Attenuated Strains of Foot and Mouth Disease Virus</article-title><source>Front. Microbiol.</source><year>2020</year><volume>11</volume><elocation-id>610286</elocation-id><pub-id pub-id-type="doi">10.3389/fmicb.2020.610286</pub-id><pub-id pub-id-type="pmid">33552021</pub-id><pub-id pub-id-type="pmcid">PMC7861043</pub-id></element-citation></ref><ref id="B60-vaccines-12-01071"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Medina</surname><given-names>G.N.</given-names></name><name name-style="western"><surname>Spinard</surname><given-names>E.</given-names></name><name name-style="western"><surname>Azzinaro</surname><given-names>P.A.</given-names></name><name name-style="western"><surname>Rodriguez-Calzada</surname><given-names>M.</given-names></name><name name-style="western"><surname>Gutkoska</surname><given-names>J.</given-names></name><name name-style="western"><surname>Kloc</surname><given-names>A.</given-names></name><name name-style="western"><surname>Rieder</surname><given-names>E.A.</given-names></name><name name-style="western"><surname>Taillon</surname><given-names>B.E.</given-names></name><name name-style="western"><surname>Mueller</surname><given-names>S.</given-names></name><name name-style="western"><surname>de Los Santos</surname><given-names>T.</given-names></name><etal/></person-group><article-title>Deoptimization of FMDV P1 Region Results in Robust Serotype-Independent Viral Attenuation</article-title><source>Viruses</source><year>2023</year><volume>15</volume><elocation-id>1332</elocation-id><pub-id pub-id-type="doi">10.3390/v15061332</pub-id><pub-id pub-id-type="pmid">37376631</pub-id><pub-id pub-id-type="pmcid">PMC10301631</pub-id></element-citation></ref><ref id="B61-vaccines-12-01071"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Herod</surname><given-names>M.R.</given-names></name><name name-style="western"><surname>Gold</surname><given-names>S.</given-names></name><name name-style="western"><surname>Lasecka-Dykes</surname><given-names>L.</given-names></name><name name-style="western"><surname>Wright</surname><given-names>C.</given-names></name><name name-style="western"><surname>Ward</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>McLean</surname><given-names>T.C.</given-names></name><name name-style="western"><surname>Forrest</surname><given-names>S.</given-names></name><name name-style="western"><surname>Jackson</surname><given-names>T.</given-names></name><name name-style="western"><surname>Tuthill</surname><given-names>T.J.</given-names></name><name name-style="western"><surname>Rowlands</surname><given-names>D.J.</given-names></name><etal/></person-group><article-title>Genetic economy in picornaviruses: Foot-and-mouth disease virus replication exploits alternative precursor cleavage pathways</article-title><source>PLoS Pathog.</source><year>2017</year><volume>13</volume><elocation-id>e1006666</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1006666</pub-id><pub-id pub-id-type="pmid">28968463</pub-id><pub-id pub-id-type="pmcid">PMC5638621</pub-id></element-citation></ref><ref id="B62-vaccines-12-01071"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gao</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>S.Q.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>H.C.</given-names></name></person-group><article-title>Biological function of Foot-and-mouth disease virus non-structural proteins and non-coding elements</article-title><source>Virol. J.</source><year>2016</year><volume>13</volume><fpage>107</fpage><pub-id pub-id-type="doi">10.1186/s12985-016-0561-z</pub-id><pub-id pub-id-type="pmid">27334704</pub-id><pub-id pub-id-type="pmcid">PMC4917953</pub-id></element-citation></ref><ref id="B63-vaccines-12-01071"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rodriguez Pulido</surname><given-names>M.</given-names></name><name name-style="western"><surname>Saiz</surname><given-names>M.</given-names></name></person-group><article-title>Molecular Mechanisms of Foot-and-Mouth Disease Virus Targeting the Host Antiviral Response</article-title><source>Front. Cell Infect. Microbiol.</source><year>2017</year><volume>7</volume><elocation-id>252</elocation-id><pub-id pub-id-type="doi">10.3389/fcimb.2017.00252</pub-id><pub-id pub-id-type="pmid">28660175</pub-id><pub-id pub-id-type="pmcid">PMC5468379</pub-id></element-citation></ref><ref id="B64-vaccines-12-01071"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rodriguez-Pulido</surname><given-names>M.</given-names></name><name name-style="western"><surname>Borrego</surname><given-names>B.</given-names></name><name name-style="western"><surname>Sobrino</surname><given-names>F.</given-names></name><name name-style="western"><surname>Saiz</surname><given-names>M.</given-names></name></person-group><article-title>RNA structural domains in noncoding regions of the foot-and-mouth disease virus genome trigger innate immunity in porcine cells and mice</article-title><source>J. Virol.</source><year>2011</year><volume>85</volume><fpage>6492</fpage><lpage>6501</lpage><pub-id pub-id-type="doi">10.1128/JVI.00599-11</pub-id><pub-id pub-id-type="pmid">21525336</pub-id><pub-id pub-id-type="pmcid">PMC3126542</pub-id></element-citation></ref><ref id="B65-vaccines-12-01071"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>F.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Cao</surname><given-names>W.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Wei</surname><given-names>T.</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>M.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>K.</given-names></name><name name-style="western"><surname>Jin</surname><given-names>Y.</given-names></name><name name-style="western"><surname>He</surname><given-names>J.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Genetic Determinants of Altered Virulence of Type O Foot-and-Mouth Disease Virus</article-title><source>J. Virol.</source><year>2020</year><volume>94</volume><fpage>10</fpage><lpage>1128</lpage><pub-id pub-id-type="doi">10.1128/JVI.01657-19</pub-id><pub-id pub-id-type="pmid">31915277</pub-id><pub-id pub-id-type="pmcid">PMC7081894</pub-id></element-citation></ref><ref id="B66-vaccines-12-01071"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Penza</surname><given-names>V.</given-names></name><name name-style="western"><surname>Russell</surname><given-names>S.J.</given-names></name><name name-style="western"><surname>Schulze</surname><given-names>A.J.</given-names></name></person-group><article-title>The long-lasting enigma of polycytidine (polyC) tract</article-title><source>PLoS Pathog.</source><year>2021</year><volume>17</volume><elocation-id>e1009739</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1009739</pub-id><pub-id pub-id-type="pmid">34347852</pub-id><pub-id pub-id-type="pmcid">PMC8336851</pub-id></element-citation></ref><ref id="B67-vaccines-12-01071"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Escarmis</surname><given-names>C.</given-names></name><name name-style="western"><surname>Toja</surname><given-names>M.</given-names></name><name name-style="western"><surname>Medina</surname><given-names>M.</given-names></name><name name-style="western"><surname>Domingo</surname><given-names>E.</given-names></name></person-group><article-title>Modifications of the 5&#8242; untranslated region of foot-and-mouth disease virus after prolonged persistence in cell culture</article-title><source>Virus Res.</source><year>1992</year><volume>26</volume><fpage>113</fpage><lpage>125</lpage><pub-id pub-id-type="doi">10.1016/0168-1702(92)90151-X</pub-id><pub-id pub-id-type="pmid">1335672</pub-id></element-citation></ref><ref id="B68-vaccines-12-01071"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Harris</surname><given-names>T.J.</given-names></name><name name-style="western"><surname>Brown</surname><given-names>F.</given-names></name></person-group><article-title>Biochemical analysis of a virulent and an avirulent strain of foot-and-mouth disease virus</article-title><source>J. Gen. Virol.</source><year>1977</year><volume>34</volume><fpage>87</fpage><lpage>105</lpage><pub-id pub-id-type="doi">10.1099/0022-1317-34-1-87</pub-id><pub-id pub-id-type="pmid">188983</pub-id></element-citation></ref><ref id="B69-vaccines-12-01071"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Costa Giomi</surname><given-names>M.P.</given-names></name><name name-style="western"><surname>Bergmann</surname><given-names>I.E.</given-names></name><name name-style="western"><surname>Scodeller</surname><given-names>E.A.</given-names></name><name name-style="western"><surname>Auge de Mello</surname><given-names>P.</given-names></name><name name-style="western"><surname>Gomez</surname><given-names>I.</given-names></name><name name-style="western"><surname>La Torre</surname><given-names>J.L.</given-names></name></person-group><article-title>Heterogeneity of the polyribocytidylic acid tract in aphthovirus: Biochemical and biological studies of viruses carrying polyribocytidylic acid tracts of different lengths</article-title><source>J. Virol.</source><year>1984</year><volume>51</volume><fpage>799</fpage><lpage>805</lpage><pub-id pub-id-type="doi">10.1128/jvi.51.3.799-805.1984</pub-id><pub-id pub-id-type="pmid">6088803</pub-id><pub-id pub-id-type="pmcid">PMC255847</pub-id></element-citation></ref><ref id="B70-vaccines-12-01071"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhu</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>F.</given-names></name><name name-style="western"><surname>Cao</surname><given-names>W.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>K.</given-names></name><name name-style="western"><surname>Tian</surname><given-names>H.</given-names></name><name name-style="western"><surname>Dang</surname><given-names>W.</given-names></name><name name-style="western"><surname>He</surname><given-names>J.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>J.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>X.</given-names></name><etal/></person-group><article-title>The Pseudoknot Region of the 5&#8242; Untranslated Region Is a Determinant of Viral Tropism and Virulence of Foot-and-Mouth Disease Virus</article-title><source>J. Virol.</source><year>2019</year><volume>93</volume><fpage>10</fpage><lpage>1128</lpage><pub-id pub-id-type="doi">10.1128/JVI.02039-18</pub-id><pub-id pub-id-type="pmcid">PMC6450104</pub-id><pub-id pub-id-type="pmid">30728251</pub-id></element-citation></ref><ref id="B71-vaccines-12-01071"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ward</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>Lasecka-Dykes</surname><given-names>L.</given-names></name><name name-style="western"><surname>Neil</surname><given-names>C.</given-names></name><name name-style="western"><surname>Adeyemi</surname><given-names>O.O.</given-names></name><name name-style="western"><surname>Gold</surname><given-names>S.</given-names></name><name name-style="western"><surname>McLean-Pell</surname><given-names>N.</given-names></name><name name-style="western"><surname>Wright</surname><given-names>C.</given-names></name><name name-style="western"><surname>Herod</surname><given-names>M.R.</given-names></name><name name-style="western"><surname>Kealy</surname><given-names>D.</given-names></name><name name-style="western"><surname>Warner</surname><given-names>E.</given-names></name><etal/></person-group><article-title>The RNA pseudoknots in foot-and-mouth disease virus are dispensable for genome replication, but essential for the production of infectious virus</article-title><source>PLoS Pathog.</source><year>2022</year><volume>18</volume><elocation-id>e1010589</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1010589</pub-id><pub-id pub-id-type="pmid">35666744</pub-id><pub-id pub-id-type="pmcid">PMC9203018</pub-id></element-citation></ref><ref id="B72-vaccines-12-01071"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Logan</surname><given-names>G.</given-names></name><name name-style="western"><surname>Newman</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wright</surname><given-names>C.F.</given-names></name><name name-style="western"><surname>Lasecka-Dykes</surname><given-names>L.</given-names></name><name name-style="western"><surname>Haydon</surname><given-names>D.T.</given-names></name><name name-style="western"><surname>Cottam</surname><given-names>E.M.</given-names></name><name name-style="western"><surname>Tuthill</surname><given-names>T.J.</given-names></name></person-group><article-title>Deep Sequencing of Foot-and-Mouth Disease Virus Reveals RNA Sequences Involved in Genome Packaging</article-title><source>J. Virol.</source><year>2018</year><volume>92</volume><fpage>10</fpage><lpage>1128</lpage><pub-id pub-id-type="doi">10.1128/JVI.01159-17</pub-id><pub-id pub-id-type="pmid">29046452</pub-id><pub-id pub-id-type="pmcid">PMC5730773</pub-id></element-citation></ref><ref id="B73-vaccines-12-01071"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>D.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>C.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>R.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>W.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>K.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>G.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>B.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>L.</given-names></name></person-group><article-title>A Temperature-Dependent Translation Defect Caused by Internal Ribosome Entry Site Mutation Attenuates Foot-and-Mouth Disease Virus: Implications for Rational Vaccine Design</article-title><source>J. Virol.</source><year>2020</year><volume>94</volume><fpage>10</fpage><lpage>1128</lpage><pub-id pub-id-type="doi">10.1128/JVI.00990-20</pub-id><pub-id pub-id-type="pmid">32493820</pub-id><pub-id pub-id-type="pmcid">PMC7394902</pub-id></element-citation></ref><ref id="B74-vaccines-12-01071"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Serrano</surname><given-names>P.</given-names></name><name name-style="western"><surname>Pulido</surname><given-names>M.R.</given-names></name><name name-style="western"><surname>Saiz</surname><given-names>M.</given-names></name><name name-style="western"><surname>Martinez-Salas</surname><given-names>E.</given-names></name></person-group><article-title>The 3&#8242; end of the foot-and-mouth disease virus genome establishes two distinct long-range RNA-RNA interactions with the 5&#8242; end region</article-title><source>J. Gen. Virol.</source><year>2006</year><volume>87</volume><fpage>3013</fpage><lpage>3022</lpage><pub-id pub-id-type="doi">10.1099/vir.0.82059-0</pub-id><pub-id pub-id-type="pmid">16963760</pub-id></element-citation></ref><ref id="B75-vaccines-12-01071"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Garcia-Nunez</surname><given-names>S.</given-names></name><name name-style="western"><surname>Gismondi</surname><given-names>M.I.</given-names></name><name name-style="western"><surname>Konig</surname><given-names>G.</given-names></name><name name-style="western"><surname>Berinstein</surname><given-names>A.</given-names></name><name name-style="western"><surname>Taboga</surname><given-names>O.</given-names></name><name name-style="western"><surname>Rieder</surname><given-names>E.</given-names></name><name name-style="western"><surname>Martinez-Salas</surname><given-names>E.</given-names></name><name name-style="western"><surname>Carrillo</surname><given-names>E.</given-names></name></person-group><article-title>Enhanced IRES activity by the 3&#8242;UTR element determines the virulence of FMDV isolates</article-title><source>Virology</source><year>2014</year><volume>448</volume><fpage>303</fpage><lpage>313</lpage><pub-id pub-id-type="doi">10.1016/j.virol.2013.10.027</pub-id><pub-id pub-id-type="pmid">24314661</pub-id></element-citation></ref><ref id="B76-vaccines-12-01071"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lopez de Quinto</surname><given-names>S.</given-names></name><name name-style="western"><surname>Saiz</surname><given-names>M.</given-names></name><name name-style="western"><surname>de la Morena</surname><given-names>D.</given-names></name><name name-style="western"><surname>Sobrino</surname><given-names>F.</given-names></name><name name-style="western"><surname>Martinez-Salas</surname><given-names>E.</given-names></name></person-group><article-title>IRES-driven translation is stimulated separately by the FMDV 3&#8242;-NCR and poly(A) sequences</article-title><source>Nucleic Acids Res.</source><year>2002</year><volume>30</volume><fpage>4398</fpage><lpage>4405</lpage><pub-id pub-id-type="doi">10.1093/nar/gkf569</pub-id><pub-id pub-id-type="pmid">12384586</pub-id><pub-id pub-id-type="pmcid">PMC137133</pub-id></element-citation></ref><ref id="B77-vaccines-12-01071"><label>77.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Han</surname><given-names>S.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Guan</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Li</surname><given-names>P.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Abdullah</surname><given-names>S.W.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Jin</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>Nucleolin Promotes IRES-Driven Translation of Foot-and-Mouth Disease Virus by Supporting the Assembly of Translation Initiation Complexes</article-title><source>J. Virol.</source><year>2021</year><volume>95</volume><fpage>e0023821</fpage><pub-id pub-id-type="doi">10.1128/JVI.00238-21</pub-id><pub-id pub-id-type="pmid">33853964</pub-id><pub-id pub-id-type="pmcid">PMC8315980</pub-id></element-citation></ref><ref id="B78-vaccines-12-01071"><label>78.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rodriguez Pulido</surname><given-names>M.</given-names></name><name name-style="western"><surname>Serrano</surname><given-names>P.</given-names></name><name name-style="western"><surname>Saiz</surname><given-names>M.</given-names></name><name name-style="western"><surname>Martinez-Salas</surname><given-names>E.</given-names></name></person-group><article-title>Foot-and-mouth disease virus infection induces proteolytic cleavage of PTB, eIF3a,b, and PABP RNA-binding proteins</article-title><source>Virology</source><year>2007</year><volume>364</volume><fpage>466</fpage><lpage>474</lpage><pub-id pub-id-type="doi">10.1016/j.virol.2007.03.013</pub-id><pub-id pub-id-type="pmid">17445855</pub-id></element-citation></ref><ref id="B79-vaccines-12-01071"><label>79.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Abdullah</surname><given-names>S.W.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Bai</surname><given-names>M.</given-names></name><name name-style="western"><surname>Guan</surname><given-names>J.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>S.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>H.</given-names></name></person-group><article-title>DDX21, a Host Restriction Factor of FMDV IRES-Dependent Translation and Replication</article-title><source>Viruses</source><year>2021</year><volume>13</volume><elocation-id>1765</elocation-id><pub-id pub-id-type="doi">10.3390/v13091765</pub-id><pub-id pub-id-type="pmid">34578346</pub-id><pub-id pub-id-type="pmcid">PMC8473184</pub-id></element-citation></ref><ref id="B80-vaccines-12-01071"><label>80.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Piccone</surname><given-names>M.E.</given-names></name><name name-style="western"><surname>Rieder</surname><given-names>E.</given-names></name><name name-style="western"><surname>Mason</surname><given-names>P.W.</given-names></name><name name-style="western"><surname>Grubman</surname><given-names>M.J.</given-names></name></person-group><article-title>The foot-and-mouth disease virus leader proteinase gene is not required for viral replication</article-title><source>J. Virol.</source><year>1995</year><volume>69</volume><fpage>5376</fpage><lpage>5382</lpage><pub-id pub-id-type="doi">10.1128/jvi.69.9.5376-5382.1995</pub-id><pub-id pub-id-type="pmid">7636982</pub-id><pub-id pub-id-type="pmcid">PMC189380</pub-id></element-citation></ref><ref id="B81-vaccines-12-01071"><label>81.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>M.</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>H.</given-names></name></person-group><article-title>Multifunctional roles of leader protein of foot-and-mouth disease viruses in suppressing host antiviral responses</article-title><source>Vet. Res.</source><year>2015</year><volume>46</volume><fpage>127</fpage><pub-id pub-id-type="doi">10.1186/s13567-015-0273-1</pub-id><pub-id pub-id-type="pmid">26511922</pub-id><pub-id pub-id-type="pmcid">PMC4625562</pub-id></element-citation></ref><ref id="B82-vaccines-12-01071"><label>82.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>de los Santos</surname><given-names>T.</given-names></name><name name-style="western"><surname>Segundo</surname><given-names>F.D.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Koster</surname><given-names>M.</given-names></name><name name-style="western"><surname>Dias</surname><given-names>C.C.</given-names></name><name name-style="western"><surname>Grubman</surname><given-names>M.J.</given-names></name></person-group><article-title>A conserved domain in the leader proteinase of foot-and-mouth disease virus is required for proper subcellular localization and function</article-title><source>J. Virol.</source><year>2009</year><volume>83</volume><fpage>1800</fpage><lpage>1810</lpage><pub-id pub-id-type="doi">10.1128/JVI.02112-08</pub-id><pub-id pub-id-type="pmid">19052079</pub-id><pub-id pub-id-type="pmcid">PMC2643771</pub-id></element-citation></ref><ref id="B83-vaccines-12-01071"><label>83.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Eschbaumer</surname><given-names>M.</given-names></name><name name-style="western"><surname>Dill</surname><given-names>V.</given-names></name><name name-style="western"><surname>Carlson</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>Arzt</surname><given-names>J.</given-names></name><name name-style="western"><surname>Stenfeldt</surname><given-names>C.</given-names></name><name name-style="western"><surname>Krug</surname><given-names>P.W.</given-names></name><name name-style="western"><surname>Hardham</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Stegner</surname><given-names>J.E.</given-names></name><name name-style="western"><surname>Rodriguez</surname><given-names>L.L.</given-names></name><name name-style="western"><surname>Rieder</surname><given-names>E.</given-names></name></person-group><article-title>Foot-and-Mouth Disease Virus Lacking the Leader Protein and Containing Two Negative DIVA Markers (FMDV LL3B3D A(24)) Is Highly Attenuated in Pigs</article-title><source>Pathogens</source><year>2020</year><volume>9</volume><elocation-id>129</elocation-id><pub-id pub-id-type="doi">10.3390/pathogens9020129</pub-id><pub-id pub-id-type="pmid">32079312</pub-id><pub-id pub-id-type="pmcid">PMC7168223</pub-id></element-citation></ref><ref id="B84-vaccines-12-01071"><label>84.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mason</surname><given-names>P.W.</given-names></name><name name-style="western"><surname>Piccone</surname><given-names>M.E.</given-names></name><name name-style="western"><surname>McKenna</surname><given-names>T.S.</given-names></name><name name-style="western"><surname>Chinsangaram</surname><given-names>J.</given-names></name><name name-style="western"><surname>Grubman</surname><given-names>M.J.</given-names></name></person-group><article-title>Evaluation of a live-attenuated foot-and-mouth disease virus as a vaccine candidate</article-title><source>Virology</source><year>1997</year><volume>227</volume><fpage>96</fpage><lpage>102</lpage><pub-id pub-id-type="doi">10.1006/viro.1996.8309</pub-id><pub-id pub-id-type="pmid">9007062</pub-id></element-citation></ref><ref id="B85-vaccines-12-01071"><label>85.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brown</surname><given-names>C.C.</given-names></name><name name-style="western"><surname>Piccone</surname><given-names>M.E.</given-names></name><name name-style="western"><surname>Mason</surname><given-names>P.W.</given-names></name><name name-style="western"><surname>McKenna</surname><given-names>T.S.</given-names></name><name name-style="western"><surname>Grubman</surname><given-names>M.J.</given-names></name></person-group><article-title>Pathogenesis of wild-type and leaderless foot-and-mouth disease virus in cattle</article-title><source>J. Virol.</source><year>1996</year><volume>70</volume><fpage>5638</fpage><lpage>5641</lpage><pub-id pub-id-type="doi">10.1128/jvi.70.8.5638-5641.1996</pub-id><pub-id pub-id-type="pmid">8764079</pub-id><pub-id pub-id-type="pmcid">PMC190525</pub-id></element-citation></ref><ref id="B86-vaccines-12-01071"><label>86.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Carrillo</surname><given-names>C.</given-names></name><name name-style="western"><surname>Tulman</surname><given-names>E.R.</given-names></name><name name-style="western"><surname>Delhon</surname><given-names>G.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Carreno</surname><given-names>A.</given-names></name><name name-style="western"><surname>Vagnozzi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kutish</surname><given-names>G.F.</given-names></name><name name-style="western"><surname>Rock</surname><given-names>D.L.</given-names></name></person-group><article-title>Comparative genomics of foot-and-mouth disease virus</article-title><source>J. Virol.</source><year>2005</year><volume>79</volume><fpage>6487</fpage><lpage>6504</lpage><pub-id pub-id-type="doi">10.1128/JVI.79.10.6487-6504.2005</pub-id><pub-id pub-id-type="pmid">15858032</pub-id><pub-id pub-id-type="pmcid">PMC1091679</pub-id></element-citation></ref><ref id="B87-vaccines-12-01071"><label>87.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gladue</surname><given-names>D.P.</given-names></name><name name-style="western"><surname>Largo</surname><given-names>E.</given-names></name><name name-style="western"><surname>de la Arada</surname><given-names>I.</given-names></name><name name-style="western"><surname>Aguilella</surname><given-names>V.M.</given-names></name><name name-style="western"><surname>Alcaraz</surname><given-names>A.</given-names></name><name name-style="western"><surname>Arrondo</surname><given-names>J.L.R.</given-names></name><name name-style="western"><surname>Holinka</surname><given-names>L.G.</given-names></name><name name-style="western"><surname>Brocchi</surname><given-names>E.</given-names></name><name name-style="western"><surname>Ramirez-Medina</surname><given-names>E.</given-names></name><name name-style="western"><surname>Vuono</surname><given-names>E.A.</given-names></name><etal/></person-group><article-title>Molecular Characterization of the Viroporin Function of Foot-and-Mouth Disease Virus Nonstructural Protein 2B</article-title><source>J. Virol.</source><year>2018</year><volume>92</volume><fpage>10</fpage><lpage>1128</lpage><pub-id pub-id-type="doi">10.1128/JVI.01360-18</pub-id><pub-id pub-id-type="pmcid">PMC6232471</pub-id><pub-id pub-id-type="pmid">30232178</pub-id></element-citation></ref><ref id="B88-vaccines-12-01071"><label>88.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ao</surname><given-names>D.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>H.C.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>S.Q.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>D.H.</given-names></name><name name-style="western"><surname>Fung</surname><given-names>T.S.</given-names></name><name name-style="western"><surname>Wei</surname><given-names>Y.Q.</given-names></name><name name-style="western"><surname>Han</surname><given-names>S.C.</given-names></name><name name-style="western"><surname>Yao</surname><given-names>X.P.</given-names></name><name name-style="western"><surname>Cao</surname><given-names>S.Z.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>D.X.</given-names></name><etal/></person-group><article-title>Viroporin Activity of the Foot-and-Mouth Disease Virus Non-Structural 2B Protein</article-title><source>PLoS ONE</source><year>2015</year><volume>10</volume><elocation-id>e0125828</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0125828</pub-id><pub-id pub-id-type="pmid">25946195</pub-id><pub-id pub-id-type="pmcid">PMC4422707</pub-id></element-citation></ref><ref id="B89-vaccines-12-01071"><label>89.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Weerawardhana</surname><given-names>A.</given-names></name><name name-style="western"><surname>Uddin</surname><given-names>M.B.</given-names></name><name name-style="western"><surname>Choi</surname><given-names>J.H.</given-names></name><name name-style="western"><surname>Pathinayake</surname><given-names>P.</given-names></name><name name-style="western"><surname>Shin</surname><given-names>S.H.</given-names></name><name name-style="western"><surname>Chathuranga</surname><given-names>K.</given-names></name><name name-style="western"><surname>Park</surname><given-names>J.H.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>J.S.</given-names></name></person-group><article-title>Foot-and-mouth disease virus non-structural protein 2B downregulates the RLR signaling pathway via degradation of RIG-I and MDA5</article-title><source>Front. Immunol.</source><year>2022</year><volume>13</volume><elocation-id>1020262</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2022.1020262</pub-id><pub-id pub-id-type="pmid">36248821</pub-id><pub-id pub-id-type="pmcid">PMC9556895</pub-id></element-citation></ref><ref id="B90-vaccines-12-01071"><label>90.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhi</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>S.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Dong</surname><given-names>H.</given-names></name><name name-style="western"><surname>Luo</surname><given-names>X.</given-names></name><name name-style="western"><surname>Wei</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Dou</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>R.</given-names></name><etal/></person-group><article-title>NLRP3 inflammasome activation by Foot-and-mouth disease virus infection mainly induced by viral RNA and non-structural protein 2B</article-title><source>RNA Biol.</source><year>2020</year><volume>17</volume><fpage>335</fpage><lpage>349</lpage><pub-id pub-id-type="doi">10.1080/15476286.2019.1700058</pub-id><pub-id pub-id-type="pmid">31840571</pub-id><pub-id pub-id-type="pmcid">PMC6999635</pub-id></element-citation></ref><ref id="B91-vaccines-12-01071"><label>91.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Xue</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>F.</given-names></name><name name-style="western"><surname>Cao</surname><given-names>W.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>K.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>H.</given-names></name></person-group><article-title>Foot-and-Mouth Disease Virus Antagonizes NOD2-Mediated Antiviral Effects by Inhibiting NOD2 Protein Expression</article-title><source>J. Virol.</source><year>2019</year><volume>93</volume><fpage>10</fpage><lpage>1128</lpage><pub-id pub-id-type="doi">10.1128/JVI.00124-19</pub-id><pub-id pub-id-type="pmcid">PMC6532107</pub-id><pub-id pub-id-type="pmid">30894473</pub-id></element-citation></ref><ref id="B92-vaccines-12-01071"><label>92.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhu</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Li</surname><given-names>C.</given-names></name><name name-style="western"><surname>Du</surname><given-names>X.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>G.</given-names></name><name name-style="western"><surname>Cao</surname><given-names>W.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>F.</given-names></name><name name-style="western"><surname>Feng</surname><given-names>H.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Shi</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>H.</given-names></name><etal/></person-group><article-title>Foot-and-mouth disease virus infection inhibits LGP2 protein expression to exaggerate inflammatory response and promote viral replication</article-title><source>Cell Death Dis.</source><year>2017</year><volume>8</volume><fpage>e2747</fpage><pub-id pub-id-type="doi">10.1038/cddis.2017.170</pub-id><pub-id pub-id-type="pmid">28406479</pub-id><pub-id pub-id-type="pmcid">PMC5477588</pub-id></element-citation></ref><ref id="B93-vaccines-12-01071"><label>93.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nishi</surname><given-names>T.</given-names></name><name name-style="western"><surname>Morioka</surname><given-names>K.</given-names></name><name name-style="western"><surname>Saito</surname><given-names>N.</given-names></name><name name-style="western"><surname>Yamakawa</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kanno</surname><given-names>T.</given-names></name><name name-style="western"><surname>Fukai</surname><given-names>K.</given-names></name></person-group><article-title>Genetic Determinants of Virulence between Two Foot-and-Mouth Disease Virus Isolates Which Caused Outbreaks of Differing Severity</article-title><source>Msphere</source><year>2019</year><volume>4</volume><fpage>10</fpage><lpage>1128</lpage><pub-id pub-id-type="doi">10.1128/mSphere.00294-19</pub-id><pub-id pub-id-type="pmcid">PMC6695517</pub-id><pub-id pub-id-type="pmid">31413173</pub-id></element-citation></ref><ref id="B94-vaccines-12-01071"><label>94.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Moraes</surname><given-names>M.P.</given-names></name><name name-style="western"><surname>Segundo</surname><given-names>F.D.</given-names></name><name name-style="western"><surname>Dias</surname><given-names>C.C.</given-names></name><name name-style="western"><surname>Pena</surname><given-names>L.</given-names></name><name name-style="western"><surname>Grubman</surname><given-names>M.J.</given-names></name></person-group><article-title>Increased efficacy of an adenovirus-vectored foot-and-mouth disease capsid subunit vaccine expressing nonstructural protein 2B is associated with a specific T cell response</article-title><source>Vaccine</source><year>2011</year><volume>29</volume><fpage>9431</fpage><lpage>9440</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2011.10.037</pub-id><pub-id pub-id-type="pmid">22027486</pub-id></element-citation></ref><ref id="B95-vaccines-12-01071"><label>95.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Moffat</surname><given-names>K.</given-names></name><name name-style="western"><surname>Howell</surname><given-names>G.</given-names></name><name name-style="western"><surname>Knox</surname><given-names>C.</given-names></name><name name-style="western"><surname>Belsham</surname><given-names>G.J.</given-names></name><name name-style="western"><surname>Monaghan</surname><given-names>P.</given-names></name><name name-style="western"><surname>Ryan</surname><given-names>M.D.</given-names></name><name name-style="western"><surname>Wileman</surname><given-names>T.</given-names></name></person-group><article-title>Effects of foot-and-mouth disease virus nonstructural proteins on the structure and function of the early secretory pathway: 2BC but not 3A blocks endoplasmic reticulum-to-Golgi transport</article-title><source>J. Virol.</source><year>2005</year><volume>79</volume><fpage>4382</fpage><lpage>4395</lpage><pub-id pub-id-type="doi">10.1128/JVI.79.7.4382-4395.2005</pub-id><pub-id pub-id-type="pmid">15767438</pub-id><pub-id pub-id-type="pmcid">PMC1061540</pub-id></element-citation></ref><ref id="B96-vaccines-12-01071"><label>96.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gladue</surname><given-names>D.P.</given-names></name><name name-style="western"><surname>O&#8217;Donnell</surname><given-names>V.</given-names></name><name name-style="western"><surname>Baker-Branstetter</surname><given-names>R.</given-names></name><name name-style="western"><surname>Holinka</surname><given-names>L.G.</given-names></name><name name-style="western"><surname>Pacheco</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Fernandez Sainz</surname><given-names>I.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Ambroggio</surname><given-names>X.</given-names></name><name name-style="western"><surname>Rodriguez</surname><given-names>L.</given-names></name><name name-style="western"><surname>Borca</surname><given-names>M.V.</given-names></name></person-group><article-title>Foot-and-mouth disease virus modulates cellular vimentin for virus survival</article-title><source>J. Virol.</source><year>2013</year><volume>87</volume><fpage>6794</fpage><lpage>6803</lpage><pub-id pub-id-type="doi">10.1128/JVI.00448-13</pub-id><pub-id pub-id-type="pmid">23576498</pub-id><pub-id pub-id-type="pmcid">PMC3676138</pub-id></element-citation></ref><ref id="B97-vaccines-12-01071"><label>97.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gladue</surname><given-names>D.P.</given-names></name><name name-style="western"><surname>O&#8217;Donnell</surname><given-names>V.</given-names></name><name name-style="western"><surname>Baker-Branstetter</surname><given-names>R.</given-names></name><name name-style="western"><surname>Holinka</surname><given-names>L.G.</given-names></name><name name-style="western"><surname>Pacheco</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Fernandez-Sainz</surname><given-names>I.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Brocchi</surname><given-names>E.</given-names></name><name name-style="western"><surname>Baxt</surname><given-names>B.</given-names></name><name name-style="western"><surname>Piccone</surname><given-names>M.E.</given-names></name><etal/></person-group><article-title>Foot-and-mouth disease virus nonstructural protein 2C interacts with Beclin1, modulating virus replication</article-title><source>J. Virol.</source><year>2012</year><volume>86</volume><fpage>12080</fpage><lpage>12090</lpage><pub-id pub-id-type="doi">10.1128/JVI.01610-12</pub-id><pub-id pub-id-type="pmid">22933281</pub-id><pub-id pub-id-type="pmcid">PMC3486479</pub-id></element-citation></ref><ref id="B98-vaccines-12-01071"><label>98.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Agudo</surname><given-names>R.</given-names></name><name name-style="western"><surname>de la Higuera</surname><given-names>I.</given-names></name><name name-style="western"><surname>Arias</surname><given-names>A.</given-names></name><name name-style="western"><surname>Grande-Perez</surname><given-names>A.</given-names></name><name name-style="western"><surname>Domingo</surname><given-names>E.</given-names></name></person-group><article-title>Involvement of a joker mutation in a polymerase-independent lethal mutagenesis escape mechanism</article-title><source>Virology</source><year>2016</year><volume>494</volume><fpage>257</fpage><lpage>266</lpage><pub-id pub-id-type="doi">10.1016/j.virol.2016.04.023</pub-id><pub-id pub-id-type="pmid">27136067</pub-id><pub-id pub-id-type="pmcid">PMC7111656</pub-id></element-citation></ref><ref id="B99-vaccines-12-01071"><label>99.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Domingo</surname><given-names>E.</given-names></name><name name-style="western"><surname>Schuster</surname><given-names>P.</given-names></name></person-group><article-title>What Is a Quasispecies? Historical Origins and Current Scope</article-title><source>Curr. Top. Microbiol. Immunol.</source><year>2016</year><volume>392</volume><fpage>1</fpage><lpage>22</lpage><pub-id pub-id-type="doi">10.1007/82_2015_453</pub-id><pub-id pub-id-type="pmid">26318138</pub-id></element-citation></ref><ref id="B100-vaccines-12-01071"><label>100.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yuan</surname><given-names>T.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Li</surname><given-names>C.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>D.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>G.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>L.</given-names></name></person-group><article-title>T135I substitution in the nonstructural protein 2C enhances foot-and-mouth disease virus replication</article-title><source>Virus Genes</source><year>2017</year><volume>53</volume><fpage>840</fpage><lpage>847</lpage><pub-id pub-id-type="doi">10.1007/s11262-017-1480-9</pub-id><pub-id pub-id-type="pmid">28634750</pub-id></element-citation></ref><ref id="B101-vaccines-12-01071"><label>101.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dunn</surname><given-names>C.S.</given-names></name><name name-style="western"><surname>Donaldson</surname><given-names>A.I.</given-names></name></person-group><article-title>Natural adaption to pigs of a Taiwanese isolate of foot-and-mouth disease virus</article-title><source>Vet. Rec.</source><year>1997</year><volume>141</volume><fpage>174</fpage><lpage>175</lpage><pub-id pub-id-type="doi">10.1136/vr.141.7.174</pub-id><pub-id pub-id-type="pmid">9290197</pub-id></element-citation></ref><ref id="B102-vaccines-12-01071"><label>102.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Beard</surname><given-names>C.W.</given-names></name><name name-style="western"><surname>Mason</surname><given-names>P.W.</given-names></name></person-group><article-title>Genetic determinants of altered virulence of Taiwanese foot-and-mouth disease virus</article-title><source>J. Virol.</source><year>2000</year><volume>74</volume><fpage>987</fpage><lpage>991</lpage><pub-id pub-id-type="doi">10.1128/JVI.74.2.987-991.2000</pub-id><pub-id pub-id-type="pmid">10623761</pub-id><pub-id pub-id-type="pmcid">PMC111619</pub-id></element-citation></ref><ref id="B103-vaccines-12-01071"><label>103.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ma</surname><given-names>X.</given-names></name><name name-style="western"><surname>Ling</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Li</surname><given-names>P.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>P.</given-names></name><name name-style="western"><surname>Cao</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Bai</surname><given-names>X.</given-names></name><name name-style="western"><surname>Li</surname><given-names>K.</given-names></name><name name-style="western"><surname>Fu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Li</surname><given-names>D.</given-names></name><etal/></person-group><article-title>Cellular Vimentin Interacts with Foot-and-Mouth Disease Virus Nonstructural Protein 3A and Negatively Modulates Viral Replication</article-title><source>J. Virol.</source><year>2020</year><volume>94</volume><fpage>10</fpage><lpage>1128</lpage><pub-id pub-id-type="doi">10.1128/JVI.00273-20</pub-id><pub-id pub-id-type="pmcid">PMC7394891</pub-id><pub-id pub-id-type="pmid">32493819</pub-id></element-citation></ref><ref id="B104-vaccines-12-01071"><label>104.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>H.W.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>Y.F.</given-names></name><name name-style="western"><surname>Chang</surname><given-names>H.W.</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>I.C.</given-names></name></person-group><article-title>Foot-and-Mouth Disease Virus 3A Hijacks Sar1 and Sec12 for ER Remodeling in a COPII-Independent Manner</article-title><source>Viruses</source><year>2022</year><volume>14</volume><elocation-id>839</elocation-id><pub-id pub-id-type="doi">10.3390/v14040839</pub-id><pub-id pub-id-type="pmid">35458569</pub-id><pub-id pub-id-type="pmcid">PMC9028839</pub-id></element-citation></ref><ref id="B105-vaccines-12-01071"><label>105.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pacheco</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Gladue</surname><given-names>D.P.</given-names></name><name name-style="western"><surname>Holinka</surname><given-names>L.G.</given-names></name><name name-style="western"><surname>Arzt</surname><given-names>J.</given-names></name><name name-style="western"><surname>Bishop</surname><given-names>E.</given-names></name><name name-style="western"><surname>Smoliga</surname><given-names>G.</given-names></name><name name-style="western"><surname>Pauszek</surname><given-names>S.J.</given-names></name><name name-style="western"><surname>Bracht</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>O&#8217;Donnell</surname><given-names>V.</given-names></name><name name-style="western"><surname>Fernandez-Sainz</surname><given-names>I.</given-names></name><etal/></person-group><article-title>A partial deletion in non-structural protein 3A can attenuate foot-and-mouth disease virus in cattle</article-title><source>Virology</source><year>2013</year><volume>446</volume><fpage>260</fpage><lpage>267</lpage><pub-id pub-id-type="doi">10.1016/j.virol.2013.08.003</pub-id><pub-id pub-id-type="pmid">24074589</pub-id></element-citation></ref><ref id="B106-vaccines-12-01071"><label>106.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stenfeldt</surname><given-names>C.</given-names></name><name name-style="western"><surname>Arzt</surname><given-names>J.</given-names></name><name name-style="western"><surname>Pacheco</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Gladue</surname><given-names>D.P.</given-names></name><name name-style="western"><surname>Smoliga</surname><given-names>G.</given-names></name><name name-style="western"><surname>Silva</surname><given-names>E.B.</given-names></name><name name-style="western"><surname>Rodriguez</surname><given-names>L.L.</given-names></name><name name-style="western"><surname>Borca</surname><given-names>M.V.</given-names></name></person-group><article-title>A partial deletion within foot-and-mouth disease virus non-structural protein 3A causes clinical attenuation in cattle but does not prevent subclinical infection</article-title><source>Virology</source><year>2018</year><volume>516</volume><fpage>115</fpage><lpage>126</lpage><pub-id pub-id-type="doi">10.1016/j.virol.2018.01.008</pub-id><pub-id pub-id-type="pmid">29346074</pub-id></element-citation></ref><ref id="B107-vaccines-12-01071"><label>107.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fu</surname><given-names>S.Z.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>W.P.</given-names></name><name name-style="western"><surname>Ru</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>K.S.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>X.T.</given-names></name><name name-style="western"><surname>Li</surname><given-names>D.</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>H.X.</given-names></name></person-group><article-title>DDX56 cooperates with FMDV 3A to enhance FMDV replication by inhibiting the phosphorylation of IRF3</article-title><source>Cell. Signal.</source><year>2019</year><volume>64</volume><fpage>109393</fpage><pub-id pub-id-type="doi">10.1016/j.cellsig.2019.109393</pub-id><pub-id pub-id-type="pmid">31445188</pub-id></element-citation></ref><ref id="B108-vaccines-12-01071"><label>108.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>D.</given-names></name><name name-style="western"><surname>Lei</surname><given-names>C.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>F.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Li</surname><given-names>S.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Shu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>H.</given-names></name></person-group><article-title>Foot-and-mouth disease virus non-structural protein 3A inhibits the interferon-beta signaling pathway</article-title><source>Sci. Rep.</source><year>2016</year><volume>6</volume><elocation-id>21888</elocation-id><pub-id pub-id-type="doi">10.1038/srep21888</pub-id><pub-id pub-id-type="pmid">26883855</pub-id><pub-id pub-id-type="pmcid">PMC4756384</pub-id></element-citation></ref><ref id="B109-vaccines-12-01071"><label>109.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Li</surname><given-names>D.</given-names></name><name name-style="western"><surname>Ru</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Bai</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ren</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Li</surname><given-names>L.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>H.</given-names></name></person-group><article-title>Foot-and-Mouth Disease Virus 3A Protein Causes Upregulation of Autophagy-Related Protein LRRC25 To Inhibit the G3BP1-Mediated RIG-Like Helicase-Signaling Pathway</article-title><source>J. Virol.</source><year>2020</year><volume>94</volume><fpage>10</fpage><lpage>1128</lpage><pub-id pub-id-type="doi">10.1128/JVI.02086-19</pub-id><pub-id pub-id-type="pmcid">PMC7108857</pub-id><pub-id pub-id-type="pmid">31996428</pub-id></element-citation></ref><ref id="B110-vaccines-12-01071"><label>110.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Grubman</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Baxt</surname><given-names>B.</given-names></name></person-group><article-title>Foot-and-mouth disease</article-title><source>Clin. Microbiol. Rev.</source><year>2004</year><volume>17</volume><fpage>465</fpage><lpage>493</lpage><pub-id pub-id-type="doi">10.1128/CMR.17.2.465-493.2004</pub-id><pub-id pub-id-type="pmid">15084510</pub-id><pub-id pub-id-type="pmcid">PMC387408</pub-id></element-citation></ref><ref id="B111-vaccines-12-01071"><label>111.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>F.</given-names></name><name name-style="western"><surname>Cao</surname><given-names>W.</given-names></name><name name-style="western"><surname>Li</surname><given-names>P.</given-names></name><name name-style="western"><surname>Du</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>F.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>H.</given-names></name></person-group><article-title>Foot-and-Mouth Disease Virus 3B Protein Interacts with Pattern Recognition Receptor RIG-I to Block RIG-I-Mediated Immune Signaling and Inhibit Host Antiviral Response</article-title><source>J. Immunol.</source><year>2020</year><volume>205</volume><fpage>2207</fpage><lpage>2221</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.1901333</pub-id><pub-id pub-id-type="pmid">32917788</pub-id><pub-id pub-id-type="pmcid">PMC7533709</pub-id></element-citation></ref><ref id="B112-vaccines-12-01071"><label>112.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Falk</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Sobrino</surname><given-names>F.</given-names></name><name name-style="western"><surname>Beck</surname><given-names>E.</given-names></name></person-group><article-title>VPg gene amplification correlates with infective particle formation in foot-and-mouth disease virus</article-title><source>J. Virol.</source><year>1992</year><volume>66</volume><fpage>2251</fpage><lpage>2260</lpage><pub-id pub-id-type="doi">10.1128/jvi.66.4.2251-2260.1992</pub-id><pub-id pub-id-type="pmid">1312630</pub-id><pub-id pub-id-type="pmcid">PMC289018</pub-id></element-citation></ref><ref id="B113-vaccines-12-01071"><label>113.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pacheco</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Henry</surname><given-names>T.M.</given-names></name><name name-style="western"><surname>O&#8217;Donnell</surname><given-names>V.K.</given-names></name><name name-style="western"><surname>Gregory</surname><given-names>J.B.</given-names></name><name name-style="western"><surname>Mason</surname><given-names>P.W.</given-names></name></person-group><article-title>Role of nonstructural proteins 3A and 3B in host range and pathogenicity of foot-and-mouth disease virus</article-title><source>J. Virol.</source><year>2003</year><volume>77</volume><fpage>13017</fpage><lpage>13027</lpage><pub-id pub-id-type="doi">10.1128/JVI.77.24.13017-13027.2003</pub-id><pub-id pub-id-type="pmid">14645558</pub-id><pub-id pub-id-type="pmcid">PMC296074</pub-id></element-citation></ref><ref id="B114-vaccines-12-01071"><label>114.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Belsham</surname><given-names>G.J.</given-names></name><name name-style="western"><surname>McInerney</surname><given-names>G.M.</given-names></name><name name-style="western"><surname>Ross-Smith</surname><given-names>N.</given-names></name></person-group><article-title>Foot-and-mouth disease virus 3C protease induces cleavage of translation initiation factors eIF4A and eIF4G within infected cells</article-title><source>J. Virol.</source><year>2000</year><volume>74</volume><fpage>272</fpage><lpage>280</lpage><pub-id pub-id-type="doi">10.1128/JVI.74.1.272-280.2000</pub-id><pub-id pub-id-type="pmid">10590115</pub-id><pub-id pub-id-type="pmcid">PMC111537</pub-id></element-citation></ref><ref id="B115-vaccines-12-01071"><label>115.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Du</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Bi</surname><given-names>J.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>P.</given-names></name><name name-style="western"><surname>Yoo</surname><given-names>D.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wan</surname><given-names>R.</given-names></name><etal/></person-group><article-title>3Cpro of foot-and-mouth disease virus antagonizes the interferon signaling pathway by blocking STAT1/STAT2 nuclear translocation</article-title><source>J. Virol.</source><year>2014</year><volume>88</volume><fpage>4908</fpage><lpage>4920</lpage><pub-id pub-id-type="doi">10.1128/JVI.03668-13</pub-id><pub-id pub-id-type="pmid">24554650</pub-id><pub-id pub-id-type="pmcid">PMC3993825</pub-id></element-citation></ref><ref id="B116-vaccines-12-01071"><label>116.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>D.</given-names></name><name name-style="western"><surname>Fang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Li</surname><given-names>K.</given-names></name><name name-style="western"><surname>Zhong</surname><given-names>H.</given-names></name><name name-style="western"><surname>Fan</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ouyang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Duan</surname><given-names>E.</given-names></name><name name-style="western"><surname>Luo</surname><given-names>R.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Z.</given-names></name><etal/></person-group><article-title>Foot-and-mouth disease virus 3C protease cleaves NEMO to impair innate immune signaling</article-title><source>J. Virol.</source><year>2012</year><volume>86</volume><fpage>9311</fpage><lpage>9322</lpage><pub-id pub-id-type="doi">10.1128/JVI.00722-12</pub-id><pub-id pub-id-type="pmid">22718831</pub-id><pub-id pub-id-type="pmcid">PMC3416110</pub-id></element-citation></ref><ref id="B117-vaccines-12-01071"><label>117.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ekanayaka</surname><given-names>P.</given-names></name><name name-style="western"><surname>Shin</surname><given-names>S.H.</given-names></name><name name-style="western"><surname>Weeratunga</surname><given-names>P.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>H.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>T.H.</given-names></name><name name-style="western"><surname>Chathuranga</surname><given-names>K.</given-names></name><name name-style="western"><surname>Subasinghe</surname><given-names>A.</given-names></name><name name-style="western"><surname>Park</surname><given-names>J.H.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>J.S.</given-names></name></person-group><article-title>Foot-and-Mouth Disease Virus 3C Protease Antagonizes Interferon Signaling and C142T Substitution Attenuates the FMD Virus</article-title><source>Front. Microbiol.</source><year>2021</year><volume>12</volume><elocation-id>737031</elocation-id><pub-id pub-id-type="doi">10.3389/fmicb.2021.737031</pub-id><pub-id pub-id-type="pmid">34867853</pub-id><pub-id pub-id-type="pmcid">PMC8639872</pub-id></element-citation></ref><ref id="B118-vaccines-12-01071"><label>118.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ye</surname><given-names>X.</given-names></name><name name-style="western"><surname>Pan</surname><given-names>T.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>D.</given-names></name><name name-style="western"><surname>Fang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Shi</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>K.</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>H.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>H.</given-names></name><etal/></person-group><article-title>Foot-and-Mouth Disease Virus Counteracts on Internal Ribosome Entry Site Suppression by G3BP1 and Inhibits G3BP1-Mediated Stress Granule Assembly via Post-Translational Mechanisms</article-title><source>Front. Immunol.</source><year>2018</year><volume>9</volume><elocation-id>1142</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2018.01142</pub-id><pub-id pub-id-type="pmid">29887867</pub-id><pub-id pub-id-type="pmcid">PMC5980976</pub-id></element-citation></ref><ref id="B119-vaccines-12-01071"><label>119.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Domingo</surname><given-names>E.</given-names></name></person-group><article-title>Mechanisms of viral emergence</article-title><source>Vet. Res.</source><year>2010</year><volume>41</volume><fpage>38</fpage><pub-id pub-id-type="doi">10.1051/vetres/2010010</pub-id><pub-id pub-id-type="pmid">20167200</pub-id><pub-id pub-id-type="pmcid">PMC2831534</pub-id></element-citation></ref><ref id="B120-vaccines-12-01071"><label>120.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zeng</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Xie</surname><given-names>X.</given-names></name><name name-style="western"><surname>Li</surname><given-names>C.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>G.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>D.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>L.</given-names></name></person-group><article-title>Ribavirin-resistant variants of foot-and-mouth disease virus: The effect of restricted quasispecies diversity on viral virulence</article-title><source>J. Virol.</source><year>2014</year><volume>88</volume><fpage>4008</fpage><lpage>4020</lpage><pub-id pub-id-type="doi">10.1128/JVI.03594-13</pub-id><pub-id pub-id-type="pmid">24453363</pub-id><pub-id pub-id-type="pmcid">PMC3993757</pub-id></element-citation></ref><ref id="B121-vaccines-12-01071"><label>121.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>C.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Yuan</surname><given-names>T.</given-names></name><name name-style="western"><surname>Woodman</surname><given-names>A.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>D.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>G.</given-names></name><name name-style="western"><surname>Cameron</surname><given-names>C.E.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>L.</given-names></name></person-group><article-title>Foot-and-mouth disease virus type O specific mutations determine RNA-dependent RNA polymerase fidelity and virus attenuation</article-title><source>Virology</source><year>2018</year><volume>518</volume><fpage>87</fpage><lpage>94</lpage><pub-id pub-id-type="doi">10.1016/j.virol.2018.01.030</pub-id><pub-id pub-id-type="pmid">29455065</pub-id><pub-id pub-id-type="pmcid">PMC5911202</pub-id></element-citation></ref><ref id="B122-vaccines-12-01071"><label>122.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vignuzzi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Wendt</surname><given-names>E.</given-names></name><name name-style="western"><surname>Andino</surname><given-names>R.</given-names></name></person-group><article-title>Engineering attenuated virus vaccines by controlling replication fidelity</article-title><source>Nat. Med.</source><year>2008</year><volume>14</volume><fpage>154</fpage><lpage>161</lpage><pub-id pub-id-type="doi">10.1038/nm1726</pub-id><pub-id pub-id-type="pmid">18246077</pub-id></element-citation></ref><ref id="B123-vaccines-12-01071"><label>123.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yuan</surname><given-names>H.</given-names></name><name name-style="western"><surname>Li</surname><given-names>P.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>X.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>P.</given-names></name><name name-style="western"><surname>Bai</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Bao</surname><given-names>H.</given-names></name><name name-style="western"><surname>Cao</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Li</surname><given-names>D.</given-names></name><etal/></person-group><article-title>The pH stability of foot-and-mouth disease virus</article-title><source>Virol. J.</source><year>2017</year><volume>14</volume><fpage>233</fpage><pub-id pub-id-type="doi">10.1186/s12985-017-0897-z</pub-id><pub-id pub-id-type="pmid">29183342</pub-id><pub-id pub-id-type="pmcid">PMC5706165</pub-id></element-citation></ref><ref id="B124-vaccines-12-01071"><label>124.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Curry</surname><given-names>S.</given-names></name><name name-style="western"><surname>Abrams</surname><given-names>C.C.</given-names></name><name name-style="western"><surname>Fry</surname><given-names>E.</given-names></name><name name-style="western"><surname>Crowther</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>Belsham</surname><given-names>G.J.</given-names></name><name name-style="western"><surname>Stuart</surname><given-names>D.I.</given-names></name><name name-style="western"><surname>King</surname><given-names>A.M.</given-names></name></person-group><article-title>Viral RNA modulates the acid sensitivity of foot-and-mouth disease virus capsids</article-title><source>J. Virol.</source><year>1995</year><volume>69</volume><fpage>430</fpage><lpage>438</lpage><pub-id pub-id-type="doi">10.1128/jvi.69.1.430-438.1995</pub-id><pub-id pub-id-type="pmid">7983739</pub-id><pub-id pub-id-type="pmcid">PMC188591</pub-id></element-citation></ref><ref id="B125-vaccines-12-01071"><label>125.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Doel</surname><given-names>T.R.</given-names></name><name name-style="western"><surname>Baccarini</surname><given-names>P.J.</given-names></name></person-group><article-title>Thermal stability of foot-and-mouth disease virus</article-title><source>Arch. Virol.</source><year>1981</year><volume>70</volume><fpage>21</fpage><lpage>32</lpage><pub-id pub-id-type="doi">10.1007/BF01320790</pub-id><pub-id pub-id-type="pmid">6277281</pub-id></element-citation></ref><ref id="B126-vaccines-12-01071"><label>126.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fox</surname><given-names>G.</given-names></name><name name-style="western"><surname>Parry</surname><given-names>N.R.</given-names></name><name name-style="western"><surname>Barnett</surname><given-names>P.V.</given-names></name><name name-style="western"><surname>McGinn</surname><given-names>B.</given-names></name><name name-style="western"><surname>Rowlands</surname><given-names>D.J.</given-names></name><name name-style="western"><surname>Brown</surname><given-names>F.</given-names></name></person-group><article-title>The cell attachment site on foot-and-mouth disease virus includes the amino acid sequence RGD (arginine-glycine-aspartic acid)</article-title><source>J. Gen. Virol.</source><year>1989</year><volume>70</volume><issue-part>Pt 3</issue-part><fpage>625</fpage><lpage>637</lpage><pub-id pub-id-type="doi">10.1099/0022-1317-70-3-625</pub-id><pub-id pub-id-type="pmid">2543752</pub-id></element-citation></ref><ref id="B127-vaccines-12-01071"><label>127.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rowlands</surname><given-names>D.J.</given-names></name><name name-style="western"><surname>Clarke</surname><given-names>B.E.</given-names></name><name name-style="western"><surname>Carroll</surname><given-names>A.R.</given-names></name><name name-style="western"><surname>Brown</surname><given-names>F.</given-names></name><name name-style="western"><surname>Nicholson</surname><given-names>B.H.</given-names></name><name name-style="western"><surname>Bittle</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Houghten</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>Lerner</surname><given-names>R.A.</given-names></name></person-group><article-title>Chemical basis of antigenic variation in foot-and-mouth disease virus</article-title><source>Nature</source><year>1983</year><volume>306</volume><fpage>694</fpage><lpage>697</lpage><pub-id pub-id-type="doi">10.1038/306694a0</pub-id><pub-id pub-id-type="pmid">6318114</pub-id></element-citation></ref><ref id="B128-vaccines-12-01071"><label>128.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Francis</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Hastings</surname><given-names>G.Z.</given-names></name><name name-style="western"><surname>Clarke</surname><given-names>B.E.</given-names></name><name name-style="western"><surname>Brown</surname><given-names>A.L.</given-names></name><name name-style="western"><surname>Beddell</surname><given-names>C.R.</given-names></name><name name-style="western"><surname>Rowlands</surname><given-names>D.J.</given-names></name><name name-style="western"><surname>Brown</surname><given-names>F.</given-names></name></person-group><article-title>Neutralizing antibodies to all seven serotypes of foot-and-mouth disease virus elicited by synthetic peptides</article-title><source>Immunology</source><year>1990</year><volume>69</volume><fpage>171</fpage><lpage>176</lpage><pub-id pub-id-type="pmid">2155177</pub-id><pub-id pub-id-type="pmcid">PMC1385585</pub-id></element-citation></ref><ref id="B129-vaccines-12-01071"><label>129.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jackson</surname><given-names>T.</given-names></name><name name-style="western"><surname>Blakemore</surname><given-names>W.</given-names></name><name name-style="western"><surname>Newman</surname><given-names>J.W.</given-names></name><name name-style="western"><surname>Knowles</surname><given-names>N.J.</given-names></name><name name-style="western"><surname>Mould</surname><given-names>A.P.</given-names></name><name name-style="western"><surname>Humphries</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>King</surname><given-names>A.M.</given-names></name></person-group><article-title>Foot-and-mouth disease virus is a ligand for the high-affinity binding conformation of integrin alpha5beta1: Influence of the leucine residue within the RGDL motif on selectivity of integrin binding</article-title><source>J. Gen. Virol.</source><year>2000</year><volume>81</volume><fpage>1383</fpage><lpage>1391</lpage><pub-id pub-id-type="pmid">10769082</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1099/0022-1317-81-5-1383</pub-id></element-citation></ref><ref id="B130-vaccines-12-01071"><label>130.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>K.</given-names></name><name name-style="western"><surname>Yan</surname><given-names>M.</given-names></name><name name-style="western"><surname>Hao</surname><given-names>J.</given-names></name><name name-style="western"><surname>Shen</surname><given-names>C.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>D.</given-names></name><name name-style="western"><surname>Hou</surname><given-names>J.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>G.</given-names></name><name name-style="western"><surname>Li</surname><given-names>D.</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>H.</given-names></name><etal/></person-group><article-title>Foot-and-Mouth Disease Virus Structural Protein VP1 Destroys the Stability of TPL2 Trimer by Degradation TPL2 to Evade Host Antiviral Immunity</article-title><source>J. Virol.</source><year>2021</year><volume>95</volume><fpage>10</fpage><lpage>1128</lpage><pub-id pub-id-type="doi">10.1128/JVI.02149-20</pub-id><pub-id pub-id-type="pmcid">PMC8092693</pub-id><pub-id pub-id-type="pmid">33361430</pub-id></element-citation></ref><ref id="B131-vaccines-12-01071"><label>131.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>D.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>F.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Lian</surname><given-names>K.</given-names></name><name name-style="western"><surname>Lei</surname><given-names>C.</given-names></name><name name-style="western"><surname>Li</surname><given-names>S.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>H.</given-names></name><etal/></person-group><article-title>The VP3 structural protein of foot-and-mouth disease virus inhibits the IFN-beta signaling pathway</article-title><source>FASEB J.</source><year>2016</year><volume>30</volume><fpage>1757</fpage><lpage>1766</lpage><pub-id pub-id-type="doi">10.1096/fj.15-281410</pub-id><pub-id pub-id-type="pmid">26813975</pub-id></element-citation></ref><ref id="B132-vaccines-12-01071"><label>132.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stenfeldt</surname><given-names>C.</given-names></name><name name-style="western"><surname>Eschbaumer</surname><given-names>M.</given-names></name><name name-style="western"><surname>Pacheco</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Rekant</surname><given-names>S.I.</given-names></name><name name-style="western"><surname>Rodriguez</surname><given-names>L.L.</given-names></name><name name-style="western"><surname>Arzt</surname><given-names>J.</given-names></name></person-group><article-title>Pathogenesis of Primary Foot-and-Mouth Disease Virus Infection in the Nasopharynx of Vaccinated and Non-Vaccinated Cattle</article-title><source>PLoS ONE</source><year>2015</year><volume>10</volume><elocation-id>e0143666</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0143666</pub-id><pub-id pub-id-type="pmid">26599543</pub-id><pub-id pub-id-type="pmcid">PMC4658095</pub-id></element-citation></ref><ref id="B133-vaccines-12-01071"><label>133.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stenfeldt</surname><given-names>C.</given-names></name><name name-style="western"><surname>Pacheco</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Borca</surname><given-names>M.V.</given-names></name><name name-style="western"><surname>Rodriguez</surname><given-names>L.L.</given-names></name><name name-style="western"><surname>Arzt</surname><given-names>J.</given-names></name></person-group><article-title>Morphologic and phenotypic characteristics of myocarditis in two pigs infected by foot-and mouth disease virus strains of serotypes O or A</article-title><source>Acta Vet. Scand.</source><year>2014</year><volume>56</volume><fpage>42</fpage><pub-id pub-id-type="doi">10.1186/s13028-014-0042-6</pub-id><pub-id pub-id-type="pmid">25015718</pub-id><pub-id pub-id-type="pmcid">PMC4105858</pub-id></element-citation></ref><ref id="B134-vaccines-12-01071"><label>134.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stenfeldt</surname><given-names>C.</given-names></name><name name-style="western"><surname>Eschbaumer</surname><given-names>M.</given-names></name><name name-style="western"><surname>Rekant</surname><given-names>S.I.</given-names></name><name name-style="western"><surname>Pacheco</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Smoliga</surname><given-names>G.R.</given-names></name><name name-style="western"><surname>Hartwig</surname><given-names>E.J.</given-names></name><name name-style="western"><surname>Rodriguez</surname><given-names>L.L.</given-names></name><name name-style="western"><surname>Arzt</surname><given-names>J.</given-names></name></person-group><article-title>The Foot-and-Mouth Disease Carrier State Divergence in Cattle</article-title><source>J. Virol.</source><year>2016</year><volume>90</volume><fpage>6344</fpage><lpage>6364</lpage><pub-id pub-id-type="doi">10.1128/JVI.00388-16</pub-id><pub-id pub-id-type="pmid">27147736</pub-id><pub-id pub-id-type="pmcid">PMC4936139</pub-id></element-citation></ref><ref id="B135-vaccines-12-01071"><label>135.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stenfeldt</surname><given-names>C.</given-names></name><name name-style="western"><surname>Pacheco</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Smoliga</surname><given-names>G.R.</given-names></name><name name-style="western"><surname>Bishop</surname><given-names>E.</given-names></name><name name-style="western"><surname>Pauszek</surname><given-names>S.J.</given-names></name><name name-style="western"><surname>Hartwig</surname><given-names>E.J.</given-names></name><name name-style="western"><surname>Rodriguez</surname><given-names>L.L.</given-names></name><name name-style="western"><surname>Arzt</surname><given-names>J.</given-names></name></person-group><article-title>Detection of Foot-and-mouth Disease Virus RNA and Capsid Protein in Lymphoid Tissues of Convalescent Pigs Does Not Indicate Existence of a Carrier State</article-title><source>Transbound. Emerg. Dis.</source><year>2016</year><volume>63</volume><fpage>152</fpage><lpage>164</lpage><pub-id pub-id-type="doi">10.1111/tbed.12235</pub-id><pub-id pub-id-type="pmid">24943477</pub-id></element-citation></ref><ref id="B136-vaccines-12-01071"><label>136.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pacheco</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Smoliga</surname><given-names>G.R.</given-names></name><name name-style="western"><surname>O&#8217;Donnell</surname><given-names>V.</given-names></name><name name-style="western"><surname>Brito</surname><given-names>B.P.</given-names></name><name name-style="western"><surname>Stenfeldt</surname><given-names>C.</given-names></name><name name-style="western"><surname>Rodriguez</surname><given-names>L.L.</given-names></name><name name-style="western"><surname>Arzt</surname><given-names>J.</given-names></name></person-group><article-title>Persistent Foot-and-Mouth Disease Virus Infection in the Nasopharynx of Cattle; Tissue-Specific Distribution and Local Cytokine Expression</article-title><source>PLoS ONE</source><year>2015</year><volume>10</volume><elocation-id>e0125698</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0125698</pub-id><pub-id pub-id-type="pmid">25996935</pub-id><pub-id pub-id-type="pmcid">PMC4440813</pub-id></element-citation></ref><ref id="B137-vaccines-12-01071"><label>137.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>Z.D.</given-names></name><name name-style="western"><surname>Kitching</surname><given-names>R.P.</given-names></name></person-group><article-title>The localization of persistent foot and mouth disease virus in the epithelial cells of the soft palate and pharynx</article-title><source>J. Comp. Pathol.</source><year>2001</year><volume>124</volume><fpage>89</fpage><lpage>94</lpage><pub-id pub-id-type="doi">10.1053/jcpa.2000.0431</pub-id><pub-id pub-id-type="pmid">11222004</pub-id></element-citation></ref><ref id="B138-vaccines-12-01071"><label>138.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>O&#8217;Neill</surname><given-names>A.</given-names></name><name name-style="western"><surname>Mantri</surname><given-names>C.K.</given-names></name><name name-style="western"><surname>Tan</surname><given-names>C.W.</given-names></name><name name-style="western"><surname>Saron</surname><given-names>W.A.A.</given-names></name><name name-style="western"><surname>Nagaraj</surname><given-names>S.K.</given-names></name><name name-style="western"><surname>Kala</surname><given-names>M.P.</given-names></name><name name-style="western"><surname>Joy</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Rathore</surname><given-names>A.P.S.</given-names></name><name name-style="western"><surname>Tripathi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L.F.</given-names></name><etal/></person-group><article-title>Mucosal SARS-CoV-2 vaccination of rodents elicits superior systemic T central memory function and cross-neutralising antibodies against variants of concern</article-title><source>EBioMedicine</source><year>2024</year><volume>99</volume><elocation-id>104924</elocation-id><pub-id pub-id-type="doi">10.1016/j.ebiom.2023.104924</pub-id><pub-id pub-id-type="pmid">38113758</pub-id><pub-id pub-id-type="pmcid">PMC10772395</pub-id></element-citation></ref><ref id="B139-vaccines-12-01071"><label>139.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Windsor</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Carr</surname><given-names>B.V.</given-names></name><name name-style="western"><surname>Bankowski</surname><given-names>B.</given-names></name><name name-style="western"><surname>Gibson</surname><given-names>D.</given-names></name><name name-style="western"><surname>Reid</surname><given-names>E.</given-names></name><name name-style="western"><surname>Hamblin</surname><given-names>P.</given-names></name><name name-style="western"><surname>Gubbins</surname><given-names>S.</given-names></name><name name-style="western"><surname>Juleff</surname><given-names>N.</given-names></name><name name-style="western"><surname>Charleston</surname><given-names>B.</given-names></name></person-group><article-title>Cattle remain immunocompetent during the acute phase of foot-and-mouth disease virus infection</article-title><source>Vet. Res.</source><year>2011</year><volume>42</volume><fpage>108</fpage><pub-id pub-id-type="doi">10.1186/1297-9716-42-108</pub-id><pub-id pub-id-type="pmid">22014145</pub-id><pub-id pub-id-type="pmcid">PMC3207891</pub-id></element-citation></ref><ref id="B140-vaccines-12-01071"><label>140.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Arzt</surname><given-names>J.</given-names></name><name name-style="western"><surname>Pacheco</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Smoliga</surname><given-names>G.R.</given-names></name><name name-style="western"><surname>Tucker</surname><given-names>M.T.</given-names></name><name name-style="western"><surname>Bishop</surname><given-names>E.</given-names></name><name name-style="western"><surname>Pauszek</surname><given-names>S.J.</given-names></name><name name-style="western"><surname>Hartwig</surname><given-names>E.J.</given-names></name><name name-style="western"><surname>de los Santos</surname><given-names>T.</given-names></name><name name-style="western"><surname>Rodriguez</surname><given-names>L.L.</given-names></name></person-group><article-title>Foot-and-mouth disease virus virulence in cattle is co-determined by viral replication dynamics and route of infection</article-title><source>Virology</source><year>2014</year><volume>452</volume><fpage>12</fpage><lpage>22</lpage><pub-id pub-id-type="doi">10.1016/j.virol.2014.01.001</pub-id><pub-id pub-id-type="pmid">24606678</pub-id></element-citation></ref><ref id="B141-vaccines-12-01071"><label>141.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Eschbaumer</surname><given-names>M.</given-names></name><name name-style="western"><surname>Stenfeldt</surname><given-names>C.</given-names></name><name name-style="western"><surname>Rekant</surname><given-names>S.I.</given-names></name><name name-style="western"><surname>Pacheco</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Hartwig</surname><given-names>E.J.</given-names></name><name name-style="western"><surname>Smoliga</surname><given-names>G.R.</given-names></name><name name-style="western"><surname>Kenney</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Golde</surname><given-names>W.T.</given-names></name><name name-style="western"><surname>Rodriguez</surname><given-names>L.L.</given-names></name><name name-style="western"><surname>Arzt</surname><given-names>J.</given-names></name></person-group><article-title>Systemic immune response and virus persistence after foot-and-mouth disease virus infection of naive cattle and cattle vaccinated with a homologous adenovirus-vectored vaccine</article-title><source>BMC Vet. Res.</source><year>2016</year><volume>12</volume><elocation-id>205</elocation-id><pub-id pub-id-type="doi">10.1186/s12917-016-0838-x</pub-id><pub-id pub-id-type="pmid">27634113</pub-id><pub-id pub-id-type="pmcid">PMC5025598</pub-id></element-citation></ref><ref id="B142-vaccines-12-01071"><label>142.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stenfeldt</surname><given-names>C.</given-names></name><name name-style="western"><surname>Heegaard</surname><given-names>P.M.</given-names></name><name name-style="western"><surname>Stockmarr</surname><given-names>A.</given-names></name><name name-style="western"><surname>Tjornehoj</surname><given-names>K.</given-names></name><name name-style="western"><surname>Belsham</surname><given-names>G.J.</given-names></name></person-group><article-title>Analysis of the acute phase responses of serum amyloid a, haptoglobin and type 1 interferon in cattle experimentally infected with foot-and-mouth disease virus serotype O</article-title><source>Vet. Res.</source><year>2011</year><volume>42</volume><fpage>66</fpage><pub-id pub-id-type="doi">10.1186/1297-9716-42-66</pub-id><pub-id pub-id-type="pmid">21592356</pub-id><pub-id pub-id-type="pmcid">PMC3123197</pub-id></element-citation></ref><ref id="B143-vaccines-12-01071"><label>143.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Reid</surname><given-names>E.</given-names></name><name name-style="western"><surname>Juleff</surname><given-names>N.</given-names></name><name name-style="western"><surname>Gubbins</surname><given-names>S.</given-names></name><name name-style="western"><surname>Prentice</surname><given-names>H.</given-names></name><name name-style="western"><surname>Seago</surname><given-names>J.</given-names></name><name name-style="western"><surname>Charleston</surname><given-names>B.</given-names></name></person-group><article-title>Bovine plasmacytoid dendritic cells are the major source of type I interferon in response to foot-and-mouth disease virus in vitro and in vivo</article-title><source>J. Virol.</source><year>2011</year><volume>85</volume><fpage>4297</fpage><lpage>4308</lpage><pub-id pub-id-type="doi">10.1128/JVI.02495-10</pub-id><pub-id pub-id-type="pmid">21307187</pub-id><pub-id pub-id-type="pmcid">PMC3126242</pub-id></element-citation></ref><ref id="B144-vaccines-12-01071"><label>144.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Perez-Martin</surname><given-names>E.</given-names></name><name name-style="western"><surname>Weiss</surname><given-names>M.</given-names></name><name name-style="western"><surname>Diaz-San Segundo</surname><given-names>F.</given-names></name><name name-style="western"><surname>Pacheco</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Arzt</surname><given-names>J.</given-names></name><name name-style="western"><surname>Grubman</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>de los Santos</surname><given-names>T.</given-names></name></person-group><article-title>Bovine type III interferon significantly delays and reduces the severity of foot-and-mouth disease in cattle</article-title><source>J. Virol.</source><year>2012</year><volume>86</volume><fpage>4477</fpage><lpage>4487</lpage><pub-id pub-id-type="doi">10.1128/JVI.06683-11</pub-id><pub-id pub-id-type="pmid">22301155</pub-id><pub-id pub-id-type="pmcid">PMC3318609</pub-id></element-citation></ref><ref id="B145-vaccines-12-01071"><label>145.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Diaz-San Segundo</surname><given-names>F.</given-names></name><name name-style="western"><surname>Moraes</surname><given-names>M.P.</given-names></name><name name-style="western"><surname>de Los Santos</surname><given-names>T.</given-names></name><name name-style="western"><surname>Dias</surname><given-names>C.C.</given-names></name><name name-style="western"><surname>Grubman</surname><given-names>M.J.</given-names></name></person-group><article-title>Interferon-induced protection against foot-and-mouth disease virus infection correlates with enhanced tissue-specific innate immune cell infiltration and interferon-stimulated gene expression</article-title><source>J. Virol.</source><year>2010</year><volume>84</volume><fpage>2063</fpage><lpage>2077</lpage><pub-id pub-id-type="doi">10.1128/JVI.01874-09</pub-id><pub-id pub-id-type="pmid">19955313</pub-id><pub-id pub-id-type="pmcid">PMC2812365</pub-id></element-citation></ref><ref id="B146-vaccines-12-01071"><label>146.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nfon</surname><given-names>C.K.</given-names></name><name name-style="western"><surname>Toka</surname><given-names>F.N.</given-names></name><name name-style="western"><surname>Kenney</surname><given-names>M.</given-names></name><name name-style="western"><surname>Pacheco</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Golde</surname><given-names>W.T.</given-names></name></person-group><article-title>Loss of plasmacytoid dendritic cell function coincides with lymphopenia and viremia during foot-and-mouth disease virus infection</article-title><source>Viral Immunol.</source><year>2010</year><volume>23</volume><fpage>29</fpage><lpage>41</lpage><pub-id pub-id-type="doi">10.1089/vim.2009.0078</pub-id><pub-id pub-id-type="pmid">20121400</pub-id></element-citation></ref><ref id="B147-vaccines-12-01071"><label>147.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Summerfield</surname><given-names>A.</given-names></name></person-group><article-title>Viewpoint: Factors involved in type I interferon responses during porcine virus infections</article-title><source>Vet. Immunol. Immunopathol.</source><year>2012</year><volume>148</volume><fpage>168</fpage><lpage>171</lpage><pub-id pub-id-type="doi">10.1016/j.vetimm.2011.03.011</pub-id><pub-id pub-id-type="pmid">21458079</pub-id></element-citation></ref><ref id="B148-vaccines-12-01071"><label>148.</label><element-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Diaz-San Segundo</surname><given-names>F.</given-names></name><name name-style="western"><surname>Montiel</surname><given-names>N.</given-names></name><name name-style="western"><surname>de Los Santos</surname><given-names>T.</given-names></name><name name-style="western"><surname>Grubman</surname><given-names>M.J.</given-names></name></person-group><article-title>Understanding the Mechanisms of Interferon-Induced Protection against Foot-and-Mouth Disease</article-title><source>Virology II-Advanced Issues</source><publisher-name>iConcept Press</publisher-name><publisher-loc>Hong Kong, China</publisher-loc><year>2013</year></element-citation></ref><ref id="B149-vaccines-12-01071"><label>149.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sei</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Waters</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>Kenney</surname><given-names>M.</given-names></name><name name-style="western"><surname>Barlow</surname><given-names>J.W.</given-names></name><name name-style="western"><surname>Golde</surname><given-names>W.T.</given-names></name></person-group><article-title>Effect of Foot-and-Mouth Disease Virus Infection on the Frequency, Phenotype and Function of Circulating Dendritic Cells in Cattle</article-title><source>PLoS ONE</source><year>2016</year><volume>11</volume><elocation-id>e0152192</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0152192</pub-id><pub-id pub-id-type="pmid">27008425</pub-id><pub-id pub-id-type="pmcid">PMC4805171</pub-id></element-citation></ref><ref id="B150-vaccines-12-01071"><label>150.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Medina</surname><given-names>G.N.</given-names></name><name name-style="western"><surname>de Los Santos</surname><given-names>T.</given-names></name><name name-style="western"><surname>Diaz-San Segundo</surname><given-names>F.</given-names></name></person-group><article-title>Use of IFN-Based Biotherapeutics to Harness the Host Against Foot-And-Mouth Disease</article-title><source>Front. Vet. Sci.</source><year>2020</year><volume>7</volume><elocation-id>465</elocation-id><pub-id pub-id-type="doi">10.3389/fvets.2020.00465</pub-id><pub-id pub-id-type="pmid">32851039</pub-id><pub-id pub-id-type="pmcid">PMC7431487</pub-id></element-citation></ref><ref id="B151-vaccines-12-01071"><label>151.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rigden</surname><given-names>R.C.</given-names></name><name name-style="western"><surname>Carrasco</surname><given-names>C.P.</given-names></name><name name-style="western"><surname>Summerfield</surname><given-names>A.</given-names></name><name name-style="western"><surname>KC</surname><given-names>M.C.</given-names></name></person-group><article-title>Macrophage phagocytosis of foot-and-mouth disease virus may create infectious carriers</article-title><source>Immunology</source><year>2002</year><volume>106</volume><fpage>537</fpage><lpage>548</lpage><pub-id pub-id-type="doi">10.1046/j.1365-2567.2002.01460.x</pub-id><pub-id pub-id-type="pmid">12153517</pub-id><pub-id pub-id-type="pmcid">PMC1782748</pub-id></element-citation></ref><ref id="B152-vaccines-12-01071"><label>152.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Toka</surname><given-names>F.N.</given-names></name><name name-style="western"><surname>Nfon</surname><given-names>C.K.</given-names></name><name name-style="western"><surname>Dawson</surname><given-names>H.</given-names></name><name name-style="western"><surname>Estes</surname><given-names>D.M.</given-names></name><name name-style="western"><surname>Golde</surname><given-names>W.T.</given-names></name></person-group><article-title>Activation of porcine natural killer cells and lysis of foot-and-mouth disease virus infected cells</article-title><source>J. Interferon Cytokine Res.</source><year>2009</year><volume>29</volume><fpage>179</fpage><lpage>192</lpage><pub-id pub-id-type="doi">10.1089/jir.2008.0058</pub-id><pub-id pub-id-type="pmid">19196070</pub-id></element-citation></ref><ref id="B153-vaccines-12-01071"><label>153.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McCullough</surname><given-names>K.C.</given-names></name><name name-style="western"><surname>Parkinson</surname><given-names>D.</given-names></name><name name-style="western"><surname>Crowther</surname><given-names>J.R.</given-names></name></person-group><article-title>Opsonization-enhanced phagocytosis of foot-and-mouth disease virus</article-title><source>Immunology</source><year>1988</year><volume>65</volume><fpage>187</fpage><lpage>191</lpage><pub-id pub-id-type="pmid">2847979</pub-id><pub-id pub-id-type="pmcid">PMC1384912</pub-id></element-citation></ref><ref id="B154-vaccines-12-01071"><label>154.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Guzylack-Piriou</surname><given-names>L.</given-names></name><name name-style="western"><surname>Bergamin</surname><given-names>F.</given-names></name><name name-style="western"><surname>Gerber</surname><given-names>M.</given-names></name><name name-style="western"><surname>McCullough</surname><given-names>K.C.</given-names></name><name name-style="western"><surname>Summerfield</surname><given-names>A.</given-names></name></person-group><article-title>Plasmacytoid dendritic cell activation by foot-and-mouth disease virus requires immune complexes</article-title><source>Eur. J. Immunol.</source><year>2006</year><volume>36</volume><fpage>1674</fpage><lpage>1683</lpage><pub-id pub-id-type="doi">10.1002/eji.200635866</pub-id><pub-id pub-id-type="pmid">16783856</pub-id></element-citation></ref><ref id="B155-vaccines-12-01071"><label>155.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Toka</surname><given-names>F.N.</given-names></name><name name-style="western"><surname>Nfon</surname><given-names>C.</given-names></name><name name-style="western"><surname>Dawson</surname><given-names>H.</given-names></name><name name-style="western"><surname>Golde</surname><given-names>W.T.</given-names></name></person-group><article-title>Natural killer cell dysfunction during acute infection with foot-and-mouth disease virus</article-title><source>Clin. Vaccine Immunol.</source><year>2009</year><volume>16</volume><fpage>1738</fpage><lpage>1749</lpage><pub-id pub-id-type="doi">10.1128/CVI.00280-09</pub-id><pub-id pub-id-type="pmid">19828769</pub-id><pub-id pub-id-type="pmcid">PMC2786395</pub-id></element-citation></ref><ref id="B156-vaccines-12-01071"><label>156.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Patch</surname><given-names>J.R.</given-names></name><name name-style="western"><surname>Dar</surname><given-names>P.A.</given-names></name><name name-style="western"><surname>Waters</surname><given-names>R.</given-names></name><name name-style="western"><surname>Toka</surname><given-names>F.N.</given-names></name><name name-style="western"><surname>Barrera</surname><given-names>J.</given-names></name><name name-style="western"><surname>Schutta</surname><given-names>C.</given-names></name><name name-style="western"><surname>Kondabattula</surname><given-names>G.</given-names></name><name name-style="western"><surname>Golde</surname><given-names>W.T.</given-names></name></person-group><article-title>Infection with foot-and-mouth disease virus (FMDV) induces a natural killer (NK) cell response in cattle that is lacking following vaccination</article-title><source>Comp. Immunol. Microbiol. Infect. Dis.</source><year>2014</year><volume>37</volume><fpage>249</fpage><lpage>257</lpage><pub-id pub-id-type="doi">10.1016/j.cimid.2014.07.004</pub-id><pub-id pub-id-type="pmid">25150134</pub-id></element-citation></ref><ref id="B157-vaccines-12-01071"><label>157.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tandel</surname><given-names>N.</given-names></name><name name-style="western"><surname>Negi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Dalai</surname><given-names>S.K.</given-names></name><name name-style="western"><surname>Tyagi</surname><given-names>R.K.</given-names></name></person-group><article-title>Role of natural killer and B cell interaction in inducing pathogen specific immune responses</article-title><source>Int. Rev. Immunol.</source><year>2023</year><volume>42</volume><fpage>304</fpage><lpage>322</lpage><pub-id pub-id-type="doi">10.1080/08830185.2023.2172406</pub-id><pub-id pub-id-type="pmid">36731424</pub-id></element-citation></ref><ref id="B158-vaccines-12-01071"><label>158.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Notario</surname><given-names>L.</given-names></name><name name-style="western"><surname>Redondo-Anton</surname><given-names>J.</given-names></name><name name-style="western"><surname>Alari-Pahissa</surname><given-names>E.</given-names></name><name name-style="western"><surname>Albentosa</surname><given-names>A.</given-names></name><name name-style="western"><surname>Leiva</surname><given-names>M.</given-names></name><name name-style="western"><surname>Lopez</surname><given-names>D.</given-names></name><name name-style="western"><surname>Sabio</surname><given-names>G.</given-names></name><name name-style="western"><surname>Lauzurica</surname><given-names>P.</given-names></name></person-group><article-title>CD69 Targeting Enhances Anti-vaccinia Virus Immunity</article-title><source>J. Virol.</source><year>2019</year><volume>93</volume><fpage>10</fpage><lpage>1128</lpage><pub-id pub-id-type="doi">10.1128/JVI.00553-19</pub-id><pub-id pub-id-type="pmcid">PMC6744249</pub-id><pub-id pub-id-type="pmid">31315995</pub-id></element-citation></ref><ref id="B159-vaccines-12-01071"><label>159.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zanna</surname><given-names>M.Y.</given-names></name><name name-style="western"><surname>Yasmin</surname><given-names>A.R.</given-names></name><name name-style="western"><surname>Omar</surname><given-names>A.R.</given-names></name><name name-style="western"><surname>Arshad</surname><given-names>S.S.</given-names></name><name name-style="western"><surname>Mariatulqabtiah</surname><given-names>A.R.</given-names></name><name name-style="western"><surname>Nur-Fazila</surname><given-names>S.H.</given-names></name><name name-style="western"><surname>Mahiza</surname><given-names>M.I.N.</given-names></name></person-group><article-title>Review of Dendritic Cells, Their Role in Clinical Immunology, and Distribution in Various Animal Species</article-title><source>Int. J. Mol. Sci.</source><year>2021</year><volume>22</volume><elocation-id>8044</elocation-id><pub-id pub-id-type="doi">10.3390/ijms22158044</pub-id><pub-id pub-id-type="pmid">34360810</pub-id><pub-id pub-id-type="pmcid">PMC8348663</pub-id></element-citation></ref><ref id="B160-vaccines-12-01071"><label>160.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Diaz-San Segundo</surname><given-names>F.</given-names></name><name name-style="western"><surname>Rodriguez-Calvo</surname><given-names>T.</given-names></name><name name-style="western"><surname>de Avila</surname><given-names>A.</given-names></name><name name-style="western"><surname>Sevilla</surname><given-names>N.</given-names></name></person-group><article-title>Immunosuppression during acute infection with foot-and-mouth disease virus in swine is mediated by IL-10</article-title><source>PLoS ONE</source><year>2009</year><volume>4</volume><elocation-id>e5659</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0005659</pub-id><pub-id pub-id-type="pmid">19478852</pub-id><pub-id pub-id-type="pmcid">PMC2682558</pub-id></element-citation></ref><ref id="B161-vaccines-12-01071"><label>161.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sei</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Ochoa</surname><given-names>A.S.</given-names></name><name name-style="western"><surname>Bishop</surname><given-names>E.</given-names></name><name name-style="western"><surname>Barlow</surname><given-names>J.W.</given-names></name><name name-style="western"><surname>Golde</surname><given-names>W.T.</given-names></name></person-group><article-title>Phenotypic, ultra-structural, and functional characterization of bovine peripheral blood dendritic cell subsets</article-title><source>PLoS ONE</source><year>2014</year><volume>9</volume><elocation-id>e109273</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0109273</pub-id><pub-id pub-id-type="pmid">25295753</pub-id><pub-id pub-id-type="pmcid">PMC4190170</pub-id></element-citation></ref><ref id="B162-vaccines-12-01071"><label>162.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nfon</surname><given-names>C.K.</given-names></name><name name-style="western"><surname>Ferman</surname><given-names>G.S.</given-names></name><name name-style="western"><surname>Toka</surname><given-names>F.N.</given-names></name><name name-style="western"><surname>Gregg</surname><given-names>D.A.</given-names></name><name name-style="western"><surname>Golde</surname><given-names>W.T.</given-names></name></person-group><article-title>Interferon-alpha production by swine dendritic cells is inhibited during acute infection with foot-and-mouth disease virus</article-title><source>Viral Immunol.</source><year>2008</year><volume>21</volume><fpage>68</fpage><lpage>77</lpage><pub-id pub-id-type="doi">10.1089/vim.2007.0097</pub-id><pub-id pub-id-type="pmid">18355124</pub-id></element-citation></ref><ref id="B163-vaccines-12-01071"><label>163.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bautista</surname><given-names>E.M.</given-names></name><name name-style="western"><surname>Ferman</surname><given-names>G.S.</given-names></name><name name-style="western"><surname>Gregg</surname><given-names>D.</given-names></name><name name-style="western"><surname>Brum</surname><given-names>M.C.</given-names></name><name name-style="western"><surname>Grubman</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Golde</surname><given-names>W.T.</given-names></name></person-group><article-title>Constitutive expression of alpha interferon by skin dendritic cells confers resistance to infection by foot-and-mouth disease virus</article-title><source>J. Virol.</source><year>2005</year><volume>79</volume><fpage>4838</fpage><lpage>4847</lpage><pub-id pub-id-type="doi">10.1128/JVI.79.8.4838-4847.2005</pub-id><pub-id pub-id-type="pmid">15795269</pub-id><pub-id pub-id-type="pmcid">PMC1069522</pub-id></element-citation></ref><ref id="B164-vaccines-12-01071"><label>164.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Matsui</surname><given-names>T.</given-names></name><name name-style="western"><surname>Akahoshi</surname><given-names>T.</given-names></name><name name-style="western"><surname>Namai</surname><given-names>R.</given-names></name><name name-style="western"><surname>Hashimoto</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kurihara</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Rana</surname><given-names>M.</given-names></name><name name-style="western"><surname>Nishimura</surname><given-names>A.</given-names></name><name name-style="western"><surname>Endo</surname><given-names>H.</given-names></name><name name-style="western"><surname>Kitasato</surname><given-names>H.</given-names></name><name name-style="western"><surname>Kawai</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Selective recruitment of CCR6-expressing cells by increased production of MIP-3 alpha in rheumatoid arthritis</article-title><source>Clin. Exp. Immunol.</source><year>2001</year><volume>125</volume><fpage>155</fpage><lpage>161</lpage><pub-id pub-id-type="doi">10.1046/j.1365-2249.2001.01542.x</pub-id><pub-id pub-id-type="pmid">11472439</pub-id><pub-id pub-id-type="pmcid">PMC1906097</pub-id></element-citation></ref><ref id="B165-vaccines-12-01071"><label>165.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sumida</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>McKay</surname><given-names>P.F.</given-names></name><name name-style="western"><surname>Truitt</surname><given-names>D.M.</given-names></name><name name-style="western"><surname>Kishko</surname><given-names>M.G.</given-names></name><name name-style="western"><surname>Arthur</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>Seaman</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Jackson</surname><given-names>S.S.</given-names></name><name name-style="western"><surname>Gorgone</surname><given-names>D.A.</given-names></name><name name-style="western"><surname>Lifton</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Letvin</surname><given-names>N.L.</given-names></name><etal/></person-group><article-title>Recruitment and expansion of dendritic cells in vivo potentiate the immunogenicity of plasmid DNA vaccines</article-title><source>J. Clin. Investig.</source><year>2004</year><volume>114</volume><fpage>1334</fpage><lpage>1342</lpage><pub-id pub-id-type="doi">10.1172/JCI200422608</pub-id><pub-id pub-id-type="pmid">15520866</pub-id><pub-id pub-id-type="pmcid">PMC524232</pub-id></element-citation></ref><ref id="B166-vaccines-12-01071"><label>166.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Heesters</surname><given-names>B.A.</given-names></name><name name-style="western"><surname>Myers</surname><given-names>R.C.</given-names></name><name name-style="western"><surname>Carroll</surname><given-names>M.C.</given-names></name></person-group><article-title>Follicular dendritic cells: Dynamic antigen libraries</article-title><source>Nat. Rev. Immunol.</source><year>2014</year><volume>14</volume><fpage>495</fpage><lpage>504</lpage><pub-id pub-id-type="doi">10.1038/nri3689</pub-id><pub-id pub-id-type="pmid">24948364</pub-id></element-citation></ref><ref id="B167-vaccines-12-01071"><label>167.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Juleff</surname><given-names>N.</given-names></name><name name-style="western"><surname>Windsor</surname><given-names>M.</given-names></name><name name-style="western"><surname>Reid</surname><given-names>E.</given-names></name><name name-style="western"><surname>Seago</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Monaghan</surname><given-names>P.</given-names></name><name name-style="western"><surname>Morrison</surname><given-names>I.W.</given-names></name><name name-style="western"><surname>Charleston</surname><given-names>B.</given-names></name></person-group><article-title>Foot-and-mouth disease virus persists in the light zone of germinal centres</article-title><source>PLoS ONE</source><year>2008</year><volume>3</volume><elocation-id>e3434</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0003434</pub-id><pub-id pub-id-type="pmid">18941503</pub-id><pub-id pub-id-type="pmcid">PMC2563691</pub-id></element-citation></ref><ref id="B168-vaccines-12-01071"><label>168.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gordon</surname><given-names>L.</given-names></name><name name-style="western"><surname>Mabbott</surname><given-names>N.</given-names></name><name name-style="western"><surname>Wells</surname><given-names>J.</given-names></name><name name-style="western"><surname>Kulik</surname><given-names>L.</given-names></name><name name-style="western"><surname>Juleff</surname><given-names>N.</given-names></name><name name-style="western"><surname>Charleston</surname><given-names>B.</given-names></name><name name-style="western"><surname>Perez-Martin</surname><given-names>E.</given-names></name></person-group><article-title>Foot-and-mouth disease virus localisation on follicular dendritic cells and sustained induction of neutralising antibodies is dependent on binding to complement receptors (CR2/CR1)</article-title><source>PLoS Pathog.</source><year>2022</year><volume>18</volume><elocation-id>e1009942</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1009942</pub-id><pub-id pub-id-type="pmid">35512014</pub-id><pub-id pub-id-type="pmcid">PMC9113581</pub-id></element-citation></ref><ref id="B169-vaccines-12-01071"><label>169.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Salguero</surname><given-names>F.J.</given-names></name><name name-style="western"><surname>Sanchez-Martin</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Diaz-San Segundo</surname><given-names>F.</given-names></name><name name-style="western"><surname>de Avila</surname><given-names>A.</given-names></name><name name-style="western"><surname>Sevilla</surname><given-names>N.</given-names></name></person-group><article-title>Foot-and-mouth disease virus (FMDV) causes an acute disease that can be lethal for adult laboratory mice</article-title><source>Virology</source><year>2005</year><volume>332</volume><fpage>384</fpage><lpage>396</lpage><pub-id pub-id-type="doi">10.1016/j.virol.2004.11.005</pub-id><pub-id pub-id-type="pmid">15661169</pub-id></element-citation></ref><ref id="B170-vaccines-12-01071"><label>170.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sebastian</surname><given-names>R.</given-names></name><name name-style="western"><surname>Sravanthi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Umapathi</surname><given-names>V.</given-names></name><name name-style="western"><surname>Krishnaswamy</surname><given-names>N.</given-names></name><name name-style="western"><surname>Priyanka</surname><given-names>M.</given-names></name><name name-style="western"><surname>Dechamma</surname><given-names>H.J.</given-names></name><name name-style="western"><surname>Ganesh</surname><given-names>K.</given-names></name><name name-style="western"><surname>Basagoudanavar</surname><given-names>S.H.</given-names></name><name name-style="western"><surname>Sanyal</surname><given-names>A.</given-names></name><name name-style="western"><surname>Reddy</surname><given-names>G.R.</given-names></name></person-group><article-title>Foot and mouth disease virus undergoes non-progressive replication in mice peritoneal macrophages and induces M1 polarization</article-title><source>Virus Res.</source><year>2020</year><volume>281</volume><fpage>197906</fpage><pub-id pub-id-type="doi">10.1016/j.virusres.2020.197906</pub-id><pub-id pub-id-type="pmid">32109526</pub-id><pub-id pub-id-type="pmcid">PMC7114663</pub-id></element-citation></ref><ref id="B171-vaccines-12-01071"><label>171.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Quattrocchi</surname><given-names>V.</given-names></name><name name-style="western"><surname>Langellotti</surname><given-names>C.</given-names></name><name name-style="western"><surname>Pappalardo</surname><given-names>J.S.</given-names></name><name name-style="western"><surname>Olivera</surname><given-names>V.</given-names></name><name name-style="western"><surname>Di Giacomo</surname><given-names>S.</given-names></name><name name-style="western"><surname>van Rooijen</surname><given-names>N.</given-names></name><name name-style="western"><surname>Mongini</surname><given-names>C.</given-names></name><name name-style="western"><surname>Waldner</surname><given-names>C.</given-names></name><name name-style="western"><surname>Zamorano</surname><given-names>P.I.</given-names></name></person-group><article-title>Role of macrophages in early protective immune responses induced by two vaccines against foot and mouth disease</article-title><source>Antivir. Res.</source><year>2011</year><volume>92</volume><fpage>262</fpage><lpage>270</lpage><pub-id pub-id-type="doi">10.1016/j.antiviral.2011.08.007</pub-id><pub-id pub-id-type="pmid">21878353</pub-id></element-citation></ref><ref id="B172-vaccines-12-01071"><label>172.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Robinson</surname><given-names>L.</given-names></name><name name-style="western"><surname>Knight-Jones</surname><given-names>T.J.</given-names></name><name name-style="western"><surname>Charleston</surname><given-names>B.</given-names></name><name name-style="western"><surname>Rodriguez</surname><given-names>L.L.</given-names></name><name name-style="western"><surname>Gay</surname><given-names>C.G.</given-names></name><name name-style="western"><surname>Sumption</surname><given-names>K.J.</given-names></name><name name-style="western"><surname>Vosloo</surname><given-names>W.</given-names></name></person-group><article-title>Global Foot-and-Mouth Disease Research Update and Gap Analysis: 6-Immunology</article-title><source>Transbound. Emerg. Dis.</source><year>2016</year><volume>63</volume><issue>(Suppl. S1)</issue><fpage>56</fpage><lpage>62</lpage><pub-id pub-id-type="doi">10.1111/tbed.12518</pub-id><pub-id pub-id-type="pmid">27320167</pub-id></element-citation></ref><ref id="B173-vaccines-12-01071"><label>173.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Collen</surname><given-names>T.</given-names></name><name name-style="western"><surname>Pullen</surname><given-names>L.</given-names></name><name name-style="western"><surname>Doel</surname><given-names>T.R.</given-names></name></person-group><article-title>T cell-dependent induction of antibody against foot-and-mouth disease virus in a mouse model</article-title><source>J. Gen. Virol.</source><year>1989</year><volume>70</volume><issue-part>Pt 2</issue-part><fpage>395</fpage><lpage>403</lpage><pub-id pub-id-type="doi">10.1099/0022-1317-70-2-395</pub-id><pub-id pub-id-type="pmid">2543745</pub-id></element-citation></ref><ref id="B174-vaccines-12-01071"><label>174.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Juleff</surname><given-names>N.</given-names></name><name name-style="western"><surname>Windsor</surname><given-names>M.</given-names></name><name name-style="western"><surname>Lefevre</surname><given-names>E.A.</given-names></name><name name-style="western"><surname>Gubbins</surname><given-names>S.</given-names></name><name name-style="western"><surname>Hamblin</surname><given-names>P.</given-names></name><name name-style="western"><surname>Reid</surname><given-names>E.</given-names></name><name name-style="western"><surname>McLaughlin</surname><given-names>K.</given-names></name><name name-style="western"><surname>Beverley</surname><given-names>P.C.</given-names></name><name name-style="western"><surname>Morrison</surname><given-names>I.W.</given-names></name><name name-style="western"><surname>Charleston</surname><given-names>B.</given-names></name></person-group><article-title>Foot-and-mouth disease virus can induce a specific and rapid CD4+ T-cell-independent neutralizing and isotype class-switched antibody response in naive cattle</article-title><source>J. Virol.</source><year>2009</year><volume>83</volume><fpage>3626</fpage><lpage>3636</lpage><pub-id pub-id-type="doi">10.1128/JVI.02613-08</pub-id><pub-id pub-id-type="pmid">19176618</pub-id><pub-id pub-id-type="pmcid">PMC2663275</pub-id></element-citation></ref><ref id="B175-vaccines-12-01071"><label>175.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pacheco</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Arzt</surname><given-names>J.</given-names></name><name name-style="western"><surname>Rodriguez</surname><given-names>L.L.</given-names></name></person-group><article-title>Early events in the pathogenesis of foot-and-mouth disease in cattle after controlled aerosol exposure</article-title><source>Vet. J.</source><year>2010</year><volume>183</volume><fpage>46</fpage><lpage>53</lpage><pub-id pub-id-type="doi">10.1016/j.tvjl.2008.08.023</pub-id><pub-id pub-id-type="pmid">18930417</pub-id></element-citation></ref><ref id="B176-vaccines-12-01071"><label>176.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pega</surname><given-names>J.</given-names></name><name name-style="western"><surname>Bucafusco</surname><given-names>D.</given-names></name><name name-style="western"><surname>Di Giacomo</surname><given-names>S.</given-names></name><name name-style="western"><surname>Schammas</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Malacari</surname><given-names>D.</given-names></name><name name-style="western"><surname>Capozzo</surname><given-names>A.V.</given-names></name><name name-style="western"><surname>Arzt</surname><given-names>J.</given-names></name><name name-style="western"><surname>Perez-Beascoechea</surname><given-names>C.</given-names></name><name name-style="western"><surname>Maradei</surname><given-names>E.</given-names></name><name name-style="western"><surname>Rodriguez</surname><given-names>L.L.</given-names></name><etal/></person-group><article-title>Early adaptive immune responses in the respiratory tract of foot-and-mouth disease virus-infected cattle</article-title><source>J. Virol.</source><year>2013</year><volume>87</volume><fpage>2489</fpage><lpage>2495</lpage><pub-id pub-id-type="doi">10.1128/JVI.02879-12</pub-id><pub-id pub-id-type="pmid">23255811</pub-id><pub-id pub-id-type="pmcid">PMC3571376</pub-id></element-citation></ref><ref id="B177-vaccines-12-01071"><label>177.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Acosta-Rodriguez</surname><given-names>E.V.</given-names></name><name name-style="western"><surname>Craxton</surname><given-names>A.</given-names></name><name name-style="western"><surname>Hendricks</surname><given-names>D.W.</given-names></name><name name-style="western"><surname>Merino</surname><given-names>M.C.</given-names></name><name name-style="western"><surname>Montes</surname><given-names>C.L.</given-names></name><name name-style="western"><surname>Clark</surname><given-names>E.A.</given-names></name><name name-style="western"><surname>Gruppi</surname><given-names>A.</given-names></name></person-group><article-title>BAFF and LPS cooperate to induce B cells to become susceptible to CD95/Fas-mediated cell death</article-title><source>Eur. J. Immunol.</source><year>2007</year><volume>37</volume><fpage>990</fpage><lpage>1000</lpage><pub-id pub-id-type="doi">10.1002/eji.200636698</pub-id><pub-id pub-id-type="pmid">17357108</pub-id></element-citation></ref><ref id="B178-vaccines-12-01071"><label>178.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bossen</surname><given-names>C.</given-names></name><name name-style="western"><surname>Schneider</surname><given-names>P.</given-names></name></person-group><article-title>BAFF, APRIL and their receptors: Structure, function and signaling</article-title><source>Semin. Immunol.</source><year>2006</year><volume>18</volume><fpage>263</fpage><lpage>275</lpage><pub-id pub-id-type="doi">10.1016/j.smim.2006.04.006</pub-id><pub-id pub-id-type="pmid">16914324</pub-id></element-citation></ref><ref id="B179-vaccines-12-01071"><label>179.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Elgueta</surname><given-names>R.</given-names></name><name name-style="western"><surname>Benson</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>de Vries</surname><given-names>V.C.</given-names></name><name name-style="western"><surname>Wasiuk</surname><given-names>A.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Noelle</surname><given-names>R.J.</given-names></name></person-group><article-title>Molecular mechanism and function of CD40/CD40L engagement in the immune system</article-title><source>Immunol. Rev.</source><year>2009</year><volume>229</volume><fpage>152</fpage><lpage>172</lpage><pub-id pub-id-type="doi">10.1111/j.1600-065X.2009.00782.x</pub-id><pub-id pub-id-type="pmid">19426221</pub-id><pub-id pub-id-type="pmcid">PMC3826168</pub-id></element-citation></ref><ref id="B180-vaccines-12-01071"><label>180.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>T.H.</given-names></name><name name-style="western"><surname>Hong</surname><given-names>J.Y.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>C.C.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>C.C.</given-names></name><name name-style="western"><surname>Jan</surname><given-names>J.T.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>S.C.</given-names></name></person-group><article-title>Production of Multi-Subtype Influenza Virus-Like Particles by Molecular Fusion with BAFF or APRIL for Vaccine Development</article-title><source>Methods Mol. Biol.</source><year>2021</year><volume>2248</volume><fpage>139</fpage><lpage>153</lpage><pub-id pub-id-type="doi">10.1007/978-1-0716-1130-2_10</pub-id><pub-id pub-id-type="pmid">33185873</pub-id></element-citation></ref><ref id="B181-vaccines-12-01071"><label>181.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Clayton</surname><given-names>K.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>W.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zealey</surname><given-names>C.</given-names></name><name name-style="western"><surname>Budylowski</surname><given-names>P.</given-names></name><name name-style="western"><surname>Schwartz</surname><given-names>J.</given-names></name><name name-style="western"><surname>Yue</surname><given-names>F.Y.</given-names></name><name name-style="western"><surname>Bie</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Rini</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Trimeric HIV-1 gp140 fused with APRIL, BAFF, and CD40L on the mucosal gp140-specific antibody responses in mice</article-title><source>Vaccine</source><year>2020</year><volume>38</volume><fpage>2149</fpage><lpage>2159</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2020.01.050</pub-id><pub-id pub-id-type="pmid">32014267</pub-id></element-citation></ref><ref id="B182-vaccines-12-01071"><label>182.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cao</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Du</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>P.</given-names></name></person-group><article-title>CD40 ligand expressed in adenovirus can improve the immunogenicity of the GP3 and GP5 of porcine reproductive and respiratory syndrome virus in swine</article-title><source>Vaccine</source><year>2010</year><volume>28</volume><fpage>7514</fpage><lpage>7522</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2010.09.002</pub-id><pub-id pub-id-type="pmid">20851084</pub-id></element-citation></ref><ref id="B183-vaccines-12-01071"><label>183.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Diaz-San Segundo</surname><given-names>F.</given-names></name><name name-style="western"><surname>Salguero</surname><given-names>F.J.</given-names></name><name name-style="western"><surname>de Avila</surname><given-names>A.</given-names></name><name name-style="western"><surname>de Marco</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Sanchez-Martin</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Sevilla</surname><given-names>N.</given-names></name></person-group><article-title>Selective lymphocyte depletion during the early stage of the immune response to foot-and-mouth disease virus infection in swine</article-title><source>J. Virol.</source><year>2006</year><volume>80</volume><fpage>2369</fpage><lpage>2379</lpage><pub-id pub-id-type="doi">10.1128/JVI.80.5.2369-2379.2006</pub-id><pub-id pub-id-type="pmid">16474143</pub-id><pub-id pub-id-type="pmcid">PMC1395371</pub-id></element-citation></ref><ref id="B184-vaccines-12-01071"><label>184.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Joshi</surname><given-names>G.</given-names></name><name name-style="western"><surname>Sharma</surname><given-names>R.</given-names></name><name name-style="western"><surname>Kakker</surname><given-names>N.K.</given-names></name></person-group><article-title>Phenotypic and functional characterization of T-cells and in vitro replication of FMDV serotypes in bovine lymphocytes</article-title><source>Vaccine</source><year>2009</year><volume>27</volume><fpage>6656</fpage><lpage>6661</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2009.08.107</pub-id><pub-id pub-id-type="pmid">19751690</pub-id></element-citation></ref><ref id="B185-vaccines-12-01071"><label>185.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Guo</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name></person-group><article-title>Interleukin-10-Mediated Lymphopenia Caused by Acute Infection with Foot-and-Mouth Disease Virus in Mice</article-title><source>Viruses</source><year>2021</year><volume>13</volume><elocation-id>2358</elocation-id><pub-id pub-id-type="doi">10.3390/v13122358</pub-id><pub-id pub-id-type="pmid">34960627</pub-id><pub-id pub-id-type="pmcid">PMC8708299</pub-id></element-citation></ref><ref id="B186-vaccines-12-01071"><label>186.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Collins</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>Werling</surname><given-names>D.</given-names></name><name name-style="western"><surname>Duggan</surname><given-names>S.E.</given-names></name><name name-style="western"><surname>Bland</surname><given-names>A.P.</given-names></name><name name-style="western"><surname>Parsons</surname><given-names>K.R.</given-names></name><name name-style="western"><surname>Howard</surname><given-names>C.J.</given-names></name></person-group><article-title>Gammadelta T cells present antigen to CD4+ alphabeta T cells</article-title><source>J. Leukoc. Biol.</source><year>1998</year><volume>63</volume><fpage>707</fpage><lpage>714</lpage><pub-id pub-id-type="doi">10.1002/jlb.63.6.707</pub-id><pub-id pub-id-type="pmid">9620663</pub-id></element-citation></ref><ref id="B187-vaccines-12-01071"><label>187.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Blanco</surname><given-names>E.</given-names></name><name name-style="western"><surname>Garcia-Briones</surname><given-names>M.</given-names></name><name name-style="western"><surname>Sanz-Parra</surname><given-names>A.</given-names></name><name name-style="western"><surname>Gomes</surname><given-names>P.</given-names></name><name name-style="western"><surname>De Oliveira</surname><given-names>E.</given-names></name><name name-style="western"><surname>Valero</surname><given-names>M.L.</given-names></name><name name-style="western"><surname>Andreu</surname><given-names>D.</given-names></name><name name-style="western"><surname>Ley</surname><given-names>V.</given-names></name><name name-style="western"><surname>Sobrino</surname><given-names>F.</given-names></name></person-group><article-title>Identification of T-cell epitopes in nonstructural proteins of foot-and-mouth disease virus</article-title><source>J. Virol.</source><year>2001</year><volume>75</volume><fpage>3164</fpage><lpage>3174</lpage><pub-id pub-id-type="doi">10.1128/JVI.75.7.3164-3174.2001</pub-id><pub-id pub-id-type="pmid">11238843</pub-id><pub-id pub-id-type="pmcid">PMC114110</pub-id></element-citation></ref><ref id="B188-vaccines-12-01071"><label>188.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Garcia-Briones</surname><given-names>M.</given-names></name><name name-style="western"><surname>Rosas</surname><given-names>M.F.</given-names></name><name name-style="western"><surname>Gonzalez-Magaldi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Martin-Acebes</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Sobrino</surname><given-names>F.</given-names></name><name name-style="western"><surname>Armas-Portela</surname><given-names>R.</given-names></name></person-group><article-title>Differential distribution of non-structural proteins of foot-and-mouth disease virus in BHK-21 cells</article-title><source>Virology</source><year>2006</year><volume>349</volume><fpage>409</fpage><lpage>421</lpage><pub-id pub-id-type="doi">10.1016/j.virol.2006.02.042</pub-id><pub-id pub-id-type="pmid">16624365</pub-id></element-citation></ref><ref id="B189-vaccines-12-01071"><label>189.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brito</surname><given-names>B.P.</given-names></name><name name-style="western"><surname>Rodriguez</surname><given-names>L.L.</given-names></name><name name-style="western"><surname>Hammond</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Pinto</surname><given-names>J.</given-names></name><name name-style="western"><surname>Perez</surname><given-names>A.M.</given-names></name></person-group><article-title>Review of the Global Distribution of Foot-and-Mouth Disease Virus from 2007 to 2014</article-title><source>Transbound. Emerg. Dis.</source><year>2015</year><pub-id pub-id-type="doi">10.1111/tbed.12373</pub-id><pub-id pub-id-type="pmid">25996568</pub-id></element-citation></ref><ref id="B190-vaccines-12-01071"><label>190.</label><element-citation publication-type="book"><person-group person-group-type="author"><collab>PANAFTOSA-OPS/OMS</collab></person-group><source>Programa Hermisf&#233;rico de Erradicaci&#243;n de la Fiebre Aftosa-Plan de Acci&#243;n 2011&#8211;2020</source><publisher-name>Centro Panamericano de Fiebre Aftosa-OPS/OMS</publisher-name><publisher-loc>Rio de Janeiro, Brazil</publisher-loc><year>2011</year><fpage>52</fpage></element-citation></ref><ref id="B191-vaccines-12-01071"><label>191.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Belsham</surname><given-names>G.J.</given-names></name></person-group><article-title>Towards improvements in foot-and-mouth disease vaccine performance</article-title><source>Acta Vet. Scand.</source><year>2020</year><volume>62</volume><fpage>20</fpage><pub-id pub-id-type="doi">10.1186/s13028-020-00519-1</pub-id><pub-id pub-id-type="pmid">32434544</pub-id><pub-id pub-id-type="pmcid">PMC7240906</pub-id></element-citation></ref><ref id="B192-vaccines-12-01071"><label>192.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Doel</surname><given-names>T.R.</given-names></name></person-group><article-title>FMD vaccines</article-title><source>Virus Res.</source><year>2003</year><volume>91</volume><fpage>81</fpage><lpage>99</lpage><pub-id pub-id-type="doi">10.1016/S0168-1702(02)00261-7</pub-id><pub-id pub-id-type="pmid">12527439</pub-id></element-citation></ref><ref id="B193-vaccines-12-01071"><label>193.</label><element-citation publication-type="webpage"><person-group person-group-type="author"><collab>World Organization of Animal Health</collab></person-group><article-title>Manual of Diagnostic Tests and Vaccines for Terrestrial Animals. In <italic toggle="yes">3.1.8 Foot-and-Mouth Disease</italic></article-title><year>2018</year><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.woah.org/en/what-we-do/standards/codes-and-manuals/terrestrial-manual-online-access/" ext-link-type="uri">https://www.woah.org/en/what-we-do/standards/codes-and-manuals/terrestrial-manual-online-access/</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-08-20">(accessed on 20 August 2024)</date-in-citation></element-citation></ref><ref id="B194-vaccines-12-01071"><label>194.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cox</surname><given-names>S.J.</given-names></name><name name-style="western"><surname>Voyce</surname><given-names>C.</given-names></name><name name-style="western"><surname>Parida</surname><given-names>S.</given-names></name><name name-style="western"><surname>Reid</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Hamblin</surname><given-names>P.A.</given-names></name><name name-style="western"><surname>Hutchings</surname><given-names>G.</given-names></name><name name-style="western"><surname>Paton</surname><given-names>D.J.</given-names></name><name name-style="western"><surname>Barnett</surname><given-names>P.V.</given-names></name></person-group><article-title>Effect of emergency FMD vaccine antigen payload on protection, sub-clinical infection and persistence following direct contact challenge of cattle</article-title><source>Vaccine</source><year>2006</year><volume>24</volume><fpage>3184</fpage><lpage>3190</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2006.01.037</pub-id><pub-id pub-id-type="pmid">16488060</pub-id></element-citation></ref><ref id="B195-vaccines-12-01071"><label>195.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cao</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Z.</given-names></name></person-group><article-title>Foot-and-mouth disease vaccines: Progress and problems</article-title><source>Expert Rev. Vaccines</source><year>2016</year><volume>15</volume><fpage>783</fpage><lpage>789</lpage><pub-id pub-id-type="doi">10.1586/14760584.2016.1140042</pub-id><pub-id pub-id-type="pmid">26760264</pub-id></element-citation></ref><ref id="B196-vaccines-12-01071"><label>196.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cox</surname><given-names>S.J.</given-names></name><name name-style="western"><surname>Barnett</surname><given-names>P.V.</given-names></name></person-group><article-title>Experimental evaluation of foot-and-mouth disease vaccines for emergency use in ruminants and pigs: A review</article-title><source>Vet. Res.</source><year>2009</year><volume>40</volume><fpage>13</fpage><pub-id pub-id-type="doi">10.1051/vetres:2008051</pub-id><pub-id pub-id-type="pmid">19040829</pub-id><pub-id pub-id-type="pmcid">PMC2695037</pub-id></element-citation></ref><ref id="B197-vaccines-12-01071"><label>197.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Golde</surname><given-names>W.T.</given-names></name><name name-style="western"><surname>Pacheco</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Duque</surname><given-names>H.</given-names></name><name name-style="western"><surname>Doel</surname><given-names>T.</given-names></name><name name-style="western"><surname>Penfold</surname><given-names>B.</given-names></name><name name-style="western"><surname>Ferman</surname><given-names>G.S.</given-names></name><name name-style="western"><surname>Gregg</surname><given-names>D.R.</given-names></name><name name-style="western"><surname>Rodriguez</surname><given-names>L.L.</given-names></name></person-group><article-title>Vaccination against foot-and-mouth disease virus confers complete clinical protection in 7 days and partial protection in 4 days: Use in emergency outbreak response</article-title><source>Vaccine</source><year>2005</year><volume>23</volume><fpage>5775</fpage><lpage>5782</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2005.07.043</pub-id><pub-id pub-id-type="pmid">16153756</pub-id></element-citation></ref><ref id="B198-vaccines-12-01071"><label>198.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>LaRocco</surname><given-names>M.</given-names></name><name name-style="western"><surname>Krug</surname><given-names>P.W.</given-names></name><name name-style="western"><surname>Kramer</surname><given-names>E.</given-names></name><name name-style="western"><surname>Ahmed</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Pacheco</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Duque</surname><given-names>H.</given-names></name><name name-style="western"><surname>Baxt</surname><given-names>B.</given-names></name><name name-style="western"><surname>Rodriguez</surname><given-names>L.L.</given-names></name></person-group><article-title>A continuous bovine kidney cell line constitutively expressing bovine alphavbeta6 integrin has increased susceptibility to foot-and-mouth disease virus</article-title><source>J. Clin. Microbiol.</source><year>2013</year><volume>51</volume><fpage>1714</fpage><lpage>1720</lpage><pub-id pub-id-type="doi">10.1128/JCM.03370-12</pub-id><pub-id pub-id-type="pmid">23515553</pub-id><pub-id pub-id-type="pmcid">PMC3716081</pub-id></element-citation></ref><ref id="B199-vaccines-12-01071"><label>199.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bucafusco</surname><given-names>D.</given-names></name><name name-style="western"><surname>Di Giacomo</surname><given-names>S.</given-names></name><name name-style="western"><surname>Pega</surname><given-names>J.</given-names></name><name name-style="western"><surname>Schammas</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Cardoso</surname><given-names>N.</given-names></name><name name-style="western"><surname>Capozzo</surname><given-names>A.V.</given-names></name><name name-style="western"><surname>Perez-Filgueira</surname><given-names>M.</given-names></name></person-group><article-title>Foot-and-mouth disease vaccination induces cross-reactive IFN-gamma responses in cattle that are dependent on the integrity of the 140S particles</article-title><source>Virology</source><year>2015</year><volume>476</volume><fpage>11</fpage><lpage>18</lpage><pub-id pub-id-type="doi">10.1016/j.virol.2014.11.023</pub-id><pub-id pub-id-type="pmid">25496826</pub-id></element-citation></ref><ref id="B200-vaccines-12-01071"><label>200.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ranjitha</surname><given-names>H.B.</given-names></name><name name-style="western"><surname>Dhanesh</surname><given-names>V.V.</given-names></name><name name-style="western"><surname>Hosamani</surname><given-names>M.</given-names></name><name name-style="western"><surname>Sreenivasa</surname><given-names>B.P.</given-names></name><name name-style="western"><surname>Jabeen</surname><given-names>U.</given-names></name><name name-style="western"><surname>Biswal</surname><given-names>J.K.</given-names></name><name name-style="western"><surname>Saravanan</surname><given-names>P.</given-names></name><name name-style="western"><surname>Sanyal</surname><given-names>A.</given-names></name><name name-style="western"><surname>Bhanuprakash</surname><given-names>V.</given-names></name><name name-style="western"><surname>Basagoudanavar</surname><given-names>S.H.</given-names></name></person-group><article-title>Thermostable negative-marker foot-and-mouth disease virus serotype O induces protective immunity in guinea pigs</article-title><source>Appl. Microbiol. Biotechnol.</source><year>2023</year><volume>107</volume><fpage>1285</fpage><lpage>1297</lpage><pub-id pub-id-type="doi">10.1007/s00253-023-12359-w</pub-id><pub-id pub-id-type="pmid">36656322</pub-id><pub-id pub-id-type="pmcid">PMC9850340</pub-id></element-citation></ref><ref id="B201-vaccines-12-01071"><label>201.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Harmsen</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Fijten</surname><given-names>H.P.</given-names></name><name name-style="western"><surname>Westra</surname><given-names>D.F.</given-names></name><name name-style="western"><surname>Dekker</surname><given-names>A.</given-names></name></person-group><article-title>Stabilizing effects of excipients on dissociation of intact (146S) foot-and-mouth disease virions into 12S particles during storage as oil-emulsion vaccine</article-title><source>Vaccine</source><year>2015</year><volume>33</volume><fpage>2477</fpage><lpage>2484</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2015.03.066</pub-id><pub-id pub-id-type="pmid">25843267</pub-id></element-citation></ref><ref id="B202-vaccines-12-01071"><label>202.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>J.</given-names></name><name name-style="western"><surname>Chang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>S.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>G.</given-names></name><name name-style="western"><surname>Wei</surname><given-names>Y.</given-names></name></person-group><article-title>Formulation enhanced the stability of Foot-and-mouth virus and prolonged vaccine storage</article-title><source>Virol. J.</source><year>2022</year><volume>19</volume><fpage>207</fpage><pub-id pub-id-type="doi">10.1186/s12985-022-01928-6</pub-id><pub-id pub-id-type="pmid">36463170</pub-id><pub-id pub-id-type="pmcid">PMC9719126</pub-id></element-citation></ref><ref id="B203-vaccines-12-01071"><label>203.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Paton</surname><given-names>D.J.</given-names></name><name name-style="western"><surname>Reeve</surname><given-names>R.</given-names></name><name name-style="western"><surname>Capozzo</surname><given-names>A.V.</given-names></name><name name-style="western"><surname>Ludi</surname><given-names>A.</given-names></name></person-group><article-title>Estimating the protection afforded by foot-and-mouth disease vaccines in the laboratory</article-title><source>Vaccine</source><year>2019</year><volume>37</volume><fpage>5515</fpage><lpage>5524</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2019.07.102</pub-id><pub-id pub-id-type="pmid">31405637</pub-id></element-citation></ref><ref id="B204-vaccines-12-01071"><label>204.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Willems</surname><given-names>T.</given-names></name><name name-style="western"><surname>De Vleeschauwer</surname><given-names>A.</given-names></name><name name-style="western"><surname>Perez-Filgueira</surname><given-names>M.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Ludi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Lefebvre</surname><given-names>D.</given-names></name><name name-style="western"><surname>Wilsden</surname><given-names>G.</given-names></name><name name-style="western"><surname>Statham</surname><given-names>B.</given-names></name><name name-style="western"><surname>Haas</surname><given-names>B.</given-names></name><name name-style="western"><surname>Mattion</surname><given-names>N.</given-names></name><etal/></person-group><article-title>FMD vaccine matching: Inter laboratory study for improved understanding of r(1) values</article-title><source>J. Virol. Methods</source><year>2020</year><volume>276</volume><fpage>113786</fpage><pub-id pub-id-type="doi">10.1016/j.jviromet.2019.113786</pub-id><pub-id pub-id-type="pmid">31765721</pub-id></element-citation></ref><ref id="B205-vaccines-12-01071"><label>205.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gubbins</surname><given-names>S.</given-names></name><name name-style="western"><surname>Paton</surname><given-names>D.J.</given-names></name><name name-style="western"><surname>Dekker</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ludi</surname><given-names>A.B.</given-names></name><name name-style="western"><surname>Wilsden</surname><given-names>G.</given-names></name><name name-style="western"><surname>Browning</surname><given-names>C.F.J.</given-names></name><name name-style="western"><surname>Eschbaumer</surname><given-names>M.</given-names></name><name name-style="western"><surname>Barnabei</surname><given-names>J.</given-names></name><name name-style="western"><surname>Duque</surname><given-names>H.</given-names></name><name name-style="western"><surname>Pauszek</surname><given-names>L.L.</given-names></name><etal/></person-group><article-title>Predicting cross-protection against foot-and-mouth disease virus strains by serology after vaccination</article-title><source>Front. Vet. Sci.</source><year>2022</year><volume>9</volume><elocation-id>1027006</elocation-id><pub-id pub-id-type="doi">10.3389/fvets.2022.1027006</pub-id><pub-id pub-id-type="pmid">36532344</pub-id><pub-id pub-id-type="pmcid">PMC9751447</pub-id></element-citation></ref><ref id="B206-vaccines-12-01071"><label>206.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Childs</surname><given-names>K.</given-names></name><name name-style="western"><surname>Jackson</surname><given-names>B.</given-names></name><name name-style="western"><surname>Harvey</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Seago</surname><given-names>J.</given-names></name></person-group><article-title>Trans-Encapsidation of Foot-and-Mouth Disease Virus Genomes Facilitates Escape from Neutralizing Antibodies</article-title><source>Viruses</source><year>2022</year><volume>14</volume><elocation-id>1161</elocation-id><pub-id pub-id-type="doi">10.3390/v14061161</pub-id><pub-id pub-id-type="pmid">35746633</pub-id><pub-id pub-id-type="pmcid">PMC9229618</pub-id></element-citation></ref><ref id="B207-vaccines-12-01071"><label>207.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Malirat</surname><given-names>V.</given-names></name><name name-style="western"><surname>Caldevilla</surname><given-names>C.</given-names></name><name name-style="western"><surname>Cardillo</surname><given-names>S.</given-names></name><name name-style="western"><surname>Espinoza</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Novo</surname><given-names>S.G.</given-names></name><name name-style="western"><surname>Taffarel</surname><given-names>A.</given-names></name><name name-style="western"><surname>Benito</surname><given-names>M.B.</given-names></name><name name-style="western"><surname>Bergmann</surname><given-names>I.E.</given-names></name></person-group><article-title>Broad immunogenic spectrum of monovalent and trivalent foot-and-mouth disease virus vaccines containing O(1) campos, A24 cruzeiro and A Argentina 2001 strains against circulating viral lineages in cattle and pigs</article-title><source>Vaccine</source><year>2023</year><volume>41</volume><fpage>5782</fpage><lpage>5790</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2023.08.007</pub-id><pub-id pub-id-type="pmid">37574343</pub-id></element-citation></ref><ref id="B208-vaccines-12-01071"><label>208.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>J.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>S.H.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>H.H.</given-names></name><name name-style="western"><surname>Park</surname><given-names>J.H.</given-names></name><name name-style="western"><surname>Park</surname><given-names>C.K.</given-names></name></person-group><article-title>Heterologous Prime-Boost Vaccination with Commercial FMD Vaccines Elicits a Broader Immune Response than Homologous Prime-Boost Vaccination in Pigs</article-title><source>Vaccines</source><year>2023</year><volume>11</volume><elocation-id>551</elocation-id><pub-id pub-id-type="doi">10.3390/vaccines11030551</pub-id><pub-id pub-id-type="pmid">36992134</pub-id><pub-id pub-id-type="pmcid">PMC10058820</pub-id></element-citation></ref><ref id="B209-vaccines-12-01071"><label>209.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Di Giacomo</surname><given-names>S.</given-names></name><name name-style="western"><surname>Bucafusco</surname><given-names>D.</given-names></name><name name-style="western"><surname>Schammas</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Pega</surname><given-names>J.</given-names></name><name name-style="western"><surname>Miraglia</surname><given-names>M.C.</given-names></name><name name-style="western"><surname>Barrionuevo</surname><given-names>F.</given-names></name><name name-style="western"><surname>Capozzo</surname><given-names>A.V.</given-names></name><name name-style="western"><surname>Perez-Filgueira</surname><given-names>D.M.</given-names></name></person-group><article-title>Assessment on Different Vaccine Formulation Parameters in the Protection against Heterologous Challenge with FMDV in Cattle</article-title><source>Viruses</source><year>2022</year><volume>14</volume><elocation-id>1781</elocation-id><pub-id pub-id-type="doi">10.3390/v14081781</pub-id><pub-id pub-id-type="pmid">36016403</pub-id><pub-id pub-id-type="pmcid">PMC9416185</pub-id></element-citation></ref><ref id="B210-vaccines-12-01071"><label>210.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lavoria</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Di-Giacomo</surname><given-names>S.</given-names></name><name name-style="western"><surname>Bucafusco</surname><given-names>D.</given-names></name><name name-style="western"><surname>Franco-Mahecha</surname><given-names>O.L.</given-names></name><name name-style="western"><surname>Perez-Filgueira</surname><given-names>D.M.</given-names></name><name name-style="western"><surname>Capozzo</surname><given-names>A.V.</given-names></name></person-group><article-title>Avidity and subtyping of specific antibodies applied to the indirect assessment of heterologous protection against Foot-and-Mouth Disease Virus in cattle</article-title><source>Vaccine</source><year>2012</year><volume>30</volume><fpage>6845</fpage><lpage>6850</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2012.09.011</pub-id><pub-id pub-id-type="pmid">23000129</pub-id></element-citation></ref><ref id="B211-vaccines-12-01071"><label>211.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mansilla</surname><given-names>F.C.</given-names></name><name name-style="western"><surname>Turco</surname><given-names>C.S.</given-names></name><name name-style="western"><surname>Miraglia</surname><given-names>M.C.</given-names></name><name name-style="western"><surname>Bessone</surname><given-names>F.A.</given-names></name><name name-style="western"><surname>Franco</surname><given-names>R.</given-names></name><name name-style="western"><surname>Perez-Filgueira</surname><given-names>M.</given-names></name><name name-style="western"><surname>Sala</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Capozzo</surname><given-names>A.V.</given-names></name></person-group><article-title>The role of viral particle integrity in the serological assessment of foot-and-mouth disease virus vaccine-induced immunity in swine</article-title><source>PLoS ONE</source><year>2020</year><volume>15</volume><elocation-id>e0232782</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0232782</pub-id><pub-id pub-id-type="pmid">32369529</pub-id><pub-id pub-id-type="pmcid">PMC7199947</pub-id></element-citation></ref><ref id="B212-vaccines-12-01071"><label>212.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Maree</surname><given-names>F.F.</given-names></name><name name-style="western"><surname>Nsamba</surname><given-names>P.</given-names></name><name name-style="western"><surname>Mutowembwa</surname><given-names>P.</given-names></name><name name-style="western"><surname>Rotherham</surname><given-names>L.S.</given-names></name><name name-style="western"><surname>Esterhuysen</surname><given-names>J.</given-names></name><name name-style="western"><surname>Scott</surname><given-names>K.</given-names></name></person-group><article-title>Intra-serotype SAT2 chimeric foot-and-mouth disease vaccine protects cattle against FMDV challenge</article-title><source>Vaccine</source><year>2015</year><volume>33</volume><fpage>2909</fpage><lpage>2916</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2015.04.058</pub-id><pub-id pub-id-type="pmid">25930116</pub-id></element-citation></ref><ref id="B213-vaccines-12-01071"><label>213.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fischer</surname><given-names>W.</given-names></name><name name-style="western"><surname>Perkins</surname><given-names>S.</given-names></name><name name-style="western"><surname>Theiler</surname><given-names>J.</given-names></name><name name-style="western"><surname>Bhattacharya</surname><given-names>T.</given-names></name><name name-style="western"><surname>Yusim</surname><given-names>K.</given-names></name><name name-style="western"><surname>Funkhouser</surname><given-names>R.</given-names></name><name name-style="western"><surname>Kuiken</surname><given-names>C.</given-names></name><name name-style="western"><surname>Haynes</surname><given-names>B.</given-names></name><name name-style="western"><surname>Letvin</surname><given-names>N.L.</given-names></name><name name-style="western"><surname>Walker</surname><given-names>B.D.</given-names></name><etal/></person-group><article-title>Polyvalent vaccines for optimal coverage of potential T-cell epitopes in global HIV-1 variants</article-title><source>Nat. Med.</source><year>2007</year><volume>13</volume><fpage>100</fpage><lpage>106</lpage><pub-id pub-id-type="doi">10.1038/nm1461</pub-id><pub-id pub-id-type="pmid">17187074</pub-id></element-citation></ref><ref id="B214-vaccines-12-01071"><label>214.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wubshet</surname><given-names>A.K.</given-names></name><name name-style="western"><surname>Werid</surname><given-names>G.M.</given-names></name><name name-style="western"><surname>Teklue</surname><given-names>T.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>L.</given-names></name><name name-style="western"><surname>Bayasgalan</surname><given-names>C.</given-names></name><name name-style="western"><surname>Tserendorj</surname><given-names>A.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Heath</surname><given-names>L.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Ding</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>Foot and mouth disease vaccine efficacy in Africa: A systematic review and meta-analysis</article-title><source>Front. Vet. Sci.</source><year>2024</year><volume>11</volume><elocation-id>1360256</elocation-id><pub-id pub-id-type="doi">10.3389/fvets.2024.1360256</pub-id><pub-id pub-id-type="pmid">38903686</pub-id><pub-id pub-id-type="pmcid">PMC11187330</pub-id></element-citation></ref><ref id="B215-vaccines-12-01071"><label>215.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cao</surname><given-names>Y.</given-names></name></person-group><article-title>Adjuvants for foot-and-mouth disease virus vaccines: Recent progress</article-title><source>Expert Rev. Vaccines</source><year>2014</year><volume>13</volume><fpage>1377</fpage><lpage>1385</lpage><pub-id pub-id-type="doi">10.1586/14760584.2014.963562</pub-id><pub-id pub-id-type="pmid">25234962</pub-id></element-citation></ref><ref id="B216-vaccines-12-01071"><label>216.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Quattrocchi</surname><given-names>V.</given-names></name><name name-style="western"><surname>Pappalardo</surname><given-names>J.S.</given-names></name><name name-style="western"><surname>Langellotti</surname><given-names>C.</given-names></name><name name-style="western"><surname>Smitsaart</surname><given-names>E.</given-names></name><name name-style="western"><surname>Fondevila</surname><given-names>N.</given-names></name><name name-style="western"><surname>Zamorano</surname><given-names>P.</given-names></name></person-group><article-title>Early protection against foot-and-mouth disease virus in cattle using an inactivated vaccine formulated with Montanide ESSAI IMS D 12802 VG PR adjuvant</article-title><source>Vaccine</source><year>2014</year><volume>32</volume><fpage>2167</fpage><lpage>2172</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2014.02.061</pub-id><pub-id pub-id-type="pmid">24631088</pub-id></element-citation></ref><ref id="B217-vaccines-12-01071"><label>217.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ahn</surname><given-names>Y.H.</given-names></name><name name-style="western"><surname>Chathuranga</surname><given-names>W.A.G.</given-names></name><name name-style="western"><surname>Shim</surname><given-names>Y.J.</given-names></name><name name-style="western"><surname>Haluwana</surname><given-names>D.K.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>E.H.</given-names></name><name name-style="western"><surname>Yoon</surname><given-names>I.J.</given-names></name><name name-style="western"><surname>Lim</surname><given-names>Y.T.</given-names></name><name name-style="western"><surname>Shin</surname><given-names>S.H.</given-names></name><name name-style="western"><surname>Jo</surname><given-names>H.</given-names></name><name name-style="western"><surname>Hwang</surname><given-names>S.Y.</given-names></name><etal/></person-group><article-title>The Potential Adjuvanticity of CAvant((R))SOE for Foot-and-Mouth Disease Vaccine</article-title><source>Vaccines</source><year>2021</year><volume>9</volume><elocation-id>1091</elocation-id><pub-id pub-id-type="doi">10.3390/vaccines9101091</pub-id><pub-id pub-id-type="pmid">34696199</pub-id><pub-id pub-id-type="pmcid">PMC8539697</pub-id></element-citation></ref><ref id="B218-vaccines-12-01071"><label>218.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rodriguez-Pulido</surname><given-names>M.</given-names></name><name name-style="western"><surname>Polo</surname><given-names>M.</given-names></name><name name-style="western"><surname>Borrego</surname><given-names>B.</given-names></name><name name-style="western"><surname>Saiz</surname><given-names>M.</given-names></name></person-group><article-title>Use of Foot-and-Mouth Disease Virus Non-coding Synthetic RNAs as Vaccine Adjuvants</article-title><source>Methods Mol. Biol.</source><year>2022</year><volume>2465</volume><fpage>125</fpage><lpage>135</lpage><pub-id pub-id-type="doi">10.1007/978-1-0716-2168-4_7</pub-id><pub-id pub-id-type="pmid">35118619</pub-id></element-citation></ref><ref id="B219-vaccines-12-01071"><label>219.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>D.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Li</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>B.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>A.</given-names></name></person-group><article-title>Enhancing immune responses to inactivated foot-and-mouth virus vaccine by a polysaccharide adjuvant of aqueous extracts from <italic toggle="yes">Artemisia rupestris</italic> L</article-title><source>J. Vet. Sci.</source><year>2021</year><volume>22</volume><fpage>e30</fpage><pub-id pub-id-type="doi">10.4142/jvs.2021.22.e30</pub-id><pub-id pub-id-type="pmid">33908204</pub-id><pub-id pub-id-type="pmcid">PMC8170215</pub-id></element-citation></ref><ref id="B220-vaccines-12-01071"><label>220.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Niu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Hong</surname><given-names>W.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>W.</given-names></name><name name-style="western"><surname>Zuo</surname><given-names>X.</given-names></name><name name-style="western"><surname>Bao</surname><given-names>X.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>C.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Deng</surname><given-names>B.</given-names></name></person-group><article-title>Development of a water-in-oil-in-water adjuvant for foot-and-mouth disease vaccine based on ginseng stem-leaf saponins as an immune booster</article-title><source>Comp. Immunol. Microbiol. Infect. Dis.</source><year>2020</year><volume>71</volume><elocation-id>101499</elocation-id><pub-id pub-id-type="doi">10.1016/j.cimid.2020.101499</pub-id><pub-id pub-id-type="pmid">32505765</pub-id></element-citation></ref><ref id="B221-vaccines-12-01071"><label>221.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lu</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>S.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>W.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>K.</given-names></name><name name-style="western"><surname>Li</surname><given-names>X.</given-names></name><name name-style="western"><surname>Fan</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ding</surname><given-names>H.</given-names></name><name name-style="western"><surname>Yi</surname><given-names>L.</given-names></name><etal/></person-group><article-title>Development of Foot-and-Mouth Disease Vaccines in Recent Years</article-title><source>Vaccines</source><year>2022</year><volume>10</volume><elocation-id>1817</elocation-id><pub-id pub-id-type="doi">10.3390/vaccines10111817</pub-id><pub-id pub-id-type="pmid">36366327</pub-id><pub-id pub-id-type="pmcid">PMC9693445</pub-id></element-citation></ref><ref id="B222-vaccines-12-01071"><label>222.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Quattrocchi</surname><given-names>V.</given-names></name><name name-style="western"><surname>Bidart</surname><given-names>J.</given-names></name><name name-style="western"><surname>Mignaqui</surname><given-names>A.C.</given-names></name><name name-style="western"><surname>Ruiz</surname><given-names>V.</given-names></name><name name-style="western"><surname>Ferella</surname><given-names>A.</given-names></name><name name-style="western"><surname>Langellotti</surname><given-names>C.</given-names></name><name name-style="western"><surname>Gammella</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ferraris</surname><given-names>S.</given-names></name><name name-style="western"><surname>Carrillo</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wigdorovitz</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Bovine Dendritic Cell Activation, T Cell Proliferation and Antibody Responses to Foot-And-Mouth Disease, Is Similar With Inactivated Virus and Virus Like Particles</article-title><source>Front. Vet. Sci.</source><year>2020</year><volume>7</volume><elocation-id>594</elocation-id><pub-id pub-id-type="doi">10.3389/fvets.2020.00594</pub-id><pub-id pub-id-type="pmid">33195496</pub-id><pub-id pub-id-type="pmcid">PMC7554300</pub-id></element-citation></ref><ref id="B223-vaccines-12-01071"><label>223.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fernandez-Sainz</surname><given-names>I.</given-names></name><name name-style="western"><surname>Medina</surname><given-names>G.N.</given-names></name><name name-style="western"><surname>Ramirez-Medina</surname><given-names>E.</given-names></name><name name-style="western"><surname>Koster</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Grubman</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>de Los Santos</surname><given-names>T.</given-names></name></person-group><article-title>Adenovirus-vectored foot-and-mouth disease vaccine confers early and full protection against FMDV O1 Manisa in swine</article-title><source>Virology</source><year>2017</year><volume>502</volume><fpage>123</fpage><lpage>132</lpage><pub-id pub-id-type="doi">10.1016/j.virol.2016.12.021</pub-id><pub-id pub-id-type="pmid">28039799</pub-id></element-citation></ref><ref id="B224-vaccines-12-01071"><label>224.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>de Avila Botton</surname><given-names>S.</given-names></name><name name-style="western"><surname>Brum</surname><given-names>M.C.</given-names></name><name name-style="western"><surname>Bautista</surname><given-names>E.</given-names></name><name name-style="western"><surname>Koster</surname><given-names>M.</given-names></name><name name-style="western"><surname>Weiblen</surname><given-names>R.</given-names></name><name name-style="western"><surname>Golde</surname><given-names>W.T.</given-names></name><name name-style="western"><surname>Grubman</surname><given-names>M.J.</given-names></name></person-group><article-title>Immunopotentiation of a foot-and-mouth disease virus subunit vaccine by interferon alpha</article-title><source>Vaccine</source><year>2006</year><volume>24</volume><fpage>3446</fpage><lpage>3456</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2006.02.011</pub-id><pub-id pub-id-type="pmid">16522345</pub-id></element-citation></ref><ref id="B225-vaccines-12-01071"><label>225.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Medina</surname><given-names>G.N.</given-names></name><name name-style="western"><surname>Montiel</surname><given-names>N.</given-names></name><name name-style="western"><surname>Diaz-San Segundo</surname><given-names>F.</given-names></name><name name-style="western"><surname>Sturza</surname><given-names>D.</given-names></name><name name-style="western"><surname>Ramirez-Medina</surname><given-names>E.</given-names></name><name name-style="western"><surname>Grubman</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>de Los Santos</surname><given-names>T.</given-names></name></person-group><article-title>Evaluation of a Fiber-Modified Adenovirus Vector Vaccine against Foot-and-Mouth Disease in Cattle</article-title><source>Clin. Vaccine Immunol.</source><year>2015</year><volume>23</volume><fpage>125</fpage><lpage>136</lpage><pub-id pub-id-type="doi">10.1128/CVI.00426-15</pub-id><pub-id pub-id-type="pmid">26607309</pub-id><pub-id pub-id-type="pmcid">PMC4744924</pub-id></element-citation></ref><ref id="B226-vaccines-12-01071"><label>226.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Diaz-San Segundo</surname><given-names>F.</given-names></name><name name-style="western"><surname>Dias</surname><given-names>C.C.</given-names></name><name name-style="western"><surname>Moraes</surname><given-names>M.P.</given-names></name><name name-style="western"><surname>Weiss</surname><given-names>M.</given-names></name><name name-style="western"><surname>Perez-Martin</surname><given-names>E.</given-names></name><name name-style="western"><surname>Salazar</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Grubman</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>de los Santos</surname><given-names>T.</given-names></name></person-group><article-title>Poly ICLC increases the potency of a replication-defective human adenovirus vectored foot-and-mouth disease vaccine</article-title><source>Virology</source><year>2014</year><volume>468</volume><fpage>283</fpage><lpage>292</lpage><pub-id pub-id-type="doi">10.1016/j.virol.2014.08.012</pub-id><pub-id pub-id-type="pmid">25216089</pub-id></element-citation></ref><ref id="B227-vaccines-12-01071"><label>227.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Guo</surname><given-names>H.C.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>S.Q.</given-names></name><name name-style="western"><surname>Jin</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>S.L.</given-names></name><name name-style="western"><surname>Wei</surname><given-names>Y.Q.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>D.H.</given-names></name><name name-style="western"><surname>Yin</surname><given-names>S.H.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>J.W.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Z.X.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>J.H.</given-names></name><etal/></person-group><article-title>Foot-and-mouth disease virus-like particles produced by a SUMO fusion protein system in <italic toggle="yes">Escherichia coli</italic> induce potent protective immune responses in guinea pigs, swine and cattle</article-title><source>Vet. Res.</source><year>2013</year><volume>44</volume><fpage>48</fpage><pub-id pub-id-type="doi">10.1186/1297-9716-44-48</pub-id><pub-id pub-id-type="pmid">23826638</pub-id><pub-id pub-id-type="pmcid">PMC3720265</pub-id></element-citation></ref><ref id="B228-vaccines-12-01071"><label>228.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ge</surname><given-names>J.</given-names></name><name name-style="western"><surname>Li</surname><given-names>J.</given-names></name><name name-style="western"><surname>Li</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Shi</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>X.</given-names></name></person-group><article-title>Expression of FMD virus-like particles in yeast Hansenula polymorpha and immunogenicity of combine with CpG and aluminum adjuvant</article-title><source>J. Vet. Sci.</source><year>2023</year><volume>24</volume><fpage>e15</fpage><pub-id pub-id-type="doi">10.4142/jvs.22227</pub-id><pub-id pub-id-type="pmid">36726280</pub-id><pub-id pub-id-type="pmcid">PMC9899949</pub-id></element-citation></ref><ref id="B229-vaccines-12-01071"><label>229.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Le</surname><given-names>N.M.T.</given-names></name><name name-style="western"><surname>So</surname><given-names>K.K.</given-names></name><name name-style="western"><surname>Chun</surname><given-names>J.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>D.H.</given-names></name></person-group><article-title>Expression of virus-like particles (VLPs) of foot-and-mouth disease virus (FMDV) using <italic toggle="yes">Saccharomyces cerevisiae</italic></article-title><source>Appl. Microbiol. Biotechnol.</source><year>2024</year><volume>108</volume><elocation-id>81</elocation-id><pub-id pub-id-type="doi">10.1007/s00253-023-12902-9</pub-id><pub-id pub-id-type="pmid">38194136</pub-id><pub-id pub-id-type="pmcid">PMC10776484</pub-id></element-citation></ref><ref id="B230-vaccines-12-01071"><label>230.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mignaqui</surname><given-names>A.C.</given-names></name><name name-style="western"><surname>Ferella</surname><given-names>A.</given-names></name><name name-style="western"><surname>Cass</surname><given-names>B.</given-names></name><name name-style="western"><surname>Mukankurayija</surname><given-names>L.</given-names></name><name name-style="western"><surname>L&#8217;Abbe</surname><given-names>D.</given-names></name><name name-style="western"><surname>Bisson</surname><given-names>L.</given-names></name><name name-style="western"><surname>Sanchez</surname><given-names>C.</given-names></name><name name-style="western"><surname>Scian</surname><given-names>R.</given-names></name><name name-style="western"><surname>Cardillo</surname><given-names>S.B.</given-names></name><name name-style="western"><surname>Durocher</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>Foot-and-Mouth Disease: Optimization, Reproducibility, and Scalability of High-Yield Production of Virus-Like Particles for a Next-Generation Vaccine</article-title><source>Front. Vet. Sci.</source><year>2020</year><volume>7</volume><elocation-id>601</elocation-id><pub-id pub-id-type="doi">10.3389/fvets.2020.00601</pub-id><pub-id pub-id-type="pmid">33173790</pub-id><pub-id pub-id-type="pmcid">PMC7538550</pub-id></element-citation></ref><ref id="B231-vaccines-12-01071"><label>231.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fuenmayor</surname><given-names>J.</given-names></name><name name-style="western"><surname>Godia</surname><given-names>F.</given-names></name><name name-style="western"><surname>Cervera</surname><given-names>L.</given-names></name></person-group><article-title>Production of virus-like particles for vaccines</article-title><source>N. Biotechnol.</source><year>2017</year><volume>39</volume><fpage>174</fpage><lpage>180</lpage><pub-id pub-id-type="doi">10.1016/j.nbt.2017.07.010</pub-id><pub-id pub-id-type="pmid">28778817</pub-id><pub-id pub-id-type="pmcid">PMC7102714</pub-id></element-citation></ref><ref id="B232-vaccines-12-01071"><label>232.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bidart</surname><given-names>J.</given-names></name><name name-style="western"><surname>Mignaqui</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kornuta</surname><given-names>C.</given-names></name><name name-style="western"><surname>Lupi</surname><given-names>G.</given-names></name><name name-style="western"><surname>Gammella</surname><given-names>M.</given-names></name><name name-style="western"><surname>Soria</surname><given-names>I.</given-names></name><name name-style="western"><surname>Galarza</surname><given-names>R.</given-names></name><name name-style="western"><surname>Ferella</surname><given-names>A.</given-names></name><name name-style="western"><surname>Cardillo</surname><given-names>S.</given-names></name><name name-style="western"><surname>Langellotti</surname><given-names>C.</given-names></name><etal/></person-group><article-title>FMD empty capsids combined with the Immunostant Particle Adjuvant-ISPA or ISA206 induce protective immunity against foot and mouth disease virus</article-title><source>Virus Res.</source><year>2021</year><volume>297</volume><fpage>198339</fpage><pub-id pub-id-type="doi">10.1016/j.virusres.2021.198339</pub-id><pub-id pub-id-type="pmid">33596405</pub-id></element-citation></ref><ref id="B233-vaccines-12-01071"><label>233.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Patronov</surname><given-names>A.</given-names></name><name name-style="western"><surname>Doytchinova</surname><given-names>I.</given-names></name></person-group><article-title>T-cell epitope vaccine design by immunoinformatics</article-title><source>Open Biol.</source><year>2013</year><volume>3</volume><elocation-id>120139</elocation-id><pub-id pub-id-type="doi">10.1098/rsob.120139</pub-id><pub-id pub-id-type="pmid">23303307</pub-id><pub-id pub-id-type="pmcid">PMC3603454</pub-id></element-citation></ref><ref id="B234-vaccines-12-01071"><label>234.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cao</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>P.</given-names></name><name name-style="western"><surname>Li</surname><given-names>D.</given-names></name><name name-style="western"><surname>Li</surname><given-names>P.</given-names></name><name name-style="western"><surname>Bai</surname><given-names>X.</given-names></name><name name-style="western"><surname>Fu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Bao</surname><given-names>H.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Poly(I:C) combined with multi-epitope protein vaccine completely protects against virulent foot-and-mouth disease virus challenge in pigs</article-title><source>Antivir. Res.</source><year>2013</year><volume>97</volume><fpage>145</fpage><lpage>153</lpage><pub-id pub-id-type="doi">10.1016/j.antiviral.2012.11.009</pub-id><pub-id pub-id-type="pmid">23219974</pub-id></element-citation></ref><ref id="B235-vaccines-12-01071"><label>235.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Taboga</surname><given-names>O.</given-names></name><name name-style="western"><surname>Tami</surname><given-names>C.</given-names></name><name name-style="western"><surname>Carrillo</surname><given-names>E.</given-names></name><name name-style="western"><surname>Nunez</surname><given-names>J.I.</given-names></name><name name-style="western"><surname>Rodriguez</surname><given-names>A.</given-names></name><name name-style="western"><surname>Saiz</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>Blanco</surname><given-names>E.</given-names></name><name name-style="western"><surname>Valero</surname><given-names>M.L.</given-names></name><name name-style="western"><surname>Roig</surname><given-names>X.</given-names></name><name name-style="western"><surname>Camarero</surname><given-names>J.A.</given-names></name><etal/></person-group><article-title>A large-scale evaluation of peptide vaccines against foot-and-mouth disease: Lack of solid protection in cattle and isolation of escape mutants</article-title><source>J. Virol.</source><year>1997</year><volume>71</volume><fpage>2606</fpage><lpage>2614</lpage><pub-id pub-id-type="doi">10.1128/jvi.71.4.2606-2614.1997</pub-id><pub-id pub-id-type="pmid">9060612</pub-id><pub-id pub-id-type="pmcid">PMC191381</pub-id></element-citation></ref><ref id="B236-vaccines-12-01071"><label>236.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Heshmati</surname><given-names>L.</given-names></name><name name-style="western"><surname>Rezayat</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Madani</surname><given-names>R.</given-names></name><name name-style="western"><surname>Emami</surname><given-names>T.</given-names></name><name name-style="western"><surname>Jafari</surname><given-names>M.R.</given-names></name><name name-style="western"><surname>Golchinfar</surname><given-names>F.</given-names></name><name name-style="western"><surname>Kazemi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Azimi Dezfouli</surname><given-names>S.M.</given-names></name></person-group><article-title>Immunity Evaluation of an Experimental Designed Nanoliposomal Vaccine Containing FMDV Immunodominant Peptides</article-title><source>Arch. Razi Inst.</source><year>2021</year><volume>76</volume><fpage>1183</fpage><lpage>1190</lpage><pub-id pub-id-type="doi">10.22092/ari.2021.352498.1566</pub-id><pub-id pub-id-type="pmid">35355777</pub-id><pub-id pub-id-type="pmcid">PMC8934104</pub-id></element-citation></ref><ref id="B237-vaccines-12-01071"><label>237.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>C.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>N.</given-names></name><name name-style="western"><surname>Li</surname><given-names>M.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>A.</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Humak</surname><given-names>F.</given-names></name><name name-style="western"><surname>Qian</surname><given-names>P.</given-names></name><name name-style="western"><surname>Tao</surname><given-names>P.</given-names></name></person-group><article-title>Recombinant bacteriophage T4 displaying key epitopes of the foot-and-mouth disease virus as a novel nanoparticle vaccine</article-title><source>Int. J. Biol. Macromol.</source><year>2024</year><volume>258</volume><elocation-id>128837</elocation-id><pub-id pub-id-type="doi">10.1016/j.ijbiomac.2023.128837</pub-id><pub-id pub-id-type="pmid">38128800</pub-id></element-citation></ref><ref id="B238-vaccines-12-01071"><label>238.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ganges</surname><given-names>L.</given-names></name><name name-style="western"><surname>Borrego</surname><given-names>B.</given-names></name><name name-style="western"><surname>Fernandez-Pacheco</surname><given-names>P.</given-names></name><name name-style="western"><surname>Revilla</surname><given-names>C.</given-names></name><name name-style="western"><surname>Fernandez-Borges</surname><given-names>N.</given-names></name><name name-style="western"><surname>Dominguez</surname><given-names>J.</given-names></name><name name-style="western"><surname>Sobrino</surname><given-names>F.</given-names></name><name name-style="western"><surname>Rodriguez</surname><given-names>F.</given-names></name></person-group><article-title>DNA immunization of pigs with foot-and-mouth disease virus minigenes: From partial protection to disease exacerbation</article-title><source>Virus Res.</source><year>2011</year><volume>157</volume><fpage>121</fpage><lpage>125</lpage><pub-id pub-id-type="doi">10.1016/j.virusres.2011.02.003</pub-id><pub-id pub-id-type="pmid">21315115</pub-id></element-citation></ref><ref id="B239-vaccines-12-01071"><label>239.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Puckette</surname><given-names>M.</given-names></name><name name-style="western"><surname>Clark</surname><given-names>B.A.</given-names></name><name name-style="western"><surname>Barrera</surname><given-names>J.</given-names></name><name name-style="western"><surname>Neilan</surname><given-names>J.G.</given-names></name><name name-style="western"><surname>Rasmussen</surname><given-names>M.V.</given-names></name></person-group><article-title>Evaluation of DNA Vaccine Candidates against Foot-and-Mouth Disease Virus in Cattle</article-title><source>Vaccines</source><year>2023</year><volume>11</volume><elocation-id>386</elocation-id><pub-id pub-id-type="doi">10.3390/vaccines11020386</pub-id><pub-id pub-id-type="pmid">36851264</pub-id><pub-id pub-id-type="pmcid">PMC9960313</pub-id></element-citation></ref><ref id="B240-vaccines-12-01071"><label>240.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nagarajan</surname><given-names>G.</given-names></name><name name-style="western"><surname>Ravikumar</surname><given-names>P.</given-names></name><name name-style="western"><surname>Ashok Kumar</surname><given-names>C.</given-names></name><name name-style="western"><surname>Reddy</surname><given-names>G.R.</given-names></name><name name-style="western"><surname>Dechamma</surname><given-names>H.J.</given-names></name><name name-style="western"><surname>Suryanarayana</surname><given-names>V.V.</given-names></name></person-group><article-title>Self Replicating Gene Vaccine Carrying P1-2A Gene of FMDV Serotype O and its Effects on the Immune Responses of Cattle</article-title><source>Indian J. Virol.</source><year>2011</year><volume>22</volume><fpage>50</fpage><lpage>58</lpage><pub-id pub-id-type="doi">10.1007/s13337-011-0032-5</pub-id><pub-id pub-id-type="pmid">23637502</pub-id><pub-id pub-id-type="pmcid">PMC3550724</pub-id></element-citation></ref><ref id="B241-vaccines-12-01071"><label>241.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nanda</surname><given-names>R.K.</given-names></name><name name-style="western"><surname>Hajam</surname><given-names>I.A.</given-names></name><name name-style="western"><surname>Edao</surname><given-names>B.M.</given-names></name><name name-style="western"><surname>Ramya</surname><given-names>K.</given-names></name><name name-style="western"><surname>Rajangam</surname><given-names>M.</given-names></name><name name-style="western"><surname>Chandra Sekar</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ganesh</surname><given-names>K.</given-names></name><name name-style="western"><surname>Bhanuprakash</surname><given-names>V.</given-names></name><name name-style="western"><surname>Kishore</surname><given-names>S.</given-names></name></person-group><article-title>Immunological evaluation of mannosylated chitosan nanoparticles based foot and mouth disease virus DNA vaccine, pVAC FMDV VP1-OmpA in guinea pigs</article-title><source>Biologicals</source><year>2014</year><volume>42</volume><fpage>153</fpage><lpage>159</lpage><pub-id pub-id-type="doi">10.1016/j.biologicals.2014.01.002</pub-id><pub-id pub-id-type="pmid">24656961</pub-id></element-citation></ref><ref id="B242-vaccines-12-01071"><label>242.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Berche</surname><given-names>P.</given-names></name></person-group><article-title>Life and death of smallpox</article-title><source>Presse Med.</source><year>2022</year><volume>51</volume><fpage>104117</fpage><pub-id pub-id-type="doi">10.1016/j.lpm.2022.104117</pub-id><pub-id pub-id-type="pmid">35143880</pub-id></element-citation></ref><ref id="B243-vaccines-12-01071"><label>243.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Roeder</surname><given-names>P.</given-names></name><name name-style="western"><surname>Mariner</surname><given-names>J.</given-names></name><name name-style="western"><surname>Kock</surname><given-names>R.</given-names></name></person-group><article-title>Rinderpest: The veterinary perspective on eradication</article-title><source>Philos. Trans. R. Soc. Lond. B Biol. Sci.</source><year>2013</year><volume>368</volume><elocation-id>20120139</elocation-id><pub-id pub-id-type="doi">10.1098/rstb.2012.0139</pub-id><pub-id pub-id-type="pmid">23798687</pub-id><pub-id pub-id-type="pmcid">PMC3720037</pub-id></element-citation></ref><ref id="B244-vaccines-12-01071"><label>244.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hollister</surname><given-names>J.R.</given-names></name><name name-style="western"><surname>Vagnozzi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Knowles</surname><given-names>N.J.</given-names></name><name name-style="western"><surname>Rieder</surname><given-names>E.</given-names></name></person-group><article-title>Molecular and phylogenetic analyses of bovine rhinovirus type 2 shows it is closely related to foot-and-mouth disease virus</article-title><source>Virology</source><year>2008</year><volume>373</volume><fpage>411</fpage><lpage>425</lpage><pub-id pub-id-type="doi">10.1016/j.virol.2007.12.019</pub-id><pub-id pub-id-type="pmid">18201745</pub-id></element-citation></ref><ref id="B245-vaccines-12-01071"><label>245.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Atkinson</surname><given-names>N.J.</given-names></name><name name-style="western"><surname>Witteveldt</surname><given-names>J.</given-names></name><name name-style="western"><surname>Evans</surname><given-names>D.J.</given-names></name><name name-style="western"><surname>Simmonds</surname><given-names>P.</given-names></name></person-group><article-title>The influence of CpG and UpA dinucleotide frequencies on RNA virus replication and characterization of the innate cellular pathways underlying virus attenuation and enhanced replication</article-title><source>Nucleic Acids Res.</source><year>2014</year><volume>42</volume><fpage>4527</fpage><lpage>4545</lpage><pub-id pub-id-type="doi">10.1093/nar/gku075</pub-id><pub-id pub-id-type="pmid">24470146</pub-id><pub-id pub-id-type="pmcid">PMC3985648</pub-id></element-citation></ref><ref id="B246-vaccines-12-01071"><label>246.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Burns</surname><given-names>C.C.</given-names></name><name name-style="western"><surname>Campagnoli</surname><given-names>R.</given-names></name><name name-style="western"><surname>Shaw</surname><given-names>J.</given-names></name><name name-style="western"><surname>Vincent</surname><given-names>A.</given-names></name><name name-style="western"><surname>Jorba</surname><given-names>J.</given-names></name><name name-style="western"><surname>Kew</surname><given-names>O.</given-names></name></person-group><article-title>Genetic inactivation of poliovirus infectivity by increasing the frequencies of CpG and UpA dinucleotides within and across synonymous capsid region codons</article-title><source>J. Virol.</source><year>2009</year><volume>83</volume><fpage>9957</fpage><lpage>9969</lpage><pub-id pub-id-type="doi">10.1128/JVI.00508-09</pub-id><pub-id pub-id-type="pmid">19605476</pub-id><pub-id pub-id-type="pmcid">PMC2747992</pub-id></element-citation></ref><ref id="B247-vaccines-12-01071"><label>247.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gaunt</surname><given-names>E.</given-names></name><name name-style="western"><surname>Wise</surname><given-names>H.M.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>L.N.</given-names></name><name name-style="western"><surname>Atkinson</surname><given-names>N.J.</given-names></name><name name-style="western"><surname>Nicol</surname><given-names>M.Q.</given-names></name><name name-style="western"><surname>Highton</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Klenerman</surname><given-names>P.</given-names></name><name name-style="western"><surname>Beard</surname><given-names>P.M.</given-names></name><name name-style="western"><surname>Dutia</surname><given-names>B.M.</given-names></name><etal/></person-group><article-title>Elevation of CpG frequencies in influenza A genome attenuates pathogenicity but enhances host response to infection</article-title><source>eLife</source><year>2016</year><volume>5</volume><fpage>e12735</fpage><pub-id pub-id-type="doi">10.7554/eLife.12735</pub-id><pub-id pub-id-type="pmid">26878752</pub-id><pub-id pub-id-type="pmcid">PMC4798949</pub-id></element-citation></ref><ref id="B248-vaccines-12-01071"><label>248.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rzymski</surname><given-names>P.</given-names></name><name name-style="western"><surname>Szuster-Ciesielska</surname><given-names>A.</given-names></name><name name-style="western"><surname>Dzieciatkowski</surname><given-names>T.</given-names></name><name name-style="western"><surname>Gwenzi</surname><given-names>W.</given-names></name><name name-style="western"><surname>Fal</surname><given-names>A.</given-names></name></person-group><article-title>mRNA vaccines: The future of prevention of viral infections?</article-title><source>J. Med. Virol.</source><year>2023</year><volume>95</volume><fpage>e28572</fpage><pub-id pub-id-type="doi">10.1002/jmv.28572</pub-id><pub-id pub-id-type="pmid">36762592</pub-id></element-citation></ref><ref id="B249-vaccines-12-01071"><label>249.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Le</surname><given-names>T.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>C.</given-names></name><name name-style="western"><surname>Chang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>G.</given-names></name><name name-style="western"><surname>Yin</surname><given-names>X.</given-names></name></person-group><article-title>mRNA Vaccine Development for Emerging Animal and Zoonotic Diseases</article-title><source>Viruses</source><year>2022</year><volume>14</volume><elocation-id>401</elocation-id><pub-id pub-id-type="doi">10.3390/v14020401</pub-id><pub-id pub-id-type="pmid">35215994</pub-id><pub-id pub-id-type="pmcid">PMC8877136</pub-id></element-citation></ref><ref id="B250-vaccines-12-01071"><label>250.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alberer</surname><given-names>M.</given-names></name><name name-style="western"><surname>Gnad-Vogt</surname><given-names>U.</given-names></name><name name-style="western"><surname>Hong</surname><given-names>H.S.</given-names></name><name name-style="western"><surname>Mehr</surname><given-names>K.T.</given-names></name><name name-style="western"><surname>Backert</surname><given-names>L.</given-names></name><name name-style="western"><surname>Finak</surname><given-names>G.</given-names></name><name name-style="western"><surname>Gottardo</surname><given-names>R.</given-names></name><name name-style="western"><surname>Bica</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Garofano</surname><given-names>A.</given-names></name><name name-style="western"><surname>Koch</surname><given-names>S.D.</given-names></name><etal/></person-group><article-title>Safety and immunogenicity of a mRNA rabies vaccine in healthy adults: An open-label, non-randomised, prospective, first-in-human phase 1 clinical trial</article-title><source>Lancet</source><year>2017</year><volume>390</volume><fpage>1511</fpage><lpage>1520</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(17)31665-3</pub-id><pub-id pub-id-type="pmid">28754494</pub-id></element-citation></ref><ref id="B251-vaccines-12-01071"><label>251.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wollner</surname><given-names>C.J.</given-names></name><name name-style="western"><surname>Richner</surname><given-names>J.M.</given-names></name></person-group><article-title>mRNA Vaccines against Flaviviruses</article-title><source>Vaccines</source><year>2021</year><volume>9</volume><elocation-id>148</elocation-id><pub-id pub-id-type="doi">10.3390/vaccines9020148</pub-id><pub-id pub-id-type="pmid">33673131</pub-id><pub-id pub-id-type="pmcid">PMC7918459</pub-id></element-citation></ref><ref id="B252-vaccines-12-01071"><label>252.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pattnaik</surname><given-names>A.</given-names></name><name name-style="western"><surname>Sahoo</surname><given-names>B.R.</given-names></name><name name-style="western"><surname>Pattnaik</surname><given-names>A.K.</given-names></name></person-group><article-title>Current Status of Zika Virus Vaccines: Successes and Challenges</article-title><source>Vaccines</source><year>2020</year><volume>8</volume><elocation-id>266</elocation-id><pub-id pub-id-type="doi">10.3390/vaccines8020266</pub-id><pub-id pub-id-type="pmid">32486368</pub-id><pub-id pub-id-type="pmcid">PMC7349928</pub-id></element-citation></ref><ref id="B253-vaccines-12-01071"><label>253.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rodriguez-Pulido</surname><given-names>M.</given-names></name><name name-style="western"><surname>Sobrino</surname><given-names>F.</given-names></name><name name-style="western"><surname>Borrego</surname><given-names>B.</given-names></name><name name-style="western"><surname>Saiz</surname><given-names>M.</given-names></name></person-group><article-title>Inoculation of newborn mice with non-coding regions of foot-and-mouth disease virus RNA can induce a rapid, solid and wide-range protection against viral infection</article-title><source>Antivir. Res.</source><year>2011</year><volume>92</volume><fpage>500</fpage><lpage>504</lpage><pub-id pub-id-type="doi">10.1016/j.antiviral.2011.10.005</pub-id><pub-id pub-id-type="pmid">22020303</pub-id></element-citation></ref><ref id="B254-vaccines-12-01071"><label>254.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Newman</surname><given-names>J.</given-names></name><name name-style="western"><surname>Rowlands</surname><given-names>D.J.</given-names></name><name name-style="western"><surname>Tuthill</surname><given-names>T.J.</given-names></name></person-group><article-title>An Engineered Maturation Cleavage Provides a Recombinant Mimic of Foot-and-Mouth Disease Virus Capsid Assembly-Disassembly</article-title><source>Life</source><year>2021</year><volume>11</volume><elocation-id>500</elocation-id><pub-id pub-id-type="doi">10.3390/life11060500</pub-id><pub-id pub-id-type="pmid">34072387</pub-id><pub-id pub-id-type="pmcid">PMC8228156</pub-id></element-citation></ref><ref id="B255-vaccines-12-01071"><label>255.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Semkum</surname><given-names>P.</given-names></name><name name-style="western"><surname>Kaewborisuth</surname><given-names>C.</given-names></name><name name-style="western"><surname>Thangthamniyom</surname><given-names>N.</given-names></name><name name-style="western"><surname>Theerawatanasirikul</surname><given-names>S.</given-names></name><name name-style="western"><surname>Lekcharoensuk</surname><given-names>C.</given-names></name><name name-style="western"><surname>Hansoongnern</surname><given-names>P.</given-names></name><name name-style="western"><surname>Ramasoota</surname><given-names>P.</given-names></name><name name-style="western"><surname>Lekcharoensuk</surname><given-names>P.</given-names></name></person-group><article-title>A Novel Plasmid DNA-Based Foot and Mouth Disease Virus Minigenome for Intracytoplasmic mRNA Production</article-title><source>Viruses</source><year>2021</year><volume>13</volume><elocation-id>1047</elocation-id><pub-id pub-id-type="doi">10.3390/v13061047</pub-id><pub-id pub-id-type="pmid">34205958</pub-id><pub-id pub-id-type="pmcid">PMC8229761</pub-id></element-citation></ref><ref id="B256-vaccines-12-01071"><label>256.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Greenwood</surname><given-names>B.</given-names></name></person-group><article-title>The contribution of vaccination to global health: Past, present and future</article-title><source>Philos. Trans. R. Soc. Lond. B Biol. Sci.</source><year>2014</year><volume>369</volume><elocation-id>20130433</elocation-id><pub-id pub-id-type="doi">10.1098/rstb.2013.0433</pub-id><pub-id pub-id-type="pmid">24821919</pub-id><pub-id pub-id-type="pmcid">PMC4024226</pub-id></element-citation></ref><ref id="B257-vaccines-12-01071"><label>257.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Moss</surname><given-names>W.J.</given-names></name><name name-style="western"><surname>Strebel</surname><given-names>P.</given-names></name></person-group><article-title>Biological feasibility of measles eradication</article-title><source>J. Infect. Dis.</source><year>2011</year><volume>204</volume><issue>(Suppl. S1)</issue><fpage>S47</fpage><lpage>S53</lpage><pub-id pub-id-type="doi">10.1093/infdis/jir065</pub-id><pub-id pub-id-type="pmid">21666201</pub-id><pub-id pub-id-type="pmcid">PMC3112320</pub-id></element-citation></ref><ref id="B258-vaccines-12-01071"><label>258.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shao</surname><given-names>J.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>W.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>S.</given-names></name><name name-style="western"><surname>Chang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>H.</given-names></name></person-group><article-title>A recombinant multi-epitope trivalent vaccine for foot-and-mouth disease virus serotype O in pigs</article-title><source>Virology</source><year>2024</year><volume>596</volume><fpage>110103</fpage><pub-id pub-id-type="doi">10.1016/j.virol.2024.110103</pub-id><pub-id pub-id-type="pmid">38781710</pub-id></element-citation></ref><ref id="B259-vaccines-12-01071"><label>259.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chathuranga</surname><given-names>W.A.G.</given-names></name><name name-style="western"><surname>Hewawaduge</surname><given-names>C.</given-names></name><name name-style="western"><surname>Nethmini</surname><given-names>N.A.N.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>T.H.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>J.H.</given-names></name><name name-style="western"><surname>Ahn</surname><given-names>Y.H.</given-names></name><name name-style="western"><surname>Yoon</surname><given-names>I.J.</given-names></name><name name-style="western"><surname>Yoo</surname><given-names>S.S.</given-names></name><name name-style="western"><surname>Park</surname><given-names>J.H.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>J.S.</given-names></name></person-group><article-title>Efficacy of a Novel Multiepitope Vaccine Candidate against Foot-and-Mouth Disease Virus Serotype O and A</article-title><source>Vaccines</source><year>2022</year><volume>10</volume><elocation-id>2181</elocation-id><pub-id pub-id-type="doi">10.3390/vaccines10122181</pub-id><pub-id pub-id-type="pmid">36560591</pub-id><pub-id pub-id-type="pmcid">PMC9786174</pub-id></element-citation></ref></ref-list></back><floats-group><fig position="float" id="vaccines-12-01071-f001" orientation="portrait"><label>Figure 1</label><caption><p>FMDV Genome organization. RNA elements are shown at the 5&#8242; and 3&#8242; non-coding regions (NCRs). The 5&#8242; NCR contains several segments with secondary RNA structure, including S fragment, poly (C) tract (C(n)), pseudoknots (PKs), cis-acting replicative element (cre), and internal ribosome entry site (IRES). The 3&#8242; NCR consists of a short stretch of RNA with two elements of predicted secondary structure and a poly (A) sequence (A(n)). The 3B (VPg) protein is shown covalently linked to the 5&#8242; end of the genomic RNA. The ORF is depicted as an outlined box filled with multiple colors. The processing sites for 3C<sup>pro</sup>, 2A, and L<sup>pro</sup> are indicated by brown, blue, and green symbols, respectively. Arrows describe the two AUG initiation codons, Lab and Lb. Illustration was created with <uri>Biorender.com</uri>.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="vaccines-12-01071-g001.jpg"/></fig><fig position="float" id="vaccines-12-01071-f002" orientation="portrait"><label>Figure 2</label><caption><p>Current vaccine platforms under investigation to protect against FMD. Created with <uri>Biorender.com</uri>.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="vaccines-12-01071-g002.jpg"/></fig><table-wrap position="float" id="vaccines-12-01071-t001" orientation="portrait"><object-id pub-id-type="pii">vaccines-12-01071-t001_Table 1</object-id><label>Table 1</label><caption><p>Foot-and-mouth vaccine platforms under investigation and development.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Type</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Strategies for Vaccine Improvement</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">References of Interest</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Coding Region Targeted</th></tr></thead><tbody><tr><td rowspan="5" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Inactivated vaccines</td><td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Current inactivated vaccines</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">More permissive cell lines for viral growth </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">LaRocco et al., 2021 [<xref rid="B9-vaccines-12-01071" ref-type="bibr">9</xref>]; Harvey et al., 2022 [<xref rid="B10-vaccines-12-01071" ref-type="bibr">10</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">n/a</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">High Potency</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Brehm KE et al., 2008 [<xref rid="B11-vaccines-12-01071" ref-type="bibr">11</xref>], Dekker et al., 2020 [<xref rid="B12-vaccines-12-01071" ref-type="bibr">12</xref>], S Galdo Novo [<xref rid="B13-vaccines-12-01071" ref-type="bibr">13</xref>], Fishbourne et al., 2017 [<xref rid="B14-vaccines-12-01071" ref-type="bibr">14</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">n/a</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Capsid stabilization </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Scott et al., 2017 [<xref rid="B15-vaccines-12-01071" ref-type="bibr">15</xref>]; Dong et al., 2021 [<xref rid="B16-vaccines-12-01071" ref-type="bibr">16</xref>]; Lopez-Arguello et al., 2019 [<xref rid="B17-vaccines-12-01071" ref-type="bibr">17</xref>]; Yuan et al., 2020 [<xref rid="B18-vaccines-12-01071" ref-type="bibr">18</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">P1 capsid coding region</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Enhancing cross-protection by reverse genetic, chimeric, and mosaic capsid designs </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Kotecha et al., 2018 [<xref rid="B19-vaccines-12-01071" ref-type="bibr">19</xref>]; Li et al., 2022 [<xref rid="B20-vaccines-12-01071" ref-type="bibr">20</xref>]; Rieder et al., personal communication [<xref rid="B21-vaccines-12-01071" ref-type="bibr">21</xref>], Li et al., 2012 [<xref rid="B22-vaccines-12-01071" ref-type="bibr">22</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">P1 capsid coding region</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">New marked inactivated vaccines</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Development of avirulent FMDV strains with DIVA (differentiation between infected and vaccinated animals) markers in different NS proteins (Lpro, 3AB) that are safer for production</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Uddowla et al., 2012 [<xref rid="B23-vaccines-12-01071" ref-type="bibr">23</xref>]; Hardham et al., 2020 [<xref rid="B24-vaccines-12-01071" ref-type="bibr">24</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Lpro, 3B, and 3D</td></tr><tr><td rowspan="7" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Virus-like particles expressed by viral vectors</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<underline>Improve safety and include DIVA capabilities, possibly decreasing costs using: </underline>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Vaccinia</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Vaccinia virus to deliver FMDV empty capsids with controlled 3C expression</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Steigerwald et al., 2020 [<xref rid="B25-vaccines-12-01071" ref-type="bibr">25</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">P1 coding region, 3Cpro</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Avian poxvirus</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Fowlpox virus expressing VLPs and swine IL-18</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ma et al., 2008 [<xref rid="B26-vaccines-12-01071" ref-type="bibr">26</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">P1 coding region, 2A, 3Cpro</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pseudorabies</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pseudo rabies V vector expressing VLPs</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Hong et al., 2007 [<xref rid="B27-vaccines-12-01071" ref-type="bibr">27</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">P1 coding region, 2A, 3Cpro</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Alphavirus</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Single-cycle self-replicating RNA Semliki Forest virus vector expressing VLPs</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Gullberg et al., 2016 [<xref rid="B28-vaccines-12-01071" ref-type="bibr">28</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">P1 coding region, 2A, 3Cpro</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Adenovirus</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Replication-defective human adenovirus type 5 (Ad5) expressing VLPs </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mayr et al., 1999 [<xref rid="B29-vaccines-12-01071" ref-type="bibr">29</xref>]; Moraes et al., 2002 [<xref rid="B30-vaccines-12-01071" ref-type="bibr">30</xref>]; Pena et al., 2008 [<xref rid="B31-vaccines-12-01071" ref-type="bibr">31</xref>]; Grubman et al., 2012 [<xref rid="B32-vaccines-12-01071" ref-type="bibr">32</xref>]; Schutta et al., 2016 [<xref rid="B33-vaccines-12-01071" ref-type="bibr">33</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">P1 coding region, 2A, 2B, 3Cpro</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Bacterial vectors</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">Salmonella typhimurium</italic> or <italic toggle="yes">Lactococus lactis</italic> expressing VLPs </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Zhi et al., 2021 [<xref rid="B34-vaccines-12-01071" ref-type="bibr">34</xref>]; Liu et al., 2020 [<xref rid="B35-vaccines-12-01071" ref-type="bibr">35</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">VP1</td></tr><tr><td rowspan="5" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Purified virus-like particles</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<underline>More safety, DIVA capabilities, lower costs, and rapid adaptability to circulating strains:</underline>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Baculovirus </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Purified VLPs expressed from recombinant baculovirus</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Kotecha et al., 2015 [<xref rid="B36-vaccines-12-01071" ref-type="bibr">36</xref>]; Porta et al., 2013 [<xref rid="B37-vaccines-12-01071" ref-type="bibr">37</xref>]; Ganji et al., 2018 [<xref rid="B38-vaccines-12-01071" ref-type="bibr">38</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">P1 coding region, 2A, 3Cpro</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Bacterial </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Purified VLPs expressed in <italic toggle="yes">E. coli</italic>, VLP-based combined vaccine</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Xiao et al., 2016 [<xref rid="B39-vaccines-12-01071" ref-type="bibr">39</xref>]; Song et al., 2024 [<xref rid="B40-vaccines-12-01071" ref-type="bibr">40</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">VP0, VP1, VP3</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Plant </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">VLPs expressed in transgenic alfalfa, tomato fruits, or tobacco </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Dus Santos and Wigdorovitz, 2005 [<xref rid="B41-vaccines-12-01071" ref-type="bibr">41</xref>]; Veerapen et al., 2017 [<xref rid="B42-vaccines-12-01071" ref-type="bibr">42</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">P1 coding region, 2A,</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mammalian cells</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">VLPs expressed in mammalian cell cultures</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Puckette et al., 2022 [<xref rid="B43-vaccines-12-01071" ref-type="bibr">43</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">P1 coding region, 2A, 3Cpro</td></tr><tr><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Peptide vaccines</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">T- and B-cell peptide epitopes</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<underline>Improve safety, include DIVA capabilities, and extend shelf life by producing:</underline>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Peptides combining VP1 G-H loop epitopes with T-cell epitopes</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Wang et al., 2002 [<xref rid="B44-vaccines-12-01071" ref-type="bibr">44</xref>]; Rodriguez et al., 2003 [<xref rid="B45-vaccines-12-01071" ref-type="bibr">45</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">VP1-GH-loop</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Dendrimeric peptides containing one T-cell epitope and four B-cell epitopes </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Blanco et al., 2016 [<xref rid="B46-vaccines-12-01071" ref-type="bibr">46</xref>]; Soria et al., 2017 [<xref rid="B47-vaccines-12-01071" ref-type="bibr">47</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">P1</td></tr><tr><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">DNA vaccines</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<underline>Improve safety and include DIVA capabilities and rapid adaptability to circulating strains by:</underline>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Electroporation</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Administering DNA by electroporation</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Fowler et al., 2012 [<xref rid="B48-vaccines-12-01071" ref-type="bibr">48</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">P1, 2A, 3C, 3D </td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">APC targeting</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Using B/T cell epitopes fused to a single chain antibody or Bcl-xL anti-apoptotic signal </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Borrego et al., 2011 [<xref rid="B49-vaccines-12-01071" ref-type="bibr">49</xref>]; G&#252;l&#231;e &#304;z et al., 2013 [<xref rid="B50-vaccines-12-01071" ref-type="bibr">50</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">P1</td></tr><tr><td rowspan="6" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Modified live-attenuated vaccines</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<underline>Improve safety and immune response (more rapid and sustained) by:</underline>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mutations on Lpro</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Introducing attenuating mutations in L<sup>pro</sup> coding sequence</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Diaz-San Segundo et al., 2012 [<xref rid="B51-vaccines-12-01071" ref-type="bibr">51</xref>]; Medina et al., 2020 [<xref rid="B52-vaccines-12-01071" ref-type="bibr">52</xref>]; Azzinaro et al., 2022 [<xref rid="B53-vaccines-12-01071" ref-type="bibr">53</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Lpro</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Chimeric virus</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Substituting FMDV coding regions with other virus proteins (chimeric FMDV/bovine rhinitis B virus)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Uddowla et al., 2013 [<xref rid="B54-vaccines-12-01071" ref-type="bibr">54</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Lpro</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Fidelity</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Introducing point mutations in 3Dpol to alter replication fidelity</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Rai et al., 2017 [<xref rid="B55-vaccines-12-01071" ref-type="bibr">55</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3Dpol</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Untranslated region</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Introducing mutilations targeting RNA structures in the non-translated region </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Rodriguez-Pulido et al., 2009 [<xref rid="B56-vaccines-12-01071" ref-type="bibr">56</xref>]; Kloc et al., 2017 [<xref rid="B57-vaccines-12-01071" ref-type="bibr">57</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5&#8242; or 3&#8242; UTR</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Deoptimized virus</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Deoptimization of P1 or P2/P3 coding regions </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Diaz-San Segundo et al., 2015 [<xref rid="B58-vaccines-12-01071" ref-type="bibr">58</xref>]; 2020 [<xref rid="B59-vaccines-12-01071" ref-type="bibr">59</xref>]; Medina et al., 2023 [<xref rid="B60-vaccines-12-01071" ref-type="bibr">60</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Genome-wide</td></tr></tbody></table></table-wrap></floats-group></article></pmc-articleset>